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Background: population based approach
During the past three decades cardiovascular disease has been the primary 
cause of death in the western world. [1] Mortality due to cardiovascular disease was 
highest in the late 1980s, claiming over 50 000 deaths in the Netherlands each year 
(>40% of total mortality). From 1985 onwards, however, mortality due to cardio-
vascular diseases gradually decreased, whereas mortality due to cancer became 
more prominent (Figure 1).
 
Figure 1:  Number of deaths due to cancer and cardiovascular disease as a percentage of the total 
number of deaths for separate years between 1950 and 2010 (source: www.cbs.nl). CVD, cardio­
vascular disease. 
Coronary artery disease has been and remains the main clinical manifestation 
of cardiovascular morbidity and mortality: in 1980 half of the cardiovascular 
mortality was due to coronary artery disease whereas less than a quarter resulted 
from cerebrovascular disease. In particular, the mortality due to coronary artery 
disease has decreased over the past decades (Figure 2). 
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Figure 2:  Number of deaths due to coronary artery disease and stroke as a percentage of  
the number of deaths due to cardiovascular disease for separate years between 1980 and 2010  
(source: www.cbs.nl). CAD, coronary artery disease.  
Interestingly, deaths from coronary artery disease occur primarily in the elderly 
(Figure 3). Given that the population is aging (Figure 4), the true (age corrected) 
mortality reduction is more substantial than the above figures suggest. 
Figure 3:  Number of deaths due to acute myocardial infarction in 2010 for each age group 
(source:  www.cbs.nl). AMI, acute myocardial infarction. 
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Figure 4: The aging population: number of individuals aged 80 or 85 years or older in the total 
population for separate years between 1960 and 2010 (source: www.cbs.nl). 
Treatment
During the last 30 years, treatment of coronary artery disease has made substantial 
progress. The introduction of thrombolysis, percutaneous coronary intervention, 
aspirin, beta-blockers, ace inhibitors, statins, and novel anticoagulants should be 
mentioned in particular. [2]  The effectiveness of these therapies have been extensively 
demonstrated in randomized controlled trials, however, the combined impact of these 
treatments remains unknown. 
Risk factors
In addition to changes in treatment and demographical developments (i.e. an aging 
population), the clinical presenting characteristics and comorbidity of patients 
with coronary artery disease has changed as well. Clinical characteristics or risk 
factors can be used to predict adverse events. Also, comorbidity and risk factors can 
be used to tailor treatment, with more aggressive treatment in high risk patients 
and alternative treatment modalities for patients at lower risk, with comorbidity or 
conditions preventing the application of some treatment modality. For these reasons, 
it remains important to study changes in treatment and outcome in conjunction with 
changes in such risk factors. 
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The aim of this thesis was to expand the knowledge on treatment, outcome and risk 
factors for adverse outcome in coronary artery disease patients with focus on changes 
therein during the past three decades. 
The outline of the thesis is as follows. Part I highlights changes in clinical profile, 
treatment and mortality in patients hospitalized for acute myocardial infarction 
(Chapter 3). Chapters 4 and 5 evaluate the changes in treatment and outcome of 
patients with either renal dysfunction or anemia. 
Part II focuses on emerging risk factors. During the past decades, the population has 
been aging with an increase in pre-diabetes (hyperglycemia) and diabetes mellitus 
type II. These changes are discussed in chapters 6 to 8. 
Part III addresses gender issues and focuses on prognosis of myocardial infarction 
patients compared with age and gender matched patients of the general population. 
Part IV focuses on traditional risk factors: diabetes, hypertension, hypercholester-
olemia, and family history of coronary artery disease. These risk factors are useful in 
the prediction of cardiovascular disease in patients with no prior history of cardiovas-
cular disease. However, their value in myocardial infarction patients is controversial. 
Part V focuses on percutaneous coronary interventions. The results of percutaneous 
coronary intervention in saphenous bypass grafts is discussed in chapter 12. The 
predictive value of the SYNTAX risk score is discussed in chapters 13 and 14. Since 
primary percutaneous coronary interventions might be delayed during the weekend 
days, chapter 15 focuses on the so called ‘weekend effect’ with possibly higher mortality 
rates during the weekend. Chapters 16 and 17 focus on the current revascularization 
guidelines. 
Part VI of this thesis focuses on methodological issues related to clinical research. 
Specifically, chapter 18 describes how an appropriate control group could be selected 
and chapter 19 is a tutorial for analyses of clustered data.
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Part I
Changes in clinical 
profile, treatment, 
and mortality

Chapter 3 
Changes in clinical profile, 
treatment, and mortality 
in patients hospitalised for 
acute myocardial infarction 
between 1985 and 2008
Sjoerd T Nauta 
 Jaap W Deckers 
Martijn Akkerhuis 
 Mattie Lenzen 
Maarten L Simoons 
Ron T van Domburg
PLoS One. 2011;6(11):e26917
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Abstract
Objectives 
To quantify the impact of the implementation of treatment modalities into clinical 
practice since 1985, on outcome of patients with ST-segment elevation myocardial 
infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI).
Methods
All consecutive patients admitted for STEMI or NSTEMI at the Thoraxcenter between 
1985 and 2008 were included. Baseline characteristics, pharmacological and invasive 
treatment modalities, and survival status were collected. The study population was 
categorised in three groups of patients: those hospitalised between 1985-1990; 1990-
2000; and 2000-2008.
Results
We identified 14,434 patients hospitalised for myocardial infarction (MI). Both STEMI 
and NSTEMI patients were increasingly treated with current guideline based therapy. In 
STEMI, at 30 days following admission, cumulative mortality rate decreased from 17% 
in 1985-1990 to 13% in 1990-2000, and to 6% in 2000-2008. Adjusted 30-day and three-
year mortality in the last period was 80% and 68% lower than in 1985, respectively. In 
NSTEMI, at 30 days following admission, cumulative mortality rate decreased from 6% 
in 1985-1990 to 4% in 1990-2000, and to 2% in 2000-2008. Adjusted 30-day and three-year 
mortality in the last period was 78% and 49% lower than in 1985, respectively. For patients 
admitted between 2000 and 2008, 3 year survival of STEMI and NSTEMI patients was 
87% and 88%, respectively.
Conclusions
Our results indicate substantial improvements in acute- and long-term survival in 
patients hospitalised for MI, related to improved acute- as well as long-term treatment. 
Early medical evaluation in suspected MI and intensive early hospital treatment both 
remain warranted in the future.
Keywords
ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial 
infarction, Survival, Trends
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Introduction
During the last 25 years, the management of patients presenting with an acute 
myocardial infarction (MI) has undergone many transformations. Until 1984, treat -
ment was limited to providing symptomatic relief, and management of complications 
as arrhythmia’s, acute heart failure, or post-infarction angina. In the 1980s, the 
introduction of antithrombotic treatment with aspirin and intravenous (or intra-
coronary) fibrinolysis resulted in significant mortality reductions in patients with 
ST-segment elevation myocardial infarction (STEMI). [1] In the nineties, pre-hospital 
identification (“triage”) of patients with an acute myocardial infarction with an 
indication for reperfusion therapy and subsequent immediate (pre-hospital) initiation 
of thrombolytic treatment was introduced in some areas. [2,3] Although more effective 
thrombolytic agents became available, [4] reperfusion of the infarct-related vessel 
often failed, [5] and bleeding complications were a limiting factor of fibrinolyis. [6] 
Gradually, mechanical percutaneous techniques improved, and in the last decade 
primary percutaneous coronary intervention (PCI) became the treatment of choice in 
patients presenting with a STEMI. [7,8]
In the same time period, patients with non-ST-elevation myocardial infarction 
(NSTEMI) benefitted from improved anti-thrombotic and anti-coagulant therapy, [9] 
better risk stratification and tailored treatment with selective coronary revascu-
larization in high risk patients. [9,10,11,12] Additionally, effective secondary prevention was 
introduced with aspirin, beta-blockers, statins, and ACE inhibitors in subjects with LV 
dysfunction and, subsequently, in high risk MI survivors. [13,14,15,16,17] In  combination, all 
these developments reshaped the treatment map of the patient with an MI. [18,19,20] 
The impact of the implementation of all these treatment modalities into clinical 
practice on outcome has not yet been fully quantified. Therefore, we analysed 
changes in clinical practise, treatment, and 30-day as well as three-year outcome 
in a consecutive series of STEMI or NSTEMI patients admitted at our institution, an 
academic tertiary referral center, between 1985 and 2008. 
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Methods 
We included all consecutive patients aged >18 years admitted for STEMI or NSTEMI 
to the Intensive Coronary Care Unit (ICCU) of the Thoraxcenter, Erasmus University 
Medical Center between June 1985 and December 2008. The Thoraxcenter was the 
referral center for all PCIs in the Rotterdam region until 2005 when a second hospital 
started a PCI programme. Regional arrangements were made such that patients with 
MI were referred to either hospital according to a pre-arranged schedule. 
The primary discharge diagnosis of MI was made in the presence of the following 
characteristics: chest pain or equivalent symptoms in combination with dynamic 
ECG changes consistent with MI and a serial rise (to at least three times the upper 
normal value) and fall in serum biochemical markers of cardiac necrosis such as 
creatine kinase-MB and troponin T (as of 2002). Patients were diagnosed as STEMI in 
the presence of ST-segment elevation > 0.1 mV in at least two peripheral leads, or > 0.2 
mV in at least two precordial leads, and as NSTEMI otherwise. For patients admitted 
more than once, only the first hospitalisation was taken into account. 
Data collection
This is a prospective observational study. Trained physicians and nurses accustomed 
to the use of standardized case report forms collected the data. Demographic 
characteristics (age, gender), cardiac history (previous MI, PCI or coronary artery 
bypass surgery (CABG)), risk factors (hypertension, diabetes, family history, smoking 
status), renal dysfunction (creatinine value >150 μmol/L), and pharmacological and 
invasive treatment modalities (thrombolysis and PCI) were collected.
Follow-up and endpoints
The primary endpoint was all cause mortality at 30 days and at three-years. In-
hospital mortality was retrieved from the medical records. Survival status was 
assessed through municipal Civil Registries in 2010 and was available for 99% of all 
patients. 
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Ethics Statement
This study has been approved by the Ethical Committee of the Erasmus Medical 
Center, Rotterdam. According to Dutch laws, informed consent is not required 
for register-based research of pre-existing personal data. Therefore, the Ethical 
Committee waived the need for informed consent.
Statistical Analysis 
Data are summarized as frequencies and percentages for categorical variables. 
Continuous variables are presented as mean and standard deviation or median and 25th 
and 75th percentile. The study population was categorised in three groups of patients, 
those hospitalised between 1985-1990; 1990-2000; and 2000-2008, respectively. These 
categories were chosen according to important improvements in therapy with complete 
introduction of thrombolysis in 1991 and substantial increase in the use of primary 
PCI in 2001. Categorized variables among the three groups were compared with the 
chi-square test and continuous variables by ANOVA with Bonferroni corrections. In 
addition, we compared changes in mortality in time periods of three year, and these 
changes are presented in Forrest plots.
Cumulative survival and one-minus-survival curves were constructed using 
the Kaplan–Meier method according to date of hospitalization as presented above. 
A log-rank test was used to compare survival curves. We examined the independent 
association between year of hospitalization and mortality using logistic regression for 
30-day outcome and the Cox proportional hazards model for long-term outcome, with 
adjustment for age, gender, previous MI, previous CABG, diabetes, hypertension and 
smoking status. Results are reported as odds or hazard ratios of mortality and their 
respective 95% confidence intervals. Proportionality of hazards was tested graphically 
by inspection of log–log survival curves and by a formal test of proportionality based 
on Schoenfeld residuals for each variable in the model. Calibration refers to whether 
the model agrees with the observed probabilities and was assessed with the Hosmer–
Lemeshow statistic. 
All statistical tests were 2-tailed, and p-values were significant at <0.05. Analysis 
was performed using SPSS software version 17.0 (SPSS, Chicago, USA).
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Results
We identified 14,434 consecutive patients hospitalised for MI in our center between 
1985 and 2008: 6,820 STEMI and 7,614 NSTEMI patients. At three years follow-up, 
mortality had occurred in 2,190 patients, 1,232 in STEMI and 958 in NSTEMI patients.
ST-segment elevation myocardial infarction
The characteristics of the STEMI patients are depicted in Table 1. With time, STEMI 
patients presented older, were more likely to have diabetes, hyperlipidemia, anemia, 
and a history of PCI. Further, STEMI patients were less likely to present with renal 
dysfunction or a history of MI. 
The percentage of STEMI patients treated with PCI increased gradually. Before 1985, 
neither intracoronary- nor intravenous thrombolytic therapy was employed, while 
intra venous fibrinolysis was the main treatment modality from 1985 to 1998. From 
1998 onwards, treatment with thrombolysis was gradually replaced by primary PCI 
(Figure 1). Since our institution was initially the only hospital with PCI facilities in 
the region, the number of patients with STEMI admitted increased as a result of the 
decision to offer primary PCI to all STEMI patients in the Rotterdam Region. In the most 
recent cohort, drug therapy with aspirin, beta-blockers, statins, and ACE inhibitors or 
angiotensin receptor blockers was quite common, but calcium antagonists, diuretics 
or nitrates were prescribed less frequently.
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 Figure 1: Treatment of STEMI patients over time
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table 1:  Baseline characteristics, clinical presentation, and discharge medication of patients 
hospitalised for SteMI
period of admission p
1985-1990 1990-2000 2000-2008
No. of patients 947 1928 3945
Baseline
Age (years) 60 ±11.6 60 ±12.7 61 ±12.6 0.01
Gender (male) 731 (77%) 1432 (74%) 2937 (75%) 0.20
Cardiac history
Previous MI 334 (35%) 463 (24%) 1075 (27%) <0.001
Previous PCI 43 (5%) 127 (7%) 653 (17%) <0.001
Previous CABG 83 (9%) 124 (6%) 282 (7%) 0.09
risk factors
Hypertension 320 (34%) 549 (29%) 1295 (33%) <0.01
Diabetes 79 (8%) 204 (11%) 571 (14%) <0.001
Hyperlipidemia 76 (8%) 295 (15%) 919 (23%) <0.001
Family history 201 (21%) 400 (21%) 1062 (27%) <0.001
Current smoker 403 (43%) 675 (35%) 1518 (39%) <0.001
Renal dysfunction 104 (11%) 229 (12%) 179 (5%) <0.001
Anemia 309 (33%) 818 (42%) 1464 (37%) <0.001
Medication at ICCU discharge
Statin 0 (.) NA 2996 (76%) <0.001
Aspirin 97 (10%) 1200 (62%) 3510 (89%) <0.001
Beta­blocker 412 (44%) 958 (50%) 2341 (59%) <0.001
Calcium antagonist 306 (32%) 315 (16%) 174 (4%) <0.001
Nitrates 220 (23%) 241 (13%) 190 (5%) <0.001
Diuretics 334 (35%) 306 (16%) 321 (8%) <0.001
ACE inhibitor or ARB 0 (.) 403 (21%) 1308 (33%) <0.001
 ACE, Angiotensin­Converting Enzyme; ARB, Angiotensin receptor blocker; CABG, coronary artery 
bypass grafting surgery; ICCU, intensive coronary care unit; MI, myocardial infarction; NA, not available; 
PCI, percutaneous coronary intervention; STEMI, ST­elevation MI.
At 30 days following admission, cumulative mortality rate decreased from 17% in 
1985-1990 to 13% in 1990-2000, and to 6% in 2000-2008 (p < 0.001; Figure 2). Adjusted 
30-day mortality in the last period was 80% lower than in 1985 (adjusted odds ratio 
(OR) 0.20, 95%CI 0.14-0.28, p < 0.001) (Figure 3). 
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Figure 2: Kaplan­Meier curves for 30­day cumulative mortality (Figure 2A) or three­year 
cumulative survival (Figure 2B) according to calendar period of admission 
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Figure 3: Adjusted odds or hazard ratios of secular trends in mortality after STEMI at 30­days 
(Figure 3A), at 3­year (Figure 3B), and at 3­year among 30­day survivors (Figure 3C). The upper 
part of the figure compares changes in mortality in time periods of three year, the lower part 
among patients hospitalised between 1985­1990; 1990­2000; and 2000­2008  
*   Reference category for the subsequent ratios CI, confidence interval; HR, Hazard ratio; OR, Odds 
ratio, STEMI, ST­elevation myocardial infarction
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Cumulative three-year survival rate increased from 73% in 1985-1990 to 75% in 
1990-2000 and to 87% in 2000-2008 (p < 0.001). Adjusted three-year mortality in the 
last period was 68% lower than in 1985 (adjusted hazard ratio (HR) 0.32, 95%CI 0.26-
0.40, p < 0.001). In a landmark analysis, including only patients who survived the first 
30 days, adjusted three-year mortality was 57% lower in the most recent period than 
in 1985 (adjusted HR 0.43, 95%CI 0.31-0.58, p < 0.001, Figure 3). 
Non-ST-segment elevation myocardial infarction
With time, NSTEMI patients presented older, were more likely to have hypertension, 
diabetes, hyperlipidemia, or anemia and less likely to be a smoker (Table 2). Furthermore, 
NSTEMI patients more often presented with a history of PCI and less often presented 
with a history of MI in the most recent study period. As in STEMI, prescription of aspirin, 
beta-blockers, statins, and ACE inhibitors or angiotensin receptor blockers increased 
while the use of calcium antagonists and nitrates decreased. 
At 30 days following admission, cumulative mortality rate decreased from 6% in 
1985-1990 to 4% in 1990-2000, and to 2% in 2000-2008 (p < 0.001; Figure 4). Adjusted 
30-day mortality in the last period was 78% lower than in 1985 (adjusted OR 0.22, 
95%CI 0.13-0.37, p < 0.001; Figure 5).
Cumulative three-year survival rate did not significantly change between 1985-
1990 (85%) and 1990-2000 (86%). Three-year survival in the last period was 88% (p 
< 0.001). Adjusted three-year mortality in the last period was 49% lower than in 1985 
(adjusted HR 0.51, 95%CI 0.39-0.68, p < 0.001). In a landmark analysis, including only 
patients who survived the first 30 days, adjusted three-year mortality was 29% lower 
in the most recent period than in 1985 (adjusted HR 0.71, 95%CI 0.52-0.99, p = 0.042, 
Figure 5).
For patients admitted between 2000 and 2008, long term survival of STEMI and 
NSTEMI patients was comparable, 87% and 88%, respectively (Figures 2 and 4). The 
higher subsequent mortality in non-STEMI patients resulted from their older age. 
After correction for this confounder, the risk of 30-day to three-year mortality was 
similar in NSTEMI and STEMI (adjusted HR 1.0, 95%CI 0.86-1.2).
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table 2: Baseline characteristics, clinical presentation, and discharge medication of patients 
hospitalised for NSteMI
period of admission
p
1985-1990 1990-2000 2000-2008
No. of patients 1269 2672 3673
Baseline
Age (years) 61 ±10.3 63 ±11.7 63 ±11.8 <0.001
Gender (male) 921 (73%) 1806 (68%) 2575 (70%) <0.01
Cardiac history
Previous MI 581 (46%) 1050 (39%) 1290 (35%) <0.001
Previous PCI 130 (10%) 356 (14%) 757 (21%) <0.001
Previous CABG 196 (15%) 292 (12%) 390 (11%) <0.001
risk factors
Hypertension 455 (36%) 881 (34%) 1604 (44%) <0.001
Diabetes 95 (8%) 321 (12%) 745 (20%) <0.001
Hyperlipidemia 159 (13%) 736 (24%) 1785 (49%) <0.001
Family history 331 (26%) 666 (25%) 1122 (31%) <0.001
Current smoker 459 (36%) 741 (28%) 880 (24%) <0.001
Renal dysfunction 102 (8%) 222 (8%) 349 (10%) 0.20
Anemia 489 (39%) 1153 (43%) 1783 (49%) <0.001
Medication at ICCU discharge
Statin 0 (.) NA 1962 (68%) <0.001
Aspirin 225 (18%) 1169 (55%) 3125 (85%) <0.001
Beta­blocker 865 (68%) 1271 (60%) 2334 (64%) <0.001
Calcium antagonist 884 (70%) 972 (46%) 515 (14%) <0.001
Nitrates 475 (37%) 393 (19%) 335 (9%) <0.001
Diuretics 240 (19%) 276 (13%) 337 (9%) <0.001
ACE inhibitor or ARB 0 (.) 191 (7%) 1134 (31%) <0.001
 ACE, Angiotensin­Converting Enzyme; ARB, Angiotensin receptor blocker; CABG, coronary artery bypass 
grafting surgery; ICCU, intensive coronary care unit; MI, myocardial infarction; NA, not available; NSTEMI, 
non­ST­elevation MI; PCI, percutaneous coronary intervention.
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Figure 4: Kaplan­Meier curves for 30­day cumulative mortality or (Figure 4A) or three­year 
cumulative survival (Figure 4B) according to calendar period of admission
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Figure 5: Adjusted odds or hazard ratios of secular trends in mortality after NSTEMI at 30­ days 
(Figure 5A), at 3­year (Figure 5B), and at 3­year among 30­day survivors (Figure 5C ).  
The upper part of the figures compares changes in mortality in time periods of three year, the 
lower part among patients hospitalised between 1985­1990; 1990­2000; and 2000­2008 
*   Reference category for the subsequent ratios CI, confidence interval; NSTEMI, non­ST­elevation 
myocardial infarction; HR, Hazard ratio; OR, Odds ratio
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Discussion
We have shown that, during a period of almost 25 years, overall 30 day mortality 
in patients hospitalised for MI was reduced with 80%. In patients admitted for ST-
segment elevation MI (STEMI), 30-day mortality declined from 17% to 6%. In patients 
with a smaller, non ST-segment elevation MI (NSTEMI) 30-day mortality declined 
from 6% to 2%. In addition, we demonstrated that this early survival benefit was 
maintained over three years of follow-up, with long term survival increasing from 
73% to 87% and from 85% to 88% in STEMI and NSTEMI, respectively. The reduction in 
long- term all-cause mortality is illustrative of the strength of the improvement of the 
combined treatment effects.
There can be little doubt that such improvements have resulted from changes 
in medical therapy, both pharmacological as well as interventional. [20] The most 
important factors must have been the introduction of reperfusion therapy in the form 
of fibrinolytic therapy and later primary PCI for STEMI, [1,8] as well as the more frequent 
use of revascularization in selected patients with NSTEMI. Also, the introduction 
and subsequent employment of medical therapies including statins, and ACE 
inhibitors or angiotensin receptor blockers must have played a role. Of course, patient 
characteristics also gradually changed during the observation period. However, most 
of the observed alterations in our patient’s phenotypes, like increasing age and more 
co-morbidity such as diabetes and renal dysfunction, have previously been associated 
with impaired outcomes and do not account for the observed outcome improvement. 
A reduction in case fatality in spite of treating older patients with co-morbidity has 
also been observed in other observational studies. [20,21,22] Earlier clinical presentation 
could have contributed to improved prognosis, but we found no evidence for this. 
Better primary prevention could have influenced the severity of the acute clinical 
event, and better secondary prevention must also have contributed significantly. 
Exact details of the medication use of our patients after discharge are not known, but 
registries in our region in 1995, 2001 and 2006 indicated that the use of preventive 
medication significantly intensified during that time. [14] For instance, statins were 
used by 36%, 72% and 93% of the patients respectively, with a subsequent drop in 
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mean cholesterol level from 6.2 mmol/l in 1995 to 4.2 mmol/l in 2006. Aspirin was 
used by >90% of the patients from 1995 onwards, and smoking trends decreased from 
32% to 15% between 1995 and 2006. [14]
With time, the number of patients admitted with myocardial infarction increased. 
This was mainly the result of changes in referrals: when primary PCI became the 
treatment of choice in STEMI patients, they were specifically referred to our center from 
2000 onwards. Our STEMI patients can therefore be considered to be representative 
for this syndrome and we thus believe that the decrease in mortality in this group is 
broadly illustrative of current clinical practice. The number of NSTEMI patients also 
increased. Most likely, this was also due to changes in referrals, in particular of high 
risk patients in whom invasive therapy was warranted. Therefore, our population 
with this type of acute coronary syndrome will probably be less representative for 
that group at large. Still, given their already low mortality, the further decline in 30-
day mortality in this group with time was also impressive. 
Other studies, such as The National Registry of Myocardial Infarction, Worcester 
Heart Attack Study and Minnesota Heart Survey, [19,20,23,24,25,26,27,28] have described 
prognostic time trends after acute MI, but none of these covered both i) secular trends 
for a period longer than 10 years from 1990 and ii) follow-up data after the first 30-
days; as the present study does. 
Although the present study thus has unique strengths, some of its limitations must 
be emphasized. First, the present data are derived from a single center. Although this 
will have enhanced the quality of the data and the observed secular trends, this could 
result in a lower external validity. However, this is unlikely, since a nation wide study 
in Sweden and a state wide study in the US reported quite comparable results. [21,29] 
Second, based on our data, it is not possible to establish changes in MI incidence as 
other studies have shown. Still, the increasing age of our population provides indirect 
evidence of a lower incidence rate of myocardial infarction. Lastly, the current report 
is based on hospitalised patients, and we are therefore unable to assess the changes in 
mortality of all patients who suffered a myocardial infarction but died before clinical 
presentation. 
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Conclusions
Our results indicate very substantial improvements in acute and long term survival in 
patients hospitalised for MI, related to improved acute- as well as long-term treatment. 
Since the early survival benefit is maintained over time, the present results emphasize 
that efforts to further reduce in-hospital mortality must be rigorously pursued, and 
that early medical evaluation in suspected MI and intensive early hospital treatment 
remain warranted. Although one might envisage even lower hospital mortality rates 
associated with acute MI in the future, absolute treatment benefits will become smaller 
because of the current low mortality levels. Indirectly therefore, our data emphasize 
the need for better and more effective primary prevention, as well as the necessity to 
target high risk MI subgroups such as the elderly and those with heart failure. 
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Abstract
Cardiovascular disease is the main cause of death in patients with renal impairment. 
We examined temporal trends in treatment and mortality after myocardial infarction 
(MI) depending on renal function at presentation. Therefore, we studied 12 087 patients 
admitted for MI to a coronary care unit from 1985 to 2008. In line with the Kidney 
Foundation practice guidelines patients were categorized into normal renal function 
(eGFR >90 ml/min per 1.73 m2) stage 2 (60-89), stage 3 (30-59), and stage 4-5 (<30) 
chronic kidney disease (CKD). A total of 8632 (71%) of the 12 087 patients had stage 2-5 
CKD. Use of evidence-based care increased over time in all groups according to renal 
function. Mortality rates fell over the period. Adjusted 30-day mortality fell (adjusted 
odds (2000-2008 vs. 1985-1990) 0.33 (95% CI 0.18-0.60) in patients with stage 4-5 CKD, 
and 0.21 (95% CI 0.10-0.42) in those without renal impairment). This mortality decrease 
sustained during long-term follow-up. There was no significant interaction between 
renal function and decade of admission. Overall, median survival was >20, 15, 8 and 
1.8 years for patients with normal renal function, stage 2, stage 3 and stage 4-5 CKD, 
respectively. In conclusion, during the past 25 years, treatment of patients with an MI 
improved substantially with a concomitant decline in mortality that was similar for 
all stages of renal function, however, prognosis remains poor after stage 4-5 CKD.
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Introduction
Cardiovascular disease is the single largest cause of death in patients with renal 
impairment or progressive primary renal disease, and these cardiovascular deaths 
often occur before end stage renal failure has been reached. [1] Studies of myocardial 
infarction (MI) have reported that MI patients with renal dysfunction have a worse 
in-hospital survival. [1-5] Furthermore, recent data suggests that such patients are less 
likely to receive evidence-based therapies, although increased usage of evidence-
based medical treatment has significant potential to reduce mortality in MI patients 
with renal dysfunction. [6-7] 
Within the past 25 years, major improvements in the treatment of MI have been 
implemented, including thrombolytic therapy and primary percutaneous coronary 
intervention (PCI) for ST-elevation MI (STEMI), as well as more intensive management 
according to individual risk assessment in patients with a non-STEMI (NSTEMI). [8] A 
longitudinal analysis of MI patients with different stages of renal dysfunction will 
identify temporal changes in the use of treatment modalities, as well as temporal 
trends in early and late outcomes according to renal function. 
Against this background, the aims of our study were threefold. First, to determine 
inequalities and changes in medical care in patients with MI with different levels 
of renal dysfunction over a 24-year period. Second, to compare temporal trends in 
mortality according to renal function for patients admitted with an MI. And third, to 
quantify the effect of different stages of renal impairment on short- and long-term 
mortality after MI.
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Results
Patient characteristics
A total of 12 087 patients were included, of whom, 5 598 (46%), 2 504 (21%) and 530 (4%) 
had stage 2, stage 3 and stage 4-5 chronic kidney disease (CKD), respectively (Table 1). 
A total of 92 712 person-years were analyzed. The number of patients and total number 
of events after MI according to decade of hospitalization and renal function is shown in 
Table 2.
table 1: Baseline characteristics and clinical presentation of patients hospitalized for myocardial 
infarction according to renal function at hospitalization. 
renal function (eGFr) on admission
p  
for trendNormal (>90 ml/ min 
per 1.73 m2)
Stage 2 CKD 
(60 to 90)
Stage 3 CKD 
(30 to 60)
Stage 4-5 
CKDa 
(<30)
No. of patients 3455 (29%) 5598 (46%) 2504 (21%) 530 (4%)
Baseline
Age (±SD) 53±10 63±11 69±10 68±11 <0.001
Gender (female) 19% 27% 40% 37% <0.001
Cardiac history
Previous MI 30% 34% 39% 40% <0.001
Previous PCI 15% 15% 12% 12% <0.01
Previous CABG 7% 10% 13% 12% <0.001
risk factors
Hypertension 31% 35% 41% 56% <0.001
Diabetes 13% 13% 17% 24% <0.001
Hyperlipidemia 29% 28% 22% 22% <0.001
Family history 32% 27% 19% 14% <0.001
Current smoker 47% 30% 20% 16% <0.001
Anemia 19% 21% 34% 69% <0.001
eGFR (median, IQR) 102 (94­114) 76 (69­83) 52 (45­57) 21 (12­27) <0.001
Diagnosis
STEMI 53% 43% 44% 49% <0.001
Medication at ICCU discharge
Ca­antagonist 19% 26% 30% 32% <0.001
Diuretics 8% 12% 27% 30% <0.001
Nitrates 10% 15% 20% 25% <0.001
Antiarrhythmics 3% 4% 7% 8% <0.001
 CABG, coronary artery bypass surgery; ICCU, intensive coronary care unit; MI, myocardial infarction; PCI, 
percutaneous coronary intervention. 
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table 2: Study population outline: the number of patients at risk and total number of events  after 
myocardial infarction stratified by decade of hospitalization and renal function. 
Decade of hospitalization for myocardial infarction
1985-1990 1990-2000 2000-2008
total no. events/ No. at risk 
renal (dys)function
Normal (>90) 172/343 372/1183 179/1929
Stage 2 CKD (60 to 90) 667/1073 953/1824 452/2701
Stage 3 CKD (30 to 60) 520/607 697/900 370/997
Stage 4­5 CKD (<30) 99/105 191/209 139/216
Renal (dys)function in ml/min per 1.73 m2. 
With increasing renal impairment, patients were older, more often female; more 
often had a history of MI or coronary artery bypass surgery (CABG), hypertension, 
diabetes and anemia. In contrast, with increasing renal impairment patients were 
less often current smokers, less often had hypercholesterolemia, or a family history of 
previous MI (Table 1). With time, more patients presented with normal renal function 
and less with moderate to severe renal dysfunction (Figure 1).
Figure 1: Distribution of study population according to renal function and study period.
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Figure 2: Treatment of patients over time: use of reperfusion therapy in ST­segment elevation 
myocardial infarction (A) and use of evidence­based medical care in myocardial infarction patients 
(B and C). ACE denotes angiotensin­converting enzyme inhibitor; ASA, aspirin; ARB, angiotensin 
receptor blocker; PCI, percutaneous coronary intervention; ThT, thrombolytic therapy. Cochran 
statistic with correction for calendar period was used to calculate P values between normal and 
severe renal impairment.
 
table 3: temporal trends of 30-day and 5-year mortality for all patients and for subgroups 
according to renal function at hospitalization for myocardial infarction.
all patients
Normal 
(>90 ml/ min  
per 1.73 m2)
Stage 2 CKD 
(60 to 90)
Stage 3 CKD 
(30 to 60)
Stage 4-5 CKD 
(<30)
Calendar period
adjusted odds ratios for 30-day mortality
1985­90 Reference Reference Reference Reference Reference
1990­2000 0.75 (0.62­0.91) 0.38 (0.19­0.75) 0.61 (0.44­0.84) 1.0 (0.75­1.4) 0.60 (0.35­1.1)
2000­08 0.40 (0.32­0.49) 0.21 (0.10­0.42) 0.33 (0.24­0.47) 0.54 (0.38­0.76) 0.33 (0.18­0.60)
adjusted hazard for mortality during 5 year among 30-day survivors
1985­90 Reference Reference Reference Reference Reference
1990­2000 1.2 (1.1­1.4) 1.1 (0.70­1.7) 1.2 (0.97­1.5) 1.2 (0.97­1.5) 1.23 (0.83­1.8)
2000­08 0.90 (0.78­1.0) 0.85 (0.55­1.31) 0.80 (0.63­1.0) 0.96 (0.76­1.23) 0.90 (0.60­1.4)
 
Adjusted for age, gender, previous MI, previous CABG, hypertension, diabetes, hyperlipidemia, family history, 
smoking status, renal dysfunction, anemia and diagnosis.
P interaction = 0.15 and = 0.68, at 30 days and 5 years, respectively.


















       




















  

  
  


 
 



 






















  

  
  





 

 


 




 

 



















  

  
  





 

 


 




 


Chapter 4.    Renal function and mortality after MI     |     39
Medical and invasive treatment during the study period
The use of reperfusion therapy (either by thrombolytic therapy or primary PCI) 
increased over time in all four groups according to renal function with STEMI 
(p<0.001). However, patients with severe renal impairment in particular were less 
likely to receive reperfusion therapy during the entire study period as compared to 
patients with normal renal function (p<0.001) (Figure 2 A). In addition, prescription 
of evidence-based medical care (class 1A), including aspirin, ß-blockers, and statins 
increased over time, but was less frequent in patients with severe renal impairment 
(p<0.001 for all) (Figure 2 B and C). Prescription of other medical therapy with a lower 
level of evidence for the treatment of MI, including calcium-antagonists, nitrates and 
diuretics at Intensive Coronary Care Unit (ICCU) discharge was higher in patients with 
renal impairment (Table 1). 
Temporal trends in mortality 
In the overall study population, Kaplan-Meier short-term (30-day) mortality decreased 
from 10% in 1985-90 to 4% in 2000-08. The magnitude of this decrease was comparable 
for the merged group of patients with stage 2-5 CKD (estimated Glomerular Filtration 
Rate (eGFR) < 90 ml/min per m2): their 30-day mortality decreased from 11% in 1985-90 
to 6% in 2000-08. Similarly, for the study population as a whole, 5-year Kaplan-Meier 
mortality decreased from 24% in 1985-90 to 19% in 2000-08; for patients with stage 
2-5 CKD a reduction in 5-year mortality was observed from 26% in 1985-90 to 24% in 
2000-08. 
From 1985 to 2008, the adjusted risk of 30-day mortality decreased by about 60% 
in the whole study population (adjusted OR 0.40, 95%CI: 0.32-0.49). Although there 
was no statistical heterogeneity in this temporal mortality decrease among all four 
subgroups according to renal function (p = 0.15), 30-day mortality appeared to decrease 
less over time in patients with stage 2-5 CKD (Table 3). 
The improvement of short-term mortality was sustained during long-term follow-
up. Among 30-day survivors, the long-term mortality hazard was 10% lower in 2000-
2008 compared to 1985-1990 (adjusted hazard ratio, HR 0.90, 95%CI: 0.78-1.0). Again, 
there was no statistical heterogeneity in this temporal mortality decrease among all 
four subgroups according to renal function (p = 0.68) (Table 3).
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Renal function and Mortality 
Unadjusted mortality at 30 days after MI was much higher in patients with renal 
impair ment (25% in patients with severe renal impairment vs. 2% in those with normal 
renal function, p<0.001). This was also true during long-term follow-up (92% at 15 year 
in patients with severe renal impairment vs. 47% at 20 year in those with normal renal 
function, p<0.001) (Figure 3). Median survival in patients with stage 2, stage 3 and stage 
4-5 was 15 years, 8 years and 22 months (1.8 years) respectively, compared to >20 years 
in patients with normal renal function. Adjusted mortality for stage 2, stage 3 and stage 
4-5 CKD was 2.1, 4.3, and 8.6 fold higher at 30 days, while the long-term hazard was 1.0, 
1.5, and 3.4, fold higher, respectively, compared to patients with normal renal function 
(Table 4). 
Figure 3: Kaplan­Meier curves of mortality according to renal function.
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In a secondary analysis, unadjusted mortality at 30 days was comparable between 
patients with stage 4 CKD (eGFR 15-30, n = 332) and stage 5 CKD (eGFR<15, n = 198) 
(26% vs. 22%, respectively, p = 0.28), but, compared to stage 4 CKD, unadjusted 5-year 
mortality was higher in patients with stage 5 CKD (63% vs. 79%, respectively; p < 0.01). 
Compared to normal renal function, adjusted 30-day mortality was 8.5 (95%CI: 5.7-13) 
and 8.8 -fold (5.5-14) higher in patients with stage 4 and stage 5 CKD, respectively. The 
adjusted hazard for mortality between 30 days and 5 year was 3.3 (2.6-4.2) and 8.0-
fold (6.3-10) higher in patients with stage 4 and stage 5 CKD, respectively, compared to 
normal renal function.
table 4: Unadjusted and adjusted odds and hazard ratios of mortality depending on renal function 
at hospitalization for myocardial infarction. 
Odds ratios for 30-day mortality
Unadjusted adjusted* 
renal (dys)function
Normal (>90 ml/min per m2) Reference Reference
Stage 2 CKD (60 to 90) 2.8 (2.1­3.7) 2.1 (1.5­2.8)
Stage 3 CKD (30 to 60) 8.0 (6.1­10) 4.3 (3.2­5.9)
Stage 4­5 CKD (<30) 17 (13­24) 8.6 (6.0­12)
hazard for mortality during 20 year among 30-day survivors
Normal Reference Reference
Stage 2 1.7 (1.5­1.8) 1.0 (0.91­1.1)
Stage 3 3.6 (3.2­3.9) 1.5 (1.3­1.6)
Stage 4­5 8.3 (7.2­9.5) 3.4 (2.9­4.0)
 
* Adjusted for the same variables as Table 2 and decade of hospitalization.
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Discussion
This analysis of MI patients showed changes in treatment and outcome depending on 
renal function over 24 years of observation. During the past decades, treatment of MI 
improved in all groups of renal function, but patients with stage 4-5 renal dysfunction 
were less likely to receive evidence-based medical treatment and reperfusion therapy. 
Temporal trends in 30-day mortality reveal impressive mortality reductions during 
this 24-year period that were comparable for all stages of renal function and were 
sustained during long-term follow-up. Although the outcome after MI improved 
across the whole range of renal function, we showed that renal dysfunction remains a 
strong risk factor for increased both short- and long-term mortality.
Treatment of patients with MI and renal dysfunction is a challenge. As in the 
present study, previous studies [2-6, 9-10] showed that patients with increasing renal 
dysfunction and MI are less likely to receive cardio-protective therapies, including 
invasive treatment or reperfusion therapy. Some studies have reported that patients 
with stage 3-4 CKD and impeding dialysis, are less likely to receive percutaneous 
coronary interventions compared to patients already on dialysis. [6, 11] This suggests 
that fear for contrast-induced nephropathy influences treatment decisions. However, 
we as well as others [3-5,12-13] observed a proportional decrease in the use of percutaneous 
coronary interventions and other cardio-protective therapies with decreasing renal 
function. Other reasons for withholding treatment modalities might include medical 
uncertainty as most randomized controlled trials of MI have excluded subjects with 
renal dysfunction. [14] In addition, renal dysfunction is associated with anemia and an 
increased risk of bleeding . [2,15] Furthermore, patients with renal dysfunction more 
often have a delayed or an atypical presentation. [16] All these factors could affect 
treatment decisions, lead to reduced use of evidence-based reperfusion therapy and, 
ultimately, result in impaired outcome. The treatment discrepancies provide a window 
of opportunity to improve care in MI patients with renal impairment. [17-21] It is therefore 
encouraging to observe a persistent temporal increase in the use of such therapies 
among all groups according to renal function during our 24-year study period, and 
this provides evidence that improved clinical care in these patients is indeed possible. 
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No previous study compared temporal improvement in outcome according to 
different stages of renal function for almost a quarter of a century. We observed 
comparable temporal reductions in adjusted 30-day and long-term mortality across 
all stages of renal function. There can be little doubt that such improvements 
have resulted from changes in medical therapy, both pharmacological as well as 
interventional. [4, 17-21] The most important factors must have been the introduction 
of reperfusion therapy in the form of fibrinolytic therapy and later primary PCI for 
STEMI, as well as the more frequent use of revascularization in selected patients with 
NSTEMI. [8] Also, the introduction and subsequent employment of medical therapies 
including aspirin, statins, and ACE inhibitors or angiotensin receptor blockers must 
have played a role. In our study, there was no statistically significant heterogeneity 
for temporal trends according to renal function. The observation that the mortality 
reduction in the contemporary era was least prominent in patients with moderate 
renal impairment was probably due to chance. Our results are encouraging and the 
application of evidence-based MI therapies to appropriate patients regardless of renal 
function may even further improve these outcomes in the future.
Short-term mortality after MI deteriorated with every decline in renal function, 
including the decline from normal to mild renal (dys-)function (i.e. to stage 2 CKD). 
Patients with stage 4-5 CKD had a more than eight fold increased mortality rate 
compared to normal renal function after adjustment for baseline characteristics. 
These findings are consistent with previous studies. [3, 6, 22] Our data is unique in that 
it comprises survival data for up to 20 years after MI which is a whole life course for 
patients with stage 4-5 CKD. On the long-term, renal dysfunction remained associated 
with increased mortality. 
Limitations
There are some limitations to the present study. First, because the data is derived from 
a hospital-based registry, patients who died before admission to the hospital were by 
definition excluded from the registry. This might be in particular NSTEMI patients 
with advanced renal disease because in those patients the diagnosis of NSTEMI 
may be problematic due to the absence of “typical” symptoms and uninterpretable 
ECGs. [16] Therefore, the detrimental effect of stage 4-5 CKD on short-term mortality 
could have been underestimated. However, this has unlikely affected our temporal 
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trend analyses because these diagnostic issues were present during all past decades 
studied. Second, the assessment of creatinine at admission for MI might have 
resulted in unfavorable renal function estimates due to the effect of the acute event 
–including acute kidney injury— on the creatinine concentration. However, this is 
unlikely, since hemodynamic instability leading to renal dysfunction typically occurs 
later during the course of MI. Also, renal function was estimated using creatinine-
based GFR equations, and these estimates might not perfectly correlate with actual 
renal function.23 Still, this should not affect the validity of our results since these 
estimates are central for clinical assessment of kidney function. Third, the present 
data are derived from a single center. Although this could result in a lower external 
validity, we think that this is unlikely because the observed association between renal 
impairment and 30-day mortality corresponds well with that in previous reports. The 
relatively high proportion of patients with STEMI reflects the function of our center 
as referral center for these patients. Fourth, information on left ventricular ejection 
fraction or Killip class is unavailable for analyses.
Conclusion
Renal function is an important and independent predictor for both short- and long-term 
mortality after acute MI. Even though patients with stage 4-5 CKD remained less likely 
to receive evidence-based medical care and reperfusion therapy, temporal reductions 
in 30-day and long-term mortality during the past decades were substantial and were 
independent of renal function. Thus, patients with renal impairment also benefitted 
from improved outcomes over the past decades. This encouraging observation should 
stimulate the use of evidence based treatment in MI patients regardless of renal 
dysfunction. 
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Methods 
We considered all 14 434 consecutive patients aged >18 years admitted with STEMI or 
NSTEMI to the ICCU of the Thoraxcenter, Erasmus University Medical Center between 
June 1985 and December 2008. Of these 12 087 patients (84%) had at least one baseline 
creatinine value, and these patients thus constitute the study population.
The diagnosis of MI was made by the attending physician in the presence of the 
following characteristics: chest pain or equivalent symptoms in combination with 
dynamic ECG changes consistent with MI and a serial rise (to at least three times the 
upper normal value) and fall in serum biochemical markers of cardiac necrosis such 
as creatine kinase-MB and troponin-T (as of 2002). Patients were diagnosed as STEMI 
in the presence of ST-segment elevation > 0.1 mV in at least two peripheral leads, > 0.2 
mV in at least two precordial leads or new left bundle branch block, and as NSTEMI 
otherwise. The proportion of patients with STEMI or NSTEMI was about 50% in each 
decade of study. For patients admitted more than once, only the first hospitalization 
was taken into account. 
In line with the US National Kidney Foundation practice guidelines, [24] patients 
were categorized as having normal renal function (eGFR > 90 ml/min per 1.73 m2 body 
surface area), stage 2 (60-89), stage 3 (30-59), and stage 4-5 (<30) CKD. In a secondary 
analysis, patients with severe renal impairment were recategorized into those with 
stage 4 (eGFR 15-30) and stage 5 (eGFR < 15) CKD.
Serum creatinine was assessed by a nonkinetic alkaline picrate (Jaffe) method. [25] 
GFR was estimated with the CKD-EPI equation [23]: eGFR (ml/min per 1.73 m2 body 
surface area) = 141 x min (creatinine/κ, 1) α x max (creatinine /κ, 1)–1.209 x 0.993age x 1.018 
(if female) x 1.159 (if black), where κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min indicates the minimum of creatinine/κ or 1, and max 
indicates the maximum of creatinine/κ or 1. All analyses were also performed using 
the Modification of Diet in Renal Disease (MDRD) equation, [26] this did not result in 
significantly different results (not shown). 
Ch
ap
te
r 
4
46     |     Myocardial infarction: temporal trends over the past three decades
Trained physicians and nurses accustomed to the use of standardized case report 
forms collected the data, using definitions that have previously been described. [27] The 
study endpoint was all–cause mortality at 30 days and at 20 years. Survival status was 
assessed through municipal Civil Registries in 2010 and was available for 99% of all 
patients. 
This project was carried out in accordance with current rules of ethics and 
legislature. No additional actions involving the study participants were undertaken 
because of this registry. Register-based studies are approved by the ethical committee 
of the Erasmus Medical Center.
Statistical Analysis 
Categorical variables were summarized as percentages and the chi-square test for 
trend was used to calculate p-values. Age was normally distributed according to the 
Kolmogorov-Smirnov test and therefore summarized as mean and 95% confidence 
interval. The analysis of variance test (ANOVA) was used to calculate a p-value for age 
differences. Renal function values were presented as medians and interquartile range 
and compared with the Kruskal-Wallis test.
Patients were stratified in three groups according to decade of hospitalization: 1985-
1990; 1990-2000; 2000-2008. We assessed temporal trends in outcome by comparing 
these three periods. We examined the independent association between decade of 
hospitalization and mortality, for each stage of renal function, using logistic regression 
for 30-day outcome and the Cox proportional hazards model for long-term outcome 
(among 30-day survivors). Adjustment was performed for age, gender, previous MI, 
previous CABG, hypertension, diabetes, hyperlipidemia, family history, smoking 
status, anemia and STEMI/NSTEMI diagnosis. Information on anemia was missing 
in 324 of the patients (2.7%). The influence of decade on mortality was examined with 
a formal interaction test by adding decade crossed with renal function to the model. 
In addition, we examined the independent association between renal function and 
mortality using the analyses described above. 
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Results are reported as odds ratios (OR) –for 30-day mortality– and hazard ratios (HR) 
–for long-term mortality– and their respective 95% confidence intervals. All statistical 
tests were 2-tailed, and p-values were considered significant at <0.05. Analysis was 
performed using SPSS software version 20.0 (SPSS, Chicago, Ill).
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Abstract
Anemia is not uncommon in hospitalized cardiac patients and is associated with 
adverse outcomes. The aim of this study was to identify the association of anemia 
with early and long- term outcome in patients with Acute Coronary Syndromes 
(ACS). A total of 5304 consecutive patients (73% men, 61 ±12 years of age) admitted to a 
coronary care unit between 1985 and
2008 for ACS, were included. According to the WHO, anemia was defined as serum 
hemoglobin levels <13 g/dl for men and <12 g/dl for women. Anemia was divided into 
tertiles to compare mild, moderate and severe anemia with nonanemia. With respect 
to trend analyses, the study population was categorized in three groups: 1985-1990; 
1991-2000; and 2001-2008. Outcome measurements were all-cause mortality at 
30-days and 20 years.
Anemia was present in 2016 (38%) patients, of whom 655 had mild anemia, 717 
moderate anemia and 646 severe anemia. Median follow-up duration was 10 years 
and ranged from 2 to 25 years. When comparing to nonanemia, adjusted hazard ratios 
for mortality at 30-days were 1.40 for moderate anemia (95%CI 1.04-1.87) and 1.67 
for severe anemia (95%CI 1.25-2.24). At 20-year, hazard ratios were 1.13 for moderate 
anemia (95%CI 1.01-1.27), and 1.39 for severe anemia (95%CI 1.23-1.56). Additionally, 
survival during hospitalization improved over time. Compared to 1985-1990 adjusted 
hazard ratios were 0.52 for 1991-2000 (95%CI 0.41-0.66) and 0.36 for 2001-2008 
(95%CI 0.25-0.51). In conclusion, the presence and severity of anemia is an important 
predictor of higher in-hospital- and long-term-mortality after ACS. Additionally, since 
the 1980’s, in-hospital outcome of ACS patients with anemia has improved.
Keywords
Anemia, acute coronary syndromes, trends, prognosis.
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Introduction
Anemia is not uncommon in patients hospitalized for Acute Coronary Syndromes (ACS) 
and its prevalence ranges from 6.4% to 45%. [1-5] It is associated with adverse outcomes 
during hospitalisation. [2,4-6] Although adverse outcomes in other populations due to 
anemia have been described, [7-11] only a very few studies have examined the long-term 
effects of anemia in ST-elevation Myocardial Infarction (STEMI) and nothing is yet 
known whether this association changed over the last 25 years. In the past decades, 
new therapeutical and medical treatment interventions were introduced that reduced 
morbidity and enhanced survival after acute myocardial infarction. These strategies 
include the use of reperfusion therapy, antiplatelet agents, ACE- inhibitors, and 
β-blockers. [12-15] Furthermore, percutaneous coronary intervention (PCI) became the 
therapeutic modality of first choice in STEMI patients. [13,16,17] The effect of anemia in 
these patients has not been studied yet. And therefore, the main goal of this study 
was to identify the association of anemia on early and long-term outcome in a cohort 
of ACS patients hospitalized between 1985 and 2008 and whether this association is 
independent of renal insufficiency.
Methods
 All patients aged >18 years admitted with a first admission for STEMI or Non-ST-
elevated Myocardial Infarction (NSTEMI) in the Coronary Care Unit (CCU) of the Thorax -
center, Erasmus University Medical Center between January 1985 and December 2008, 
from whom the first haemoglobin value was obtained, were included.
The primary discharge diagnosis of STEMI was made in the presence of the following 
characteristics: chest pain or equivalent symptoms in combination with dynamic ECG 
changes consistent with MI and a serial rise and fall in serum biochemical markers of 
cardiac necrosis such as creatine kinase-MB and troponin T. Patients were diagnosed 
as STEMI in the presence of ST-segment elevation > 0·1 mV in at least two extremity 
leads, or > 0·2 mV in at least two precordial leads, and as NSTEMI otherwise.
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Data was acquired retrospectively by retrieving the hospital medical records. 
Demographic characteristics (age, gender), cardiac history (previous MI, PCI or CABG), 
risk factors (hypertension, diabetes, hypercholesterolemia, family history, smoking 
status, renal dysfunction), discharge diagnosis (STEMI or NSTEMI), and therapy (PCI, 
antithrombotic treatment), were collected.
The primary endpoint was mortality at 30-days and at 20 years follow-up. Survival 
status was assessed through municipal Civil Registries.
Haemoglobin value was determined on first admission. We adopted the definition 
of anemia by the World Health Organization , which defines anemia as a serum 
hemoglobin level <13 g/dl for men and a level <12 g/dl for women. [18] Patients with 
anemia were divided into tertiles to compare to prognosis of patients with mild (12.2-
13.0 g/dl men, 11.2-12.0 g/dl women), moderate (10.9-12.1 g/dl men, 10.3-11.1 g/dl women) 
and severe anemia (≤10.8 g/dl men, ≤10.2 g/dl women) to subjects without anemia.
Patient’s characteristics were given as mean± standard deviation for continuous 
variables, compared by one-way ANOVA test and Bonferroni correction. Pearson chi-
squared test was used for categorical variables and were presented in percentages. 
Cumulative survival was constructed using the Kaplan–Meier method. Logrank 
tests were used to compare curves. Logistic regression analyses were performed to 
adjust anemia for the other baseline characters of 30-day outcome. Cox regression 
analyses were performed to identify 20-year outcome. Adjustments were made for 
the variables age, gender, hypertension, diabetes, renal insufficiency defined in 
patients who had a creatinine value >150 mmol/L, hypercholesterolemia, smoking, 
clinical presentation, treatment, prior CABG, prior myocardial infarction, prior PTCA, 
and trends. Results are reported as hazard ratios of mortality and their respective 
95% confidence intervals. All statistical tests were 2-tailed, and p-values were 
significant at <0.05. When analysing for trends, the study population was categorised 
in three groups of patients hospitalized between 1985-1990; 1991-2000; and 2001-2008. 
Furthermore, when analysing for trends, we tried to find a possible interaction with 
anemia or renal insufficiency. All data were analyzed with SPSS software (SPSS 17.0, 
SPSS Inc., Chicago, IL, USA).
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Results
Of the 5304 patients included in the study, 73% were men. Mean age was 61 years. In 
total, 38% of the patients were anemic. When this last group was divided in tertiles, 
655 had mild anemia (12.3%), 717 moderate anemia (13.5%) and 646 severe anemia 
(12.2%). Mean haemoglobin levels were 14.2 ± 1.2 g/dL in nonanemic patients and 11.0 ± 
1.6 g/dL in patients with anemia.
Patients with anemia were more likely to be older, male, smoking, to have more 
renal insufficiency, diabetes or hypertension, family history, prior MI and arrhythmia 
(Table 1). Patients with anemia were more often treated with aspirin, antiarrhythmics, 
digitalis, diuretics and less with β-blockers oral anticoagulants as compared with 
nonanemic patients. Furthermore, patients with anemia received less additional 
therapy at admission. The prevalence of mild anemia increased from 8.5% in 1985-
1990 to 12.6% in 1991-2000 and 16.0% in 2001-2008 (p<0.001). The prevalence of 
moderate anemia increased from 10.2 % in 1985-1990 to 14.2% in 1991-2000 and 15.6% 
in 2001-2008 (p<0.001). The prevalence of severe anemia increased from 10.5% in 
1985-1990 to 13.3% in 1991-2000, and to 11.8% in 2001-2008 (p<0.05).
In the total study population, mean follow-up duration was 10 years and ranged 
from 2 to 25 years. Overall cumulative survival was 91% at 30 days, and 49% at 
20-years. Cumulative 30-day survival was 93% in nonanemic patients and 88% in 
anemic patients (p<0.001) (Figure 1A). Cumulative 30-day survival rate, in patients 
with anemia increased from 87.2% in 1985-1990 to 91.3% in 1991-2000 (p=0.002) and 
94.1% in 2001-2008 (p<0.001) (Figure 2A). 
Cumulative 20-year survival was 52.9% for nonanemic patients and 42.8% in 
anemic patients (p<0.001) (Figure 1B). The difference was predominantly made in 
the first year. Thereafter, the curves were parallel. Over time, cumulative 20-year 
survival rate was 33.8% in 1985-1990, which decreased to 33.7% in 1991-2000 and in 
2001-2008 66.8% (Figure 2B).
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table 1: Baseline characteristics according to anemia categories.
Variable
Nonanemia
(n=3288) 
(61.9%)
Mild  
anemia 
(n=655, ) 
(12.3%)
Moderate 
anemia 
(n=715) 
(13.5%)
Severe 
anemia 
(n=646) 
(12.2%)
p
Demographic
Age (years), mean±sd 60±12.0 63±11.6 64±11.3 65±11.8 <0.001
Gender (male), % 76 65 72 68 <0.001
risk factors, %
Diabetes Mellitus 11 12 14 16 0.001
Hypertension 33 32 35 40 0.01
Hypercholesterolemia 29 21 22 22 0.2
Smoking 40 33 31 25 <0.001
Family history 27 24 23 20 <0.001
Renal insufficiency 4 6 14 27 <0.001
history, %
Prior MI 29 34 34 36 <0.001
Prior PCI 8 9 11 10 0.1
Prior CABG 8 8 9 8 0.6
Arrhythmia 1.7 2.6 2.7 3.4 0.02
Clinical presentation, %  0.1
STEMI 53 50 49 49
NSTEMI 47 50 51 51
Medication, %
Aspirin 54 57 56 51 0.05
ACE inhibitor 20 19 21 22 0.5
Antiarrhythmics 5 6 7 9 0.004
Beta blocker 64 60 56 52 <0.001
Calcium antagonist 33 34 35 33 0.7
Digitalis 5 6 7 8 0.01
Diuretics 16 18 21 25 <0.001
Oral anticoagulant 57 57 56 51 0.03
treatment, % <0.001
PCI 35 43 42 36
Antithrombotic treatment 16 15 12 9
None 49 41 45 55
* P calculated with ANOVA for continuous variables and with chi­square for categorical variables. MI, 
myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting 
surgery.
 Anemia was divided into tertiles by; mild anemia (12.2­13.0 g/dl men, 11.2­12.0 g/dl women), moderate 
(10.9-12.1 g/dl men, 10.3-11.1 g/dl women) and severe anemia (≤ 10.8 g/dl men, ≤ 10.2 g/dl women)
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Figure 1a: Cumulative survival of severity of anemia at 30­days follow­up.
Figure 1B: Cumulative long­term survival according to severity of anemia.
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Figure 2a: Cumulative survival of trends in anemia patients at 30­days follow­up.
Figure 2B: Long­term cumulative survival of trends in anemia patients.
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table 2: Univariate and multivariate logistic hazards regression 30-day outcome
Univariate
hr (95% CI)
Multivariate*  
hr (95% CI)
Nonanemia Reference Reference
Mild anemia 0.82(0.60­1.11) 0.99(0.71­1.39)
Moderate anemia 1.40(1.09­1.80) 1.40 (1.04­1.87)
Severe anemia 2.16(1.71­2.73) 1.67(1.25­2.24)
Renal insufficiency 3.31(2.96­3.70) 4.11(3.14­5.38)
1985­1990 Reference Reference
1990­2000 1.10(1.02­1.18) 0.52(0.41­0.66)
2000­2008 0.86(0.77­0.97) 0.36(0.25­0.51)
*  Adjusted for: age, gender, hypertension, diabetes mellitus, hypercholesterolemia, smoking, prior MI, PCI, 
CABG, Renal insufficiency, trends and tertiles anemia.
 MI = myocardial infarction; PCI= percutaneous coronary intervention; CABG= coronary artery bypass 
grafting; HR= Hazard Ratio; 95% CI= 95% Confidence Interval
table 3: Univariate and multivariate cox proportional hazards regression for twenty-year outcome
Univariate
hr (95% CI)
Multivariate* 
hr (95% CI)
Nonanemia Reference Reference
Mild anemia 1.01(0.90­1.13) 1.05(0.93­1.18) 
Moderate anemia 1.29 (1.16­1.44) 1.13 (1.01­1.27) 
Severe anemia 1.83(1.65­2.01) 1.39 (1.23­1.56) 
Renal insufficiency 3.31(2.96­3.70) 2.28 (2.02­2.57)
1985­1990 Reference Reference
1990­2000 1.10(1.02­1.18) 0.99(0.90­1.08)
2000­2008 0.86(0.77­0.97) 0.85(0.73­0.99)
*  Adjusted for: age, gender, hypertension, diabetes mellitus, hypercholesterolemia, smoking, prior MI, PCI, 
CABG, Renal insufficiency, trends and tertiles anemia.
 MI = myocardial infarction; PCI= percutaneous coronary intervention; CABG= coronary artery bypass 
grafting; HR= Hazard Ratio; 95% CI= 95% Confidence Interval
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After adjusting for baseline characteristics including renal insufficiency, moderate 
and severe anemia were associated with an increased risk of 30 day-mortality 
(adjusted HR 1.40, 95% CI 1.04-1.87 and adjusted HR 1.67, 95% CI 1.25-2.24) (Table 2).
Hospital mortality during the 1990s and 2000s was lower than in the 1980s (adjusted 
HR 0.52, 95% CI 0.41-0.66 and adjusted HR 0.36, 95% CI 0.25-0.51).
On the long-term outcome, respectively moderate and severe anemia were 
associated with higher mortality (adjusted HR 1.13, 95% CI 1.01-1.27 and adjusted HR 
1.39, 95% CI 1.23-1.56) despite the predictor renal insufficiency on mortality (HR 2.28, 
95% CI 2.02-2.57). (Table 3) 
Long-term mortality in 1991-2000 was similar with 1985-1990 (adjusted HR 0.99, 95% 
CI 0.99-1.08). However, between 2001-2008 the mortality was lower (adjusted HR 0.85, 
95% CI 0.73-0.99). No interaction was found between the time trends and anemia, nor 
with renal insufficiency.
Discussion
Our results show that the extent of anemia at hospital admission and renal dysfunction 
is associated with in hospital and long-term mortality. Despite renal insufficiency, a 
higher mortality was observed both in moderate and severe anemia. In addition, we 
showed that over the years in-hospital survival of patients with anemia has improved 
from 83% in the 1980s to 88% in the 1990s and 92% in the 2000s.
Anemia has the potential to worsen the myocardial ischemic insult in acute MI 
and other acute coronary syndromes, both by decreasing the oxygen content of 
the blood supplied to the endangered myocardium and by increasing myocardial 
oxygen demand through necessitating a higher cardiac output to maintain adequate 
systemic oxygen delivery. [19,20 ] The origin of anemia is mostly multifactorial. The 
cause of anemia in heart failure patients is understood to be caused by malnutrition, 
iron deficiency, bone marrow depression and certain medication. [8,21-23 ] Renal 
dysfunction is a known marker with adverse prognosis in patients with ischemic 
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heart disease, [24 ] especially in those who have anemia. [25] Also demographic factors 
like age and gender have an important role. Furthermore, anemia is associated with 
changes in left ventricular anatomy among patients with chronic kidney disease and 
it is possible that these changes could contribute to worsening left ventricular diastolic 
and/or systolic dysfunction and consequent increased risk of death. [26] Westenbrink 
et al. [27 ] also showed that besides impaired renal perfusion and blunted erythropoietin 
production, fluid retention can cause anemia as well in chronic heart failure patients. 
The effect is caused by an increase in plasma volume which leads to pseudo-anemia 
due to hemodilutation. Anemia is a modifiable clinical marker. Haemotransfusion is 
considered for Hb values > 10gr/dL. [28 ] Studies with regard to blood transfusion show 
different results on 30-day mortality in patients with ACS. [2,5 ] But since the absence of 
randomized controlled trials the negative and positive effects of blood transfusion are 
not fully established. Other treatment approaches, like epoetin-α and darbepoetin-α, 
are showing promising results. Silverberg et al. [29 ] randomized 32 patients with mild 
anemia. One group was given rhEPO and intravenous iron, while the comparing group 
didn’t receive any treament. Results showed an significant improvement in New York 
Heart Association (NYHA) functional class, left ventricular function, renal function and 
heart failure hospitalisations. Ponikowski et al. [30 ] randomized 41 patients in a placebo 
controlled trial. The group which was given darbepoeitin-α had an improvement in 
quality of life. Van Veldhuisen et al. [31 ] randomized chronic heart failure patients with 
anemia and they also found an improvement in certain quality of life indexes in those 
who received darbepoetin-α. A gradually rise in haemoglobin levels was achieved. Still, 
it is uncertain whether these treatment options will decrease mortality and morbidity 
in ACS patients.
Our findings support the results from prior studies which showed an association 
between anemia and adverse outcomes on short and long-term follow-up. Wu 
et al  [5] found, in an elderly population, an association between low hematocrit level 
on admission and 30-day mortality. The results were graded, a lower survival was 
found in a lower degree of anemia. Sabatine et al. [2] examined 40,000 ACS patients 
and concluded that anemia is a powerful and independent predictor of major 
cardiovascular events on 30-day outcome, whereas STEMI patients were more at 
risk. In a study of 1,122 STEMI patients, treated with PCI, results showed that prior 
chronic anemia was an independent predictor for intra-hospital mortality. Patients 
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with new anemia showed a higher mortality rate and incidence of major bleedings. [4] 
Dunkelgrun et al. reported that, in patients, scheduled for elective vascular surgery, 
anemia was an independent predictor for perioperative and long-term cardiovascular 
outcome (30-day and 5 year), regardless of underlying heart failure or renal disease. [7 ]
On the long-term the effect of anemia is still unclear, with different results. In STEMI 
patients anemia was associated with an increased 1 and 5-year mortality. [1,3 ] Aronson 
et al. [1 ] found a hazard ratio of 1.27 (95% CI 1.16-1.40; p<0.001) of anemia at 48 months. 
Salisbury et al. [3 ] founds similar results, whereas moderate-severe hospital acquired 
anemia had a higher mortality at 1-year (HR 1.82, 95% CI 1.11-2.98). On the contrary, 
Falluji et al. [32 ] found similar outcome at 1-year mortality in the anemia and nonanemia 
group in 1986 (RR 1.005, p=0.93) and 1996 (RR 1.084, p=0.11) and concluded there was 
no difference in survival between anemic and non anemic patients.
Our study shows that also severity of anemia is associated with long-term outcome. 
The higher mortality in patients with anemia is predominantly made in the first year. 
Beyond one year the survival of both patients with and without anemia are similar. 
Our study showed for the first time that hospital mortality in ACS patients with anemia 
has improved. However, after hospital discharge, no improvements in the treatment 
of anemia was observed over the years. The improvements over time must, without 
any doubt, be attributed to improvements in treatment and changes in high profile 
of these patients during hospital admission. New medical treatment options made 
their attendance such as antiplatelet agents, ACE- inhibitors, β-blockers. Furthermore, 
fibrinolitic therapy and anti-coagulation improved survival significantly. [12,14,15,33 ] Also 
interventions like primary PCI improved survival in STEMI patients. [13,16,17]
In conclusion, the presence and severity of anemia is an important predictor of 
higher in hospital and long-term mortality after ACS. However, beyond one year 
the increased mortality stabilizes. Additionally, we showed that since the 1980’s, in-
hospital outcome of ACS patients with anemia has been improved.
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Abstract
Objectives 
To determine whether age-dependent inequalities in care and outcome changed over 
a 24 year period for patients admitted with a myocardial infarction (MI). 
Methods 
We examined four age groups (<55, 55-65, 65-75, and >75 years) and treatment and 
mortality in 14 434 consecutive patients admitted for MI to an intensive coronary 
care unit from 1985 to 2008. Temporal trend analyses were performed by comparing 
decades of admission (1985-1990 vs. 1990-2000 vs. 2000-2008). 
Results 
A total of 2040 (14%) of the patients were >75 years of age. Older patients more often 
were female and less often presented with an ST-segment elevation MI (STEMI). 
Systematic differences in care were present between the age groups: older patients 
were less likely to receive evidence-based medical care and reperfusion therapy 
during the last 24 years, although the differences became smaller over time. In 2000-
2008, 30-day (adjusted OR 0.28, 95%CI: 0.23-0.34) and 5-year (adjusted HR 0.61, 95%CI: 
0.54-0.68) mortality were lower compared to 1985-1990. These temporal trends were 
equal across all age groups. Hence, the change in mortality over the 24-year study 
period is similar among the spectrum of ages. Patients aged <55, 55-65, 65-75, and >75 
years had a 20-year mortality of 38, 63, 87 and >95%, respectively.
Conclusions 
Older patients with an MI remained less likely to receive evidence-based care during 
24 years of observation. Temporal reductions in mortality were similar among all age 
groups. The application of proven MI therapies to appropriate patients regardless of 
age may even further improve these outcomes. 
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Introduction
Due to ageing of the general population in the Western world, more elderly patients 
present to hospital with a myocardial infarction (MI). [1] Previous studies have 
suggested that elderly patients with an MI are less likely to receive evidence-based 
therapies and have a worse survival after hospitalization compared to younger 
patients. [2-4] Recent data has underlined the need for increased use of evidence-based 
management among the elderly and has shown potential for a reduction in mortality 
in this age group. [3, 5] 
Within the past 25 years, substantial improvements in the treatment and outcome 
of MI have been made with, for example the implementation of thrombolytic therapy 
in the 1990s, primary percutaneous coronary intervention (PCI) in the beginning of 
the new century and tailored treatment according to individual risk. [6-10] A long-term 
analysis of patients admitted to hospital with an MI might identify changes in the 
use of treatment modalities, and early and late outcomes for the whole spectrum of 
ages. Therefore, the aims of this study were threefold. First, to determine whether, in 
accordance with the guideline recommendations, [11-12] age-dependent inequalities in 
care changed over a 24-year period. Second to compare temporal trends in mortality 
according to age for patients admitted with an MI. And third, to quantify the effect of 
age on 30-day and long-term mortality.
Methods 
We included all consecutive patients aged >18 years admitted for ST-segment elevation 
myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) 
to the Intensive Coronary Care Unit (ICCU) of the Thoraxcenter, Erasmus University 
Medical Center between June 1985 and December 2008. 
The primary discharge diagnosis of MI was made in the presence of the following 
characteristics: chest pain or equivalent symptoms in combination with dynamic 
ECG changes consistent with MI and a typical serial rise (to at least three times the 
upper normal value) and fall in serum biochemical markers of cardiac necrosis such 
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as creatine kinase-MB or troponin-T (as of 2002). Patients were diagnosed as STEMI in 
the presence of ST-segment elevation > 0.1 mV in at least two peripheral leads, or > 0.2 
mV in at least two contiguous precordial leads, and as NSTEMI otherwise. For patients 
admitted more than once, only the first hospitalization was taken into account. 
Data collection
Trained physicians and nurses accustomed to the use of standardized case report 
forms collected the data. Demographic characteristics (age, gender), cardiac history 
(previous MI, PCI or coronary artery bypass surgery (CABG)), risk factors (hypertension, 
diabetes, family history, smoking status), anemia (Hemoglobin level < 13.0 g/dl men, 
<12.0 g/dl women), renal dysfunction (creatinine > 150 μmol/l), and pharmacological 
and invasive treatment modalities (thrombolysis and PCI) were collected. The 
decision to use or not use specific pharmacological and invasive treatment modalities 
was made according to the level of evidence and recommendations in the guidelines 
available at that time.
 
Follow-up and endpoints
The primary endpoint was all cause mortality at 30 days and at 20 years. In-hospital 
mortality was retrieved from the medical records. Long-term survival status was 
assessed through municipal Civil Registries in 2010 and was available for 99% of all 
patients. 
Ethics
The authors of this manuscript have certified that they comply with the Principles of 
Ethical Publishing in the International Journal of Cardiology. [13]
Statistical Analysis 
The study patients were categorized in four groups of patients according to age: 
those aged <55, 55-65, 65-75, and >75 years. Categorical variables were summarized 
as percentages and chi-square test for trend was used to calculate p-values. Patients 
were stratified in three groups according to decade of hospitalization: 1985-1990; 
1990-2000; 2000-2008. We assessed temporal trends in outcome by comparing these 
three periods. Cumulative survival curves were constructed using the Kaplan–Meier 
method for patients aged >75 years. The log-rank test was used to compare survival 
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curves. We examined the independent association between decade of hospitalization 
and mortality, for the whole study population and for the elderly, respectively, using 
logistic regression for 30-day outcome and the Cox proportional hazards model for 
long-term outcome. Since complete long-term (20-year) follow-up of patients admitted 
after 1991 is unavailable, we used 5-year outcomes for comparing the influence 
of decades of hospitalization on outcome. Adjustment was performed for gender, 
previous MI, previous CABG, hypertension, diabetes, hyperlipidemia, family history, 
smoking status, renal dysfunction, anemia and discharge diagnosis. In addition, we 
examined the independent association between age and mortality using the analyses 
described above. 
Results are reported as odds ratios (OR) –for 30-day mortality– and hazard ratios (HR) 
–for long-term mortality– and their respective 95% confidence intervals. All statistical 
tests were 2-tailed, and p-values were considered significant at <0.05. Analysis was 
performed using SPSS software version 17.0 (SPSS, Chicago, USA).
Ch
ap
te
r 
6
78     |     Myocardial infarction: temporal trends over the past three decades
Results
We included 14,434 patients, of whom 2,040 (14%) were >75 years of age. The distribution 
of age categories is shown in Table 1. A total of 110,690 person-years were analyzed.
Patient characteristics
Patient characteristics are shown in Table 1. Older patients were more often female; 
more often had a history of CABG, anemia and renal impairment. Older patients were 
less often current smokers, less often had hypercholesterolemia, a family history of 
previous MI, or a discharge diagnosis of STEMI. For each decade of age, the odds of 
presenting with a STEMI decreased by 15% (odds ratio, OR 0.85, 95%CI: 0.83-0.88). 
Medical and invasive care during the study period
Age-dependent inequalities in care were present in 1985 and persisted during the 
24-year study period. While use of reperfusion therapy (either by thrombolytic therapy 
or PCI) increased over time in all groups with STEMI (p<0.001), older patients were less 
likely to receive reperfusion therapy (p<0.001), although the differences appeared to 
become smaller during the study period (Figure 1A). Prescription of evidence-based 
medical care (class 1A), including aspirin, Β-blockers, and statins was and remained 
lower in the elderly during the whole study period (p<0.001 for all). The prescription 
of ACE-inhibitors/ angiotensin-receptor blockers was lower for older patients in the 
Figure 1: Treatment of patients over time: use of reperfusion therapy in STEMI (A) and use of 
evidence­based medical care in MI patients (B). ACE denotes angiotensin­converting enzyme 
inhibitor; ASA, aspirin; ARB, angiotensin receptor blocker; ThT, thrombolytic therapy. 
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1990s, but not thereafter (Figure 1B). Prescription of other medical therapy with a lower 
level of evidence for the treatment of MI, including calcium-antagonists, nitrates and 
diuretics at ICCU discharge was higher in the elderly (Table 1).  
table 1: Baseline characteristics and clinical presentation of patients hospitalized for MI according 
to age on admission. 
Age on admission p for trend
<55 55­65 65­75 >75
No. of patients 4319 (30%) 4113 (29%) 3962 (27%) 2040 (14%)
Baseline
Gender (female) 20% 23% 32% 45% <0.001
Cardiac history
Previous MI 30% 34% 36% 34% <0.001
Previous PCI 14% 15% 15% 15% 0.37
Previous CABG 7% 10% 12% 10% <0.001
risk factors
Hypertension 29% 37% 39% 39% <0.001
Diabetes 11% 14% 16% 17% <0.001
Hyperlipidemia 29% 30% 26% 21% <0.001
Family history 35% 29% 21% 14% <0.001
Current smoker 51% 35% 21% 11% <0.001
Renal dysfunction 5% 7% 12% 14% <0.001
Anemia 30% 39% 50% 58% <0.001
Discharge diagnosis
STEMI 54% 47% 41% 45% <0.001
Medication at ICCU * discharge 
Ca­antagonist 19% 24% 27% 21% <0.001
Diuretics 8% 11% 16% 20% <0.001
Nitrates 11% 13% 14% 16% <0.001
Antiarrhythmics 4% 4% 4% 4% 0.20
* ICCU, intensive coronary care unit.
Temporal trends in mortality 
In the total study population, the risk of 30-day mortality decreased between 1985 and 
2008 from 11% in 1985-90 to 4% in 2000-8. This decrease was more pronounced for 
patients aged >75 years, from 27% in 1985-90 to 9% in 2000-8 (Figure 2A). Also, for the 
study population as a whole, 5-year mortality decreased between 1985 and 2008, from 
24% in 1985-90 to 17% in 2000-8, and for patients aged >75 years from 55% in 1985-90 
vs. 40% in 2000-8 (Figure 2B). 
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From 1985 to 2008, the adjusted risk of 30-day mortality decreased by nearly 75%, 
in both the overall study population (adjusted OR 0.28, 95%CI: 0.23-0.34) as well as in 
the elderly (adjusted OR 0.29, 95%CI: 0.18-0.45; Table 2). The risk of 5-year mortality 
decreased by nearly 40% in both the overall study population (adjusted hazard ratio, 
HR 0.61, 95%CI: 0.54-0.68) and in the elderly (adjusted HR 0.63, 95%CI: 0.49-0.80; Table 
2). Hence, the relative risk reduction in 30-day and long-term mortality over the 24-
year study period was similar among the spectrum of ages. 
table 2: temporal trends of 30-day and 5-year mortality in MI patients.
Calendar period all patients >75
Odds ratios for 30-day mortality
1985­90 Reference Reference
1990­2000 0.61 (0.51­0.74) 0.59 (0.38­0.91)
2000­08 0.28 (0.23­0.34) 0.29 (0.18­0.45)
hazard ratios for 5-year mortality
1985­90 Reference Reference
1990­2000 0.93 (0.83­1.0) 0.98 (0.77­1.2)
2000­08 0.61 (0.54­0.68) 0.63 (0.49­0.80)
Adjusted for gender, previous MI, previous CABG, hypertension, diabetes, hyperlipidemia, family history, 
smoking status, renal dysfunction, anemia and discharge diagnosis.
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Figure 2: Temporal trends: Kaplan­Meier curves of mortality according to decade of admission in 
elderly patients (aged >75).
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Age and Mortality 
As expected, the risk of mortality was higher in older MI patients at 30 days follow-
up (13% for patients >75 years vs. 3% for those <55 years, p<0.001) and during long-
term follow-up (Figure 3: after 16 years, 95% for patients >75 years vs. 29% for those 
<55 years, p<0.001). The (adjusted) mortality rates for 30-day and 20-year outcomes 
are presented in Table 3. There were no significant interactions between the baseline 
characteristics and age and mortality. One in seven of the patients were >75, but one 
third of the deaths within 30 days occurred in this group. 
table 3: Unadjusted and adjusted odds and hazard ratios of mortality  
according to age at hospitalization. 
age category Unadjusted adjusted* 
Odds ratios for 30-day mortality
<55 Reference Reference
55­65 1.8 (1.4­2.2) 1.6 (1.3­2.1)
65­75 2.8 (2.3­3.5) 2.5 (2.0­3.1)
>75 5.0 (4.0­6.2) 4.6 (3.6­5.8)
hazard ratios for 20-year mortality
<55 Reference Reference
55­65 1.9 (1.7­2.1) 1.8 (1.7­2.0)
65­75 3.6 (3.4­4.0) 3.5 (3.2­3.8)
>75 7.3 (6.6­8.0) 7.3 (6.6­8.1)
*Adjusted for the same variables as Table 2 and decade of hospitalization.
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Figure 3: Kaplan-Meier curves of mortality according to age.
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Discussion
In this study conducted in a cohort of 14,434 MI patients, we showed that systematic 
differences in care were present between patients from different age groups: older 
patients were less likely to receive evidence-based medical care and reperfusion 
therapy during all 24 years of observation, although the differences became 
smaller over time. Furthermore, temporal trends in 30-day and long-term mortality 
showed substantial improvements in outcome during this 24-year period that were 
independent of age. Thus, these improvements in outcome were similar for all age 
groups. Finally, we demonstrated the association between age and mortality with 
follow-up data up to 20 years. 
The better outcomes in younger patients could in part be due to the fact that effective 
therapies are better implemented among these patients. Previous studies [11, 14] showed 
that older patients with an STEMI who are eligible for reperfusion therapy, actually 
less often receive this treatment. Furthermore, other studies [11] showed that elderly 
patients with a NSTEMI are substantially less likely to undergo an invasive treatment 
strategy, while individual trials [15-16] have suggested that the benefit from an invasive 
strategy is mainly observed in patients >65 years of age (the “risk-treatment paradox”). 
Other proven therapies are also underused in the elderly [2, 17], even in the absence of 
contra-indications. [18] These age-related treatment patterns persisted in the present 
study, although the overall temporal increase in the use of evidence-based therapies 
(especially primary PCI for STEMI) among the elderly is encouraging and confirms 
other recent observations in older patients with STEMI. [19]
Thirty-day and long-term mortality after MI have decreased during the past 
decades. [10, 20] However, two recent studies suggest that temporal mortality 
improvements did not occur in older patients. [21-22] However, data from our study 
clearly demonstrates that, in our center, similar reductions in 30-day and long-term 
mortality have occurred across all age groups. In fact, the i) numerically similar 
relative reductions over time and ii) the higher absolute mortality in the elderly, 
imply that in absolute terms, elderly patients benefit most from improved medical 
care during the past 24 years. Still, the application of evidence-based MI therapies to 
appropriate patients regardless of age may even further improve these outcomes. 
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Age is one of the most important predictors of risk in MI patients. [23] Relative odds 
of 6.2 to 7.8 for in-hospital mortality in patients >75 years compared to <55 years have 
previously been reported, [3, 22, 24] figures similar to that of the present study. Relative 
hazards for long-term mortality in the elderly are presented in this study, with follow-
up data comprising almost a whole life course. 
Strengths and limitations
To our knowledge, this is the first paper investigating temporal trends in clinical 
characteristics, treatment and outcome of older patients (>75 years) with an MI over 
a time period of 24 years and with follow-up data for up to 20 years. Although the 
present study has unique strengths, some limitations should be mentioned. First, 
the discharge diagnosis of MI was based on the diagnosis of the attending physician. 
Newer definitions of MI have been published within the study period; these might 
interfere with the probability of an acute coronary syndrome patient to be diagnosed 
with MI. Still, these inconsistencies reflect clinical practice during these transitional 
periods. Second, given the nature of ageing this study reveals important associations 
but cannot prove causation. Finally, the present data are derived from a single center. 
Although this could result in a lower external validity, we think that this is unlikely to 
be the case since the definition of myocardial infarction and its therapeutic modalities 
are quite uniform, certainly in the Western world.
Conclusion
The elderly contribute a substantial proportion to MI mortality. Subjects > 75 years 
of age were less likely to receive evidence-based medical care and reperfusion 
therapy over the 24-year study period. Despite this, improvements in the application 
of evidence-based MI care were evident across all age groups from 1985 to 2008. 
There were significant temporal reductions in 30-day and long-term mortality, that 
were equal across all age groups. In absolute terms, therefore, older patients benefit 
most from the improved medical care for MI during the last 24 years. It is likely that 
a further increase in the application of evidence-based therapies for MI in the elderly 
will further improve their short- and long term outcome.
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Abstract
Objectives 
To study temporal trends in short- and long-term outcome after myocardial infarction 
according to diabetes status. 
Research Design and Methods 
We included all 14,434 consecutive patients admitted for ST-segment elevation 
myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) at 
our center between 1985 and 2008. The study patients were compared according to 
prevalent diabetes. Temporal trend analyses were performed by comparing decades 
of admission (1985–1990 vs. 1990–2000 vs. 2000–2008).
Results 
A total of 2,015 (14%) of the patients had prevalent diabetes. The risk of presenting with 
diabetes increased from 8% to 17% from 1985 to 2008. Diabetic patients presented with 
a higher prevalence of cardiovascular risk factors. With time, the use of evidence-
based therapies increased in both patients with and without diabetes. Diabetes is 
associated with an 1.5-fold increased risk of mortality at 20 year follow-up. Ten-year 
mortality decreased over time, in patients with diabetes from 53% in 1985-90 to 39% 
in 2000-8 (adjusted HR 0.56, 95%CI: 0.43-0.73) and in those without diabetes from 38% 
in 1985-90 to 29% in 2000-8 (adjusted HR 0.66, 95%CI: 0.60-0.73; p interaction = 0.83). 
Patients with diabetes benefitted from a higher 30-day and 10-year absolute survival 
increase.
Conclusions 
Temporal mortality reductions after myocardial infarction between 1985 and 2008 
were at least as high in patients with diabetes compared to those without. However, 
long-term mortality remained higher in diabetic patients. Awareness of the high risk 
profile of diabetic patients is warranted and might stimulate optimal medical care 
and their outcome. 
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Over the last decades, the prevalence of diabetes mellitus in patients with a 
myocardial infarction (MI) has increased significantly. [1-3] Current figures indicate that 
cardiovascular events are responsible for 80% of all deaths in patients with diabetes. [3] 
Within the past 25 years, the management and prognosis of MI has shown substantial 
progress; clinical evidence and guidelines have introduced thrombolytic therapy, 
primary percutaneous coronary intervention (PCI), tailored treatment according to 
individual risk, as well as improved secondary prevention. [1, 4-8] However, some studies 
have shown that patients with diabetes suffering from acute MI are less likely to 
receive evidence-based therapies. [9-11] Furthermore, recent data have also suggested 
that patients with diabetes have not benefitted from the temporal long-term mortality 
reductions after MI, as opposed to patients without diabetes. [9] Therefore, the need for 
management that improves long-term post MI survival in patients with diabetes has 
been underlined. [9]
We aimed to investigate the effect of diabetes on (20 year) mortality, in a cohort 
of consecutive MI patients hospitalized from 1985 to 2008. Further, we aimed to 
determine whether temporal improvements in survival after MI have occurred 
equally in patients with and without diabetes. 
Research design and Methods 
We included all consecutive patients aged >18 years admitted for ST-segment elevation 
myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) 
to the Intensive Coronary Care Unit (ICCU) of the Thoraxcenter, Erasmus University 
Medical Center between June 1985 and December 2008. [1]
The primary discharge diagnosis of MI was made in the presence of the following 
characteristics: chest pain or equivalent symptoms in combination with dynamic 
ECG changes consistent with MI and a typical serial rise (to at least three times the 
upper normal value) and fall in serum biochemical markers of cardiac necrosis such 
as creatine kinase-MB or troponin-T (as of 2002). Patients were diagnosed as STEMI in 
the presence of ST-segment elevation > 0.1 mV in at least two contiguous peripheral 
leads, or > 0.2 mV in at least two contiguous precordial leads, and as NSTEMI otherwise. 
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For patients admitted more than once, only the first hospitalization was taken into 
account. 
Data collection
Diabetes was defined as previously diagnosed by a physician or as receiving 
medication to lower glucose levels. Trained physicians and nurses accustomed 
to the use of standardized case report forms collected the data. Demographic 
characteristics (age, gender), cardiac history (previous MI, PCI or coronary artery 
bypass surgery (CABG)), risk factors (hypertension, family history, smoking status), 
anemia (Hemoglobin level <13.0 g/dl in men, <12.0 g/dl in women), renal dysfunction 
(creatinine >150 μmol/l), and pharmacological and invasive treatment modalities 
(thrombolysis and PCI) were collected. Hypertension was defined as previously 
diagnosed by a physician or receiving medication to lower blood pressure. Family 
history was defined as one or more relatives (parent or sibling) with an MI diagnosed 
before the age of 60 years. 
 
Follow-up and endpoints
The primary endpoint was all-cause mortality. Survival status and date were assessed 
through municipal Civil Registries in 2010 and were available for 99% of all patients. 
Ethics
This project was carried out in accordance with current rules of ethics and legislature. 
No additional actions involving the study participants were undertaken because of 
this registry. Register based studies are approved by the ethical committee of the 
Erasmus MC and do not require informed consent according to Dutch laws (‘WMO’). 
Statistical Analysis 
The study patients were categorized in two groups of patients according to prevalent 
DM. Patients were stratified in three groups according to the year of hospitalization: 
1985-1990; 1990-2000; 2000-2008. These strata were chosen according to important 
improvements in therapy with complete introduction of thrombolytic therapy in 
1990 and a substantial increase in the use of primary PCI since 2000. Categorical 
variables were summarized as frequencies and percentages. Cochran’s statistic with 
correction for study period was used to calculate p-values. We assessed temporal 
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mortality trends by comparing one-minus-survival curves that were constructed 
using the Kaplan–Meier method. The log-rank test was used to compare survival 
curves. We examined the independent association between decade of hospitalization 
and mortality according to DM status, using logistic regression for 30-day outcome 
and the Cox proportional hazards model for long-term outcome. Adjustment was 
performed for age, gender, previous MI, previous CABG, hypertension, dyslipidemia, 
family history, smoking status, renal dysfunction, anemia and discharge diagnosis. 
Results are reported as odds ratios (OR) –for 30-day mortality– and hazard ratios 
(HR) –for long-term mortality– and their respective 95% confidence intervals. For all 
analyses that compared decades of hospitalization we analyzed up to 10 years of 
follow-up, since longer follow-up is unavailable for patients hospitalized in the last 
decade (2000-2008). Interaction between DM status and study period and mortality 
was assessed using multivariable regression models. All statistical tests were 2-tailed, 
and p-values were considered significant at <0.05. Analysis was performed using 
SPSS software version 17.0 (SPSS, Chicago, USA).
Results
Patient characteristics
We included 14,434 patients, of whom 2015 (14%) had prevalent DM. For each calendar 
year, the relative risk of presenting with DM increased by 5%, from a prevalence of 
8% in the 1980s to 17% in the last decade. The distribution of risk factors at baseline 
varied according to DM status and according to decade of admission (Table 1). Patients 
with DM were older and more often female, and more often had a history of previous 
MI, hypertension, dyslipidemia, anemia and renal impairment. Patients with DM were 
less often current smokers, and more often had a discharge diagnosis of NSTEMI. 
Medical and invasive care during the study period
The medical care provided to MI patients with and without DM was comparable, 
with no clinically relevant sex-differences. The use of reperfusion therapy (either 
by thrombolytic therapy or PCI) increased over time in both groups with STEMI 
(p<0.001), and STEMI patients with DM were equally likely to receive primary PCI as 
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table 1: Baseline characteristics and clinical presentation of patients hospitalized for MI according 
to diabetes mellitus status
 Diabetes No diabetes  
 1985- 90
1990-
2000
2000- 
8
1985- 
90
1990-
2000
2000- 
8
Overall  
p*
No. of patients 174 525 1316 2042 4075 6302
(% of total in decade)  (8%)  (11%)  (17%)  (92%)  (89%)  (83%)  
Baseline
Elderly (>65 year) 47% 45% 50% 37% 42% 41% <0.001
Gender (female) 40% 40% 34% 24% 28% 26% <0.001
Cardiac history
Previous MI 49% 39% 32% 41% 32% 31% <0.01
Previous PCI 11% 13% 18% 8% 10% 19% 0.47
Previous CABG 13% 12% 10% 13% 9% 9% 0.03
risk factors
Hypertension 41% 50% 59% 34% 29% 34% <0.001
Dyslipidemia 9% 30% 50% 11% 21% 32% <0.001
Family history 20% 21% 28% 24% 23% 29% 0.10
Current smoker 25% 26% 25% 40% 31% 33% <0.001
Renal dysfunction 11% 15% 13% 9% 9% 6% <0.001
Anemia 40% 47% 52% 34% 42% 42% <0.001
Discharge diagnosis
NSTEMI 55% 41% 57% 57% 58% 46% <0.001
reperfusion therapy**
Primary PCI 8% 14% 82% 4% 12% 85% 0.45
Thrombolytic therapy 25% 47% 7% 32% 54% 8% 0.03
Medication at ICCU discharge
Statin 0% N.A. 74% 0% N.A. 72% 0.12
Aspirin 17% 57% 85% 14% 61% 87% 0.02
Beta­blocker 49% 45% 62% 58% 54% 61% 0.02
ACE inhibitor or ARB 0% 15% 40% 0% 13% 27% <0.001
Ca­antagonist 52% 30% 10% 54% 31% 9% 0.44
Nitrates 33% 13% 11% 31% 14% 6% <0.001
Diuretics 41% 21% 16% 25% 12% 7% <0.001
Antiarrhythmics 7% 3% 4% 7% 4% 3% 0.04
* The overall P­value compares patients with and without diabetes with adjustment for calendar decade 
of admission.
** STEMI patients only, n=6820.
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those without DM. Prescription of evidence-based medical care (class 1A), including 
aspirin, β-blockers, statins and ACE-inhibitors/angiotensin-receptor blockers (ARBs) 
also increased over time in both groups. Overall, patients with DM were more likely 
to receive ACE-inhibitors/ ARBs, and less likely to receive aspirin and β-blockers. 
However, these differences were small and did not persist over time. Prescription of 
diuretics was higher in patients with DM. Other medical therapies with a lower level 
of evidence for the treatment of MI, including calcium-antagonists were prescribed at 
equal rates in both study groups (Table 1). 
Temporal trends in mortality 
A total of 106,517 person-years were analyzed. At 10-year follow-up a total of 663 
patients with and 3,285 patients without baseline DM had died. The unadjusted risk of 
30-day mortality decreased between 1985 and 2008, both in the DM group from 17% in 
1985-90 to 5% in 2000-8, and from 10% in 1985-90 to 4% in 2000-8 in the non-DM group 
(Figure 1). Also, unadjusted 10-year mortality decreased between 1985 and 2008, both 
in the DM group from 53% in 1985-90 vs. 39% in 2000-8, and in the non-DM group from 
38% in 1985-90 to 29% in 2000-8. Patients with DM benefitted from a higher 30-day 
and long-term absolute survival increase (Figure 1). 
Figure 1: Temporal trends: Kaplan­Meier curves of mortality according to decade of hospitalization 
in patients with and without diabetes.
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Figure 2: Kaplan­Meier curves of mortality according to diabetes for all MI patients.
table 2: temporal trends in 30-day and 10-year mortality in MI patients.
 Diabetes No diabetes
Calendar period Unadjusted adjusted Unadjusted adjusted
Odds ratios for 30-day mortality
1985­90 Reference Reference Reference Reference
1990­2000 0.49 (0.30­0.81) 0.40 (0.23­0.69) 0.73 (0.60­0.88) 0.63 (0.52­0.78)
2000­08 0.23 (0.14­0.37) 0.17 (0.10­0.30) 0.37 (0.31­0.45) 0.29 (0.24­0.37)
 hazard ratios for 10-year mortality
1985­90 Reference Reference Reference Reference
1990­2000 0.88 (0.69­1.1) 0.83 (0.65­1.1) 0.96 (0.88­1.0) 0.96 (0.88­1.1)
2000­08 0.63 (0.50­0.80) 0.56 (0.43­0.73) 0.64 (0.58­0.70) 0.66 (0.60­0.73)
 Adjusted for age, gender, previous MI, previous CABG, hypertension, dyslipidemia, family history, 
smoking status, renal dysfunction, anemia and discharge diagnosis.
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From 1985 to 2008, the adjusted risk of 30-day mortality decreased by about 80%, 
both in the DM group (adjusted OR 0.17, 95%CI: 0.10-0.30), and in the non-DM group 
(adjusted OR 0.29, 95%CI: 0.24-0.37; Table 2). The risk of 10-year mortality decreased 
by about 40%, both in the DM group (adjusted HR 0.56, 95%CI: 0.43-0.73) and in the 
non-DM group (adjusted hazard ratio, HR 0.66, 95%CI: 0.60-0.73; Table 2). There was 
no significant interaction between DM status and study period (p = 0.39, and p = 0.83 
for interaction for 30-day and 10-year mortality, respectively). Hence, the relative risk 
reductions in 30-day and long-term mortality over the 24-year study period were at 
least as high for MI patients with diabetes compared to those without. 
Diabetes and Mortality 
As expected, the risk of mortality was higher in MI patients with prevalent diabetes. 
The increased mortality risk persisted up to 20-year follow-up (Figure 2). Patients with 
diabetes had a median survival of 11 years compared to 15 years for those without. 
Patients in the diabetes group had a 50% increased adjusted long-term mortality risk 
in all three decades studied (adjusted HR for 10-year mortality = 1.5, 1.5, and 1.4 in 1985-
90, 1990-2000, and 2000-8, respectively, p< 0.001 for all).
Conclusions
In this study comprising a cohort of 14,434 patients with acute MI, studied over a 
period of 24 years, we showed that there is an increasing prevalence of diabetes 
mellitus in patients with an acute MI. More important, we showed that the temporal 
reductions in all-cause mortality in patients suffering acute MI, achieved between 
1985 and 2008, were at least as high in patients with diabetes as in those without 
diabetes. This improvement in outcome is most likely related to the fact that, during 
the study period, the use of MI related medical care improved significantly, both 
for patients with and without diabetes. Indeed, in the most recent decade, diabetes 
was not associated with underuse of treatment any more. Finally, we demonstrated 
that the increased mortality risk associated with diabetes persisted up to 20 years 
follow-up.
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A previous study [12] demonstrated the increasing burden of diabetes in relation to 
cardiovascular disease mortality in the general population. Relatively few studies 
have evaluated temporal trends in (long-term) mortality of MI patients with and 
without diabetes. [9, 11, 13] Moreover, the results of these studies were inconsistent. Two 
studies [11, 13] show temporal mortality reductions is patients with and without diabetes, 
while one study [9] concludes that patients with diabetes do not benefit from a reduction 
in long-term post MI mortality over time. 
Treatment
The awareness of the higher cardiovascular risk associated with diabetes has probably 
intensified cardioprotective treatment in these patients over time. We and others  [9-10, 14] 
showed that from 1985 to 2000 the use of thrombolytic therapy and β-blockers was 
lower in patients with diabetes compared to those without. Studies [14-15] have shown the 
effectiveness of these therapies in patients with diabetes. It is therefore encouraging 
to observe that these inequalities in medical care are no longer present in the last 
decade of observation. Further, our data showed that in the last decade approximately 
40% of diabetic patients were treated with ACE-inhibitors/ARBs at ICCU discharge (a 
median of 1 to 2 days after admission), a percentage higher than that for non-diabetic 
patients. ACE-inhibitors/ARBs slow myocardial remodeling and the progression of 
diabetic nephropathy. [16] This finding is consistent with other recent data. [10, 14] Diabetic 
patients received diuretics more often compared to non-diabetics, probably due to the 
higher risk profile in diabetic patients with more frequent hypertension and heart 
failure. [9]
Mortality
We found a reduction in both 30-day and long-term mortality rates over time for MI 
patients with and without diabetes. Patients with diabetes benefitted from a higher 
30-day and long-term absolute mortality reduction. The relative morality reductions 
were statistically equal for patients with and without diabetes, which is consistent 
with another study reporting on patients hospitalized with an MI between 1979 
and 1998.  [11] Furthermore, other studies in the general population have shown that 
mortality from coronary heart disease has decreased over the past decades, and 
some of these studies speculated that patients with diabetes have also benefited 
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from this reduction. [17-19] The temporal mortality reduction observed in the present 
study may be a result of several factors, including improved treatment in the acute 
phase of MI, and increased long-term survival resulting from aggressive secondary 
prevention. [1, 4-5, 7-8, 20] Although patients with diabetes benefitted at least equally from 
improved mortality rates over the last 25 years, their absolute long-term mortality 
remained about 1.5 fold higher compared to patients without diabetes. Therefore 
optimal medical care for diabetes patients and awareness of their high risk profile 
remains warranted, and may even further improve outcomes in these patients in the 
future.
Strengths and limitations
To our knowledge, this is the first paper investigating temporal trends in clinical 
characteristics, treatment and outcome of MI patients with diabetes over a time period 
of 24 years and with follow-up data up to 20 years. 
Although the present study has unique strengths, some limitations should be 
mentioned. First, the present data are derived from a single center. Although this 
could result in a lower external validity, we think that this is unlikely to be the case 
given the uniform definition and therapeutic modalities of MI. Second, we did not 
distinguish patients with type I and type II diabetes. Also, our definition of diabetes 
did not include patients who were diagnosed on the basis of glucose values during 
hospitalization for acute MI only. Therefore, the real prevalence of diabetes might have 
been underestimated, alternatively, our definition is not biased by altered glucose 
levels resulting from the acute event, [21] and allows for better comparison of our results 
with previous studies. Last, given the nature of diabetes this study reveals important 
associations but cannot prove causation. 
In conclusion, we show that there is an increasing prevalence of diabetes in patients 
with an MI. Medical care improved substantially for MI patients both with and without 
diabetes during the 24 years of observation. In the most recent decade, diabetes 
was not associated with underuse of evidence-based therapies any more, including 
primary PCI for STEMI. In the study period, outcome improved, and temporal mortality 
reductions were at least as high in patients with diabetes compared to those without 
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diabetes. However, the absolute long-term mortality rate remained about 1.5 fold 
higher in patients with diabetes compared those without. Therefore, optimal medical 
care for diabetes patients and awareness of their high risk profile remains warranted.
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Abstract
We examined temporal trends in mortality after myocardial infarction from 1985 to 
2008 depending on admission glucose levels. We included 11,324 consecutive patients 
admitted to our Intensive Coronary Care Unit for myocardial infarction between 1985 
and 2008. Patients were categorized into normal, mild and severe hyperglycemia 
(admission glucose levels <140, 140-200, and ≥200 mg/dl, respectively). Temporal 
trends were determined using three groups: 1985-1990, 1990-2000 and 2000-2008. The 
prevalence of hyperglycemia increased from 26% in the 1980s to 49% in the 2000s. 
The prevalence of hyperglycemia primarily increased in patients without diabetes. 
Kaplan-Meier mortality was 4%, 8% and 17%, at 30 days, and 64%, 71% and 82%, at 20 
years, in patients with normal, mild and severe hyperglycemia, respectively. Compared 
to normal admission glucose, adjusted 30-day mortality was 3.6-fold higher (95%CI: 
2.9-4.3) in patients with severe hyperglycemia. This association was not dependent on 
diabetic status (p-interaction =0.43), but was dependent on decade of hospitalization 
with a stronger association from 2000-2008 (adjusted OR 7.7, 95%CI: 5.4-11, p-interaction 
<0.001). Compared to diabetes, hyperglycemia was a better discriminator for 30-day 
mortality. Mortality at 30 days fell between 1985 and 2008, however, it declined less in 
patients with hyperglycemia compared to those with normoglycemia. In conclusion, 
elevated admission glucose levels are common in patients with myocardial infarction 
and strongly associated with increased mortality. Mortality fell less from 1985 to 2008 
in patients with hyperglycemia compared to those with normoglycemia. Efforts that 
establish optimal treatment for these patients remain warranted. 
Keywords
Myocardial infarction, hyperglycemia, survival, temporal trends. 
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Introduction
Elevated glucose levels are common in patients hospitalized for acute myocardial 
infarction (MI) with a prevalence of about 40%. [1-2] Although it has been established 
that hyperglycemia is associated with adverse outcome during hospitalization, [2-6] 
only a limited number of studies has examined the long-term effects of hyperglycemia 
in MI. [3,5] Also, the interplay between diabetes mellitus and hyperglycemia is still 
unclear. In addition, no previous study has reported on the changes in the impact 
of hyperglycemia on mortality during the last 25 years. Therefore, the aims of the 
present study were 1) to determine the association of hyperglycemia at admission 
with both early and long-term (up to 20 years) mortality after MI, 2) to assess the 
effect of hyperglycemia in MI patients with diabetes versus those without diabetes, 
3) to compare the predictive value of hyperglycemia with that of diabetes for long-
term mortality and 4) to study the changes in these relationships over the last three 
decades. 
Methods 
We included all patients aged >18 years with a first admission for ST-segment elevation 
myocardial infarction (STEMI) or non-STEMI (NSTEMI) to the intensive coronary care 
unit (ICCU) of the Thoraxcenter, Erasmus Medical Center between June 1985 and 
December 2008 with an available glucose level at admission.
The primary diagnosis of MI was made in the presence of the following characteristics: 
chest pain or equivalent symptoms in combination with dynamic ECG changes 
consistent with MI and a typical serial rise (to at least three times the upper normal 
value) and fall in serum biochemical markers of cardiac necrosis such as creatine 
kinase-MB or troponin-T. Patients were diagnosed as STEMI in the presence of ST-
segment elevation > 0.1 mV in at least two contiguous peripheral leads, or > 0.2 mV in at 
least two contiguous pre-cordial leads, and as NSTEMI otherwise. 
Trained physicians and nurses accustomed to the use of standardized case report 
forms collected the patient data. Definitions have previously been described. [7] 
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Glucose value was determined on admission and was therefore non-fasting. As in 
the World Health Organization definition, we defined hyperglycemia as admission 
glucose levels ≥140 mg/dl (7.8 mmol/L). [8] Patients with hyperglycemia were further 
categorized into mild (140-200 mg/dl L), or severe hyperglycemia (≥200 mg/dl; ≥11.1 
mmol/L) similar to ranges used by others previously. [4] Patients were categorized 
as diabetic if diabetes has previously been diagnosed by a physician, or when they 
received medication to lower blood glucose levels. [9]
The study endpoint was all-cause mortality at 30 days and at 20 years. Survival 
date was assessed through municipal Civil Registries which is updated regularly and 
therefore highly accurate in the Netherlands. Follow-up was available for 99% of all 
patients. 
This project was carried out in accordance with current rules of ethics and 
legislature. The Ethical Committee of the Erasmus Medical Center waived the need for 
its approval because register-based studies do not require ethical approval according 
to Dutch law. 
Categorical variables were summarized as percentages, continuous variables as mean 
and standard deviation. The Chi-square test or student’s t-test was used to calculate 
p-values, as appropriate. Cumulative survival curves according to glucose levels were 
constructed using the Kaplan–Meier method, and compared by the log-rank test. 
Logistic regression was used to model mortality at 30 days and Cox proportional 
hazards model to examine mortality during long-term follow-up. We separately 
investigated the independent association between admission glucose levels and 
mortality, as well as that between diabetes and mortality. Adjustment was performed 
for age, gender, previous MI, previous coronary artery bypass surgery (CABG), 
hypertension, hyperlipidemia, family history of coronary artery disease, smoking 
status, renal dysfunction, anemia, diagnosis (STEMI versus NSTEMI) and decade 
of hospital admission. A significant interaction term was found for 30-day mortality 
between admission glucose levels and decade of admission (p < 0.001) and for long-
term mortality between admission glucose levels and diabetes (p = 0.012). Accordingly, 
additional analysis are presented according to decade of admission and diabetes status. 
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Temporal trend analyses were performed by comparing decades of admission 
(i.e. 2000-2008 versus 1990-2000 versus 1985-1990) in patients with and without 
hyperglycemia, respectively. These strata were chosen according to important 
improvements in therapy, with complete introduction of thrombolytic therapy in 
1990 and a substantial increase in the use of primary PCI since 2000. We used 10-year 
outcomes for comparing the influence of decades of admission on outcome. 
Results are reported as odds ratios (OR) –for 30-day mortality– and hazard ratios (HR) 
–for long-term mortality– and their respective 95% confidence intervals. All statistical 
tests were 2-tailed, and p-values were considered significant at <0.05. Analyses was 
performed using SPSS software version 20.0 (SPSS, Chicago, Ill).
Results
We included 11,324 patients, of whom 4,671 (41%) had elevated admission glucose levels. 
On average, patients with hyperglycemia were 2 years older and were more often 
female compared to patients with normal glucose levels. Baseline characteristics and 
early medical management according to admission glucose levels is shown in Table 1. 
Between 1985 and 2008, the prevalence of hyperglycemia at admission increased 
from 26% in the 1980s to 49% in the 2000s (Figure 1A). This increase was not only due 
to an increase in the prevalence of diabetes at admission (from 7% to 21%; Figure 1A) 
but also due to an increase in hyperglycemia among patients without diabetes (from 
22% to 42%; Figure 1B). In those patients with diabetes, the prevalence of admission 
hyperglycemia remained rather constant during the entire study period (decreased 
from 76% to 73%; Figure 1B). 
A total of 83,585 person-years were analyzed and, during this period, 4,449 patients 
died. There was a gradual increase in 30-day mortality with increasing admission 
glucose levels (Figure 2). Kaplan-Meier 30-day mortality rates were higher in patients 
with mild (≥7.8 mmol/L) or severe (≥11.1 mmol/L) hyperglycemia (respectively 8% and 
17%) compared to patients with normal admission glucose levels (mortality of 4%; 
Figure 3). This gradual increase in mortality remained unchanged after adjustment 
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table 1: Baseline characteristics and clinical presentation of patients hospitalized for myocardial 
infarction (MI) according to admission glucose levels
Variable admission Glucose p
Normal,  
n = 6,653 (%)
Mild  
Hyperglycemia,  
n = 2,917 (%)
Severe 
Hyperglycemia,  
n = 1,754 (%)
Age (yrs) 61 ± 13 63 ± 12 63 ± 12 <0.001
Women 26 28 35 <0.001
Previous MI 35 29 29 <0.001
Previous PCI 14 14 13 0.30
Previous CABG 10 9 8 0.021
Hypertension 35 37 39 <0.001
Diabetes 7 16 45 <0.001
Dyslipidemia 27 23 22 <0.001
Family history of CAD 28 24 20 <0.001
Current smoker 35 33 27 <0.001
Anemia * 23 26 27 <0.001
renal dysfunction † <0.001
Normal 29 29 22
Mild 51 47 44
Severe 20 24 34
STEMI 52 65 66 <0.001
reperfusion therapy z
Primary PCI 48 57 54 0.08
Thrombolytic therapy 23 25 23 0.37
 CABG = coronary artery bypass surgery; CAD = coronary artery disease; eGFR = estimated glomerular 
filtration rate; PCI = percutaneous coronary intervention.
*  Anemia was defined as a hemoglobin level of <12.0 g/dl in women and <13.0 g/dl in men.
†  Normal: eGFR 2:90 ml/min; mild: eGFR 60 to 90 ml/min; and severe: eGFR <60 ml/min per 1.73 m2  of 
body surface area.
z  Patients with STEMI only.
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Figure 1: Prevalence of hyperglycemia and diabetes at hospitalization for myocardial infarction 
according to calendar year. Left: Prevalence of hyperglycemia (admission glucose ≥ 7.8 mmol/L) 
or diabetes over time. Right: Prevalence of hyperglycemia in subgroups of patients (pts) with and 
without diabetes. 
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Figure 2: 30­day mortality according to the spectrum of admission glucose levels. 
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for potential confounders (adjusted OR 1.6, 95%CI: 1.3-2.0 for mild hyperglycemia and 
3.6, 95%CI: 2.9-4.3 for severe hyperglycemia) (Table 2). Interestingly, the association 
between hyperglycemia at admission and 30-day mortality was stronger in patients 
who were hospitalized from 2000 to 2008 (adjusted OR 2.1, 95%CI: 1.5-2.9 for mild 
hyperglycemia and 7.7, 95%CI: 5.4-11 for severe hyperglycemia; p for interaction 
< 0.001) compared to those hospitalized earlier.
table 2: adjusted odds ratios and hazard ratios for mortality according to admission glucose levels 
and presence of diabetes mellitus
Variable all patients patients With Diabetes
30-Day mortality*
Hyperglycemia: 
Normal Reference Reference †
Mild 1.6 (1.3–2.0) 1.6 (0.79–3.1)
Severe 3.6 (2.9–4.3) 3.4 (1.8–6.2)
Diabetes 1.2 (0.94–1.4) NA
20-Yr mortality* 
Hyperglycemia: 
Normal Reference Reference z
Mild 1.1 (1.1–1.2) 0.88 (0.71–1.1) 
Severe 1.6 (1.5–1.8) 1.3 (1.1–e1.5)
Diabetes  1.5 (1.3–1.6) NA
20-Yr mortality among 30-day survivors* 
Hyperglycemia: 
Normal  Reference Reference x
Mild  1.1 (1.0–1.2) 0.83 (0.66–1.0)
Severe 1.4 (1.3–1.5) 1.1 (0.89–1.3)
Diabetes 1.5 (1.4–1.7) NA
NA = not applicable.
*  Adjusted for age, gender, previous MI, previous coronary artery bypass surgery, hypertension, 
hyperlipidemia, family history, smoking status, renal dysfunction, anemia, diagnosis, and decade of hospital 
admission.
†  Interaction for diabetes and admission glucose levels, p = 0.43.
z  Interaction for diabetes and admission glucose levels, p = 0.012.
x  Interaction for diabetes and admission glucose levels, p = 0.056.
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At 20-year follow-up, Kaplan-Meier mortality rates remained higher in patients with 
mild or severe hyperglycemia (respectively 71% and 82%) compared to patients with 
a normal admission glucose levels (mortality of 64%; Figure 3). This gradual increase 
in long-term mortality was also not affected by adjustment for potential confounders 
(Table 2). 
Hyperglycemia (adjusted OR 2.3, 95%CI: 2.0-2.8) was a stronger predictor than 
diabetes (adjusted OR 1.2, 95%CI: 0.94-1.4), for 30-day mortality. However, diabetes 
(adjusted HR among 30-day survivors 1.5, 95%CI: 1.4-1.7) was a stronger predictor for 
long-term mortality compared to hyperglycemia (HR among 30-day survivors 1.2, 
95%CI: 1.1-1.3). 
There was significant heterogeneity in the association between admission glucose 
levels and 20-year mortality depending on diabetic status (p for interaction = 0.012). 
This indicates that the effect of admission glucose on long-term mortality was 
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Figure 3: Kaplan­Meier curves of unadjusted mortality according to glucose levels at 
hospitalization. Sev: severe hyperglycemia (≥11.1 mmol/L), Mild: mild hyperglycemia 
(7.8­11.0 mmol/L), Nor: normal admission glucose (<7.8 mmol/L).
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significantly different in patients without compared to those with diabetes, namely 
increased glucose levels at admission were a strong predictor for long-term mortality 
in the subgroup without diabetes, but only a weak predictor in those with diabetes 
(Table 2). This was not the case for 30-day mortality, as the effect of admission glucose 
on 30-day mortality was similar in patients without and in those with diabetes (p for 
interaction = 0.43). 
Survival after MI improved during the 24-year study period (Table 3). Compared 
to the period 1985-1990, 30-day mortality was 78% lower in 2000-2008 in patients 
without hyperglycemia (adjusted OR 0.22, 95%CI: 0.15-0.31) and 50% lower in 2000-
2008 in patients with hyperglycemia (adjusted OR 0.50, 95%CI: 0.36-0.88) (p for 
interaction <0.001). Thus, patients without hyperglycemia benefitted from a higher 
reduction in 30-day mortality than subjects with hyperglycemia. During the study 
period, the long-term mortality decline was similar among patients with and without 
hyperglycemia (p for interaction = 0.49; Table 3). 
table 3: temporal trends of 30-day and 10-year mortality in myocardial infarction patients
Calendar period No hyperglycemia hyperglycemia (Mild and Severe)
Ors for 30-day mortality *,†
1985­1990 Reference Reference
1990­2000 0.51 (0.38–0.69) 0.77 (0.57–1.0)
2000­2008 0.22 (0.15–0.31) 0.50 (0.36–0.68)
hazard ratios for 10-yr mortality*,z
1985­1990 Reference Reference
1990­2000 1.0 (0.92–1.2) 0.93 (0.81–1.1)
2000­2008 0.70 (0.61–0.80) 0.63 (0.53–0.73)
*  Adjusted for the same variables as Table 2 and diabetes.
†  Interaction for decade and hyperglycemia, p <0.001.
z  Interaction for decade and hyperglycemia, p <0.49.
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Discussion
In this large, contemporary cohort of acute MI patients, we demonstrated that admission 
glucose levels were strongly related with mortality up to 20 years during all past 
three decades. Compared to diabetes, hyperglycemia was a better discriminator for 
short-term mortality. These results are important because the prevalence of elevated 
admission glucose levels has increased substantially with time. The prevalence of 
hyperglycemia at admission increased by 22% from 1985 to almost 50% in 2008. 
Remarkably, the association between hyperglycemia and short-term mortality was 
significantly stronger in the present era. Apparently, contemporary treatment has 
resulted in relatively low mortality in the most healthy subjects. Therefore, although 
we showed that mortality after acute MI declined between 1985 and 2008, the 
observed decline was less pronounced in patients with hyperglycemia. Finally, we 
demonstrated that the association between admission glucose levels and short-term 
mortality was not dependent on diabetic status; a high admission glucose level was a 
predictor of mortality in patients with diabetes as well as in those without previously 
diagnosed diabetes. 
Our results expand the current knowledge on the relationship between admission 
glucose and outcomes over the past decades in patients hospitalized with acute MI. 
Prior studies reported an association between elevated glucose on admission and 
short-term mortality in acute MI patients during limited calendar periods. [2-6,10-11] 
Similar to our findings, most of these studies also noted that this association is not 
dependent on diabetic status. [4-5,10-11] However, no previous study has compared different 
decades of hospitalization. This is important, not only because treatment of acute MI 
has changed substantially during the past three decades, but also because patient 
characteristics at presentation have evolved. [12] In the upper 2000s, 96% of our STEMI 
patients were actually treated with primary PCI. [12] Interestingly, hyperglycemia 
proved to be a significantly stronger predictor of adverse 30-day outcome after MI in 
the last decade than 25 years ago. 
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Hyperglycemia has potential as a treatment target in acute MI patients. Unfortunately, 
results of acute interventions in glucose metabolism in patients with MI are currently 
inconclusive. [13-16] Thus, further randomized controlled trials are needed in this patient 
population. [1,17] 
In our study patients were categorized into admission glucose level <140, 140-
200 and >200 mg/dL (<7.8, 7.8-11.0, and ≥11.1 mmol/L, respectively). Since admission 
glucose levels were found to be a powerful predictor of short-term mortality with a 
better discriminative ability than diabetes and independent of other clinical patient 
factors or potential confounders, risk prediction models after MI could be improved by 
including admission glucose level. This might affect treatment decisions in individual 
patients by the use of more intensive strategies in such high risk patients. 
A unique observation of the present study is the 20 year long follow-up period, 
which is much longer than in previous studies. [3-5] Although hyperglycemia remained 
associated with increased long-term mortality, the actual presence of diabetes at 
admission proved to be a better predictor in the long term. Diabetes is a chronic disease, 
and its presence therefore reflects a long-term abnormal glucose metabolism, whereas 
admission hyperglycemia could resolve during follow-up. [6] Hyperglycemia was not 
associated with long-term mortality in patients with diabetes. It is conceivable that 
part of the association between elevated admission glucose and long-term mortality 
is mediated by hyperglycemia patients who develop diabetes in the near future. [3] As 
such, admission hyperglycemia could still function as an important discriminator of 
long-term mortality in non-diabetic patients. [3]
Finally, another distinctive aspect of our study includes the observed temporal 
trends. Importantly, a substantial increase in the prevalence of hyperglycemia at 
admission for acute MI was observed during the 24 year study period. This occurred 
in patients without diabetes and therefore was not solely the result of an increase 
in the prevalence of diabetes. [9] Still, it might be that both the increase in admission 
hyperglycemia as well as in diabetes prevalence is mediated by an increasing 
prevalence of insulin resistance resulting from higher population levels of adiposity, 
sarcopenia and physical inactivity. [18-19] 
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We have previously shown that 30-day mortality in subjects hospitalized for acute 
MI declined between 1985 and 2008. [12] We have now found that, in patients with 
admission hyperglycemia, mortality fell significantly less than in patients with 
normoglycemia at admission. Although the temporal mortality decline in patients 
with normoglycemia is encouraging, improved short term outcome in patients with 
hyperglycemia is warranted.
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Part III
Gender differences
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Abstract
Background
We aimed to study sex-related differences in temporal trends in short- and long-
term mortality from 1985 to 2008 in patients hospitalized for acute myocardial 
infarction  (MI). 
Methods and Results
We included a total of 14,434 consecutive patients admitted to our Intensive Coronary 
Care Unit between 1985 and 2008 for MI. A total of 4,028 (28%) patients were women. 
Women were more likely to present with a higher risk profile and equally likely 
to receive pharmacological and invasive reperfusion therapy compared to men. 
Women had a higher unadjusted mortality rate at 30-days (OR 1.3, 95%CI: 1.1-1.5) 
and during 20-years (HR 1.1, 95%CI: 1.0-1.2) follow-up. After adjustment for baseline 
characteristics, 30-day mortality was equal (adjusted OR 1.0, 95%CI: 0.85-1.2), but the 
hazard for 20-year morta lity was lower (adjusted HR 0.77, 95%CI: 0.66-0.90) in women 
compared to men. For 30-day mortality, there was no significant interaction between 
sex and age, diagnosis or diabetes. Survival improved between 1985 and 2008. 
Temporal mortality reductions between 1985 and 2008 were at least as high in women 
compared to men  with MI, both for 30-day mortality and long-term mortality hazard.
Conclusions
The fact that adjusted mortality rates for both the men and women treated for 
myocardial infarction in an Intensive Coronary Care Unit were similar and declined 
markedly over a 24-year period suggests that both sexes benefit from the evidence-
based therapies that have been developed and implemented during this time period.
Keywords
Sex, Prognosis, Myocardial Infarction
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Introduction
Cardiovascular disease is the number one cause of death in women and, the total 
number of women who die from cardiovascular disease is higher than this number 
in men. [1] Myocardial infarction (MI) is the major cardiovascular cause of death in 
both sexes. Since 1985, considerable progress has been made in the management 
of MI and treatment outcomes; clinical evidence has guided the introduction of 
thrombolytic therapy, primary percutaneous coronary intervention (PCI), tailored 
treatment according to individual risk and improved secondary prevention. [2-4]
It has been suggested that women with an MI may have benefitted less from the 
improvements in treatment and outcome that have occurred over the past 25 years 
because they were underrepresented in clinical trials. [5-9] However, no previous study 
has compared sex differences over a calendar period that included such marked 
changes in treatment and outcome of MI. 
Furthermore, due to the progress made in the management of MI, at present, 
most patients hospitalized with MI survive until discharge. [4] For that reason, long-
term outcomes after MI become increasingly important. However, only a limited 
number of studies have reported mortality rates after MI according to sex with 
a follow-up duration longer than one year. [10-12] Awareness of sex-differences in 
patient characteristics, treatment and outcome may eventually improve the clinical 
management and survival after MI in both women and men.  
Therefore, the aims of the present study were to determine sex-related differences 
in baseline characteristics and treatment, as well as short-term mortality and long-
term (20 year) mortality. Furthermore, we investigated whether the changes in 
mortality after MI that occurred between 1985 and 2008 were different for women and 
men. For this purpose, we analyzed 14,434 consecutive MI patients admitted to the 
Intensive Coronary Care Unit (ICCU) of the Erasmus Medical Center from 1985 to 2008. 
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Methods 
We included all consecutive patients aged >18 years with a first admission for ST-
segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) to the 
ICCU of the Thoraxcenter, Erasmus University Medical Center between June 1985 and 
December 2008. [13] No other inclusion or exclusion criteria were used.
The diagnosis of MI was made in the presence of the following characteristics: chest 
pain or equivalent symptoms in combination with dynamic ECG changes consistent 
with MI and a typical serial rise (to at least three times the upper normal value) and 
fall in serum biochemical markers of cardiac necrosis such as creatine kinase-
MB or troponin-T. Patients were diagnosed as STEMI in the presence of ST-segment 
elevation > 0.1 mV in at least two contiguous peripheral leads, or > 0.2 mV in at least 
two contiguous pre-cordial leads, and as NSTEMI otherwise. 
Trained physicians and nurses accustomed to the use of standardized case report 
forms collected the data. Demographic characteristics (age, sex), cardiac history 
(previous MI, PCI or coronary artery bypass surgery, CABG), risk factors (hypertension, 
diabetes, hyperlipidemia, family history of coronary artery disease, smoking status), 
anemia (hemoglobin level < 12.0 g/dl in women, <13.0 g/dl in men), renal dysfunction, 
and pharmacological and invasive treatment modalities (thrombolysis and PCI) 
were collected. Renal dysfunction was defined according to glomerular filtration rate 
(eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation. [14] 
Hypertension, hyperlipidemia and diabetes were defined as previously diagnosed by 
a physician or receiving medication to lower blood pressure, cholesterol or glucose 
levels, respectively. Family history was defined as one or more relatives (parent or 
sibling) with an MI diagnosed before the age of 60 years. 
The study endpoint was all-cause mortality at 30 days and during 20 years. 
Survival date was assessed through municipal Civil Registries which is updated 
regularly and therefore highly accurate in the Netherlands. Follow-up was available 
for 98% of all patients. 
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This project was carried out in accordance with current rules of ethics and 
legislature. The Ethical Committee of the Erasmus Medical Center waived the need 
for its approval because register-based studies do not require ethical approval 
according to Dutch law. 
Statistical Analysis 
Categorical variables were summarized as percentages, continuous variables as 
mean and standard deviation. The Chi-square test or student’s t-test was used to 
calculate p-values, as appropriate. To ease the display of descriptive results, sex-ratios 
for each decade were computed to compare women and men. Cumulative survival 
curves according to sex were constructed using the Kaplan–Meier method, and 
compared by the log-rank test. 
We examined the independent association between sex and mortality or mortality 
hazard using logistic regression for 30-day outcome and the Cox proportional 
hazards model for long-term outcome, respectively. Adjustment was performed 
for the baseline variables age, previous MI, previous CABG, hypertension, diabetes, 
hyperlipidemia, family history of coronary artery disease, smoking status, renal 
dysfunction, anemia, diagnosis and decade of hospital admission. Proportionality 
of hazards was tested graphically by inspection of log–log survival curves and by 
a formal test of proportionality based on Schoenfeld residuals. In the multivariable 
model, a multiple imputation algorithm with five imputations was used to handle 
the 2229 (15%) and 2347 (16%) patients in whom anemia status or renal function, 
respectively, was missing. Multiple imputation methods are known to be superior to 
complete case analyses. [15] In line with the literature, the association between sex and 
30-day mortality was also examined in subgroups according to age (<65 year and ≥65 
year), diagnosis (STEMI or NSTEMI) and diabetes status. We assessed heterogeneity 
within these subgroups with a statistical test for interaction.
Similar multivariable models were used to assess changes in mortality from 1985 
to 2008 in women and men, separately. For this purpose, calendar periods of 3 years 
were compared. Results are reported as odds ratios (OR) –for 30-day mortality– and 
hazard ratios (HR) –for long-term mortality– and their respective 95% confidence 
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intervals. All statistical tests were 2-tailed, and p-values were considered significant 
at <0.05. To address multiplicity of testing for heterogeneity, p-values for interaction 
were considered significant at <0.017 (0.05 divided by three, as we defined subgroups 
according to three characteristics). [16] Analysis was performed using SPSS software 
version 20.0 (SPSS, Chicago, Ill).
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Results
Patient characteristics
We included 14,434 patients, of whom 4,028 (28%) were women. On average, women 
were 5 years older. In addition, compared to men, women more often had hypertension, 
diabetes mellitus, renal dysfunction or anemia, were less often current smokers, 
and less often had a history of prior MI, PCI or CABG, or a diagnosis of STEMI (Table 
1). From 1985 to 2008, the patients became older on presentation (Figure 1), and were 
Tables
table 1: Baseline characteristics and clinical presentation of patients hospitalized for MI 
according to gender. 
Women  
(n = 4028)
Men  
(n = 10,406) p
Gender-ratios*
1985-‘90 1990-‘00 2000-‘08
Characteristics
Age (years) 65 (12) 60 (12) <0.001
Elderly (>65 y) 55% 37% <0.001 1.7 1.4 1.5
Cardiac history
Previous MI 30% 35%  <0.001 0.80 0.77 0.94
Previous PCI 13% 15%     0.032 0.82 0.74 0.94
Previous CABG 8% 10% <0.01 0.87 0.62 0.96
risk factors
Hypertension 43% 32% <0.001 1.3 1.4 1.3
Diabetes 18% 12% <0.001 2.0 1.6 1.4
Hyperlipidemia 28% 27% 0.62 0.85 1.1 1.0
Family history  27% 26% 0.11 1.3 1.1 1.0
Current smoker 26% 35% <0.001 0.60 0.70 0.81
Renal dysfunction † <0.001
Normal 20% 32% 0.31 0.68 0.66
Mild dysfunction 46% 50% 0.79 0.92 1.0
Impaired 33% 18% 2.0 1.7 1.9
Anemia 49% 39% <0.001 1.2 1.2 1.4
Discharge diagnosis
STEMI 43% 49% <0.001 0.87 0.82 0.90
*  Gender­ratios show the percentage of women with the specific characteristic divided by the 
corresponding percentage in men within a specified decade.
†  Normal, estimated GFR (eGFR) >= 90 ml/min; Mild dysfunction, eGFR 60­90 ml/min;  
Impaired, eGFR <60 ml/ min per m2 of body­surface area. 
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more likely to have diabetes or anemia (p for trend < 0.001 for all). Age at presentation 
increased uniformly in both women and men, therefore the age difference between 
women and men remained about 5 years during the study period. However, due to 
the changes in prevalence of risk factors over time, the cardiovascular risk profile at 
baseline in women became more comparable to that in men in the most recent period 
(Table 1). 
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Figure 1: Distribution of study population according to age and study period. 
table 2: Initial and early management of patients hospitalized for MI according to gender. 
Women Men P 
No. of patients 4028 10,406
Invasive treatment
Thrombolytic therapy * 22% 24% 0.13
PCI* 53% 53% 0.80
Medication at ICCU discharge
Statins † 70% 73% <0.01
Aspirin 67% 68% 0.39
β­blockers 56% 59% <0.001
ACE­I/ARB ‡ 22% 24% 0.044
Ca­antagonist 24% 22% 0.044
Nitrates 14% 12% <0.01
Diuretics 15% 12% <0.001
Antiarrhythmics 3% 4% <0.01
 * STEMI patients only. ICCU, intensive coronary care unit.
†  Patients from 2000 to 2008 only. 
‡  Patients from 1990 to 2008 only. 
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Patient management
Overall, sex disparities in initial and early medical management were limited 
(Table 2). Women with STEMI were equally likely to receive reperfusion therapy (by 
either thrombolytic therapy or PCI). With time, more patients received guideline-
based therapy. No new sex disparities in use of evidence-based management became 
apparent during the study period.
Sex and mortality 
A total of 106,517 person-years were analyzed. During the study period, 1,544 women 
and 3,708 men died. At 30 days, unadjusted mortality rates were higher in women than 
in men (7% vs. 6%; OR 1.3, 95%CI: 1.1-1.5; Figure 2). However, after adjustment for age, 
the difference in 30-day mortality between women and men was no longer present 
(adjusted OR 1.0, 95%CI: 0.89-1.2). After adjustment for all potential confounders, 30-
day mortality remained the same (adjusted OR 1.0, 95%CI: 0.85-1.2; Table 3).
There was no heterogeneity in the association between sex and 30-day mortality 
in subgroups according to age (p interaction = 0.41), diagnosis (p interaction = 0.49) or 
diabetes (p interaction = 0.019) (with significance at p < 0.017 to address for multiplicity 
of testing). 
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Figure 2: Kaplan­Meier curves of unadjusted 20­year mortality according to gender.
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At 20-year follow-up, unadjusted mortality was slightly higher in women (71% vs. 
65%, HR 1.1, 95%CI: 1.0-1.2; Figure 2), but the adjusted 20-year mortality hazard was 
significantly lower in women compared to men (adjusted HR 0.77, 95%CI: 0.66-0.90; 
Table 3). 
table 3: Unadjusted and adjusted odds ratios for 30-day mortality and hazard ratios for 20-year 
mortality in women vs. men. 
Unadjusted adjusted*
1985-2008 1985-2008* 1985-‘90* 1990-‘00* 2000-‘08*
30-day mortality
All patients 1.3 (1.1-1.5) 1.0 (0.85-1.2) 0.91 (0.64-1.3) 1.0 (0.79-1.3) 1.0 (0.79-1.3)
<65 1.1 (0.88­1.5) 1.1 (0.82­1.4) † 0.82 (0.46­1.5) 1.5 (1.0­2.3) 1.0 (0.57­1.6)
>65 1.1 (0.92­1.3) 0.95 (0.78­1.2) 0.91 (0.59­1.4) 0.83 (0.60­1.2) 1.0 (0.77­1.4)
STEMI 1.5 (1.2­1.8) 1.0 (0.85­1.3) ‡ 0.93 (0.60­1.4) 1.0 (0.71­1.4) 1.1 (0.82­1.5)
NSTEMI 1.2 (0.91­1.5) 1.0 (0.72­1.3) 0.91 (0.52-1.6) 1.1 (0.72-1.7) 0.83 (0.50-1.4)
No DM 1.2 (1.0-1.4) 0.92 (0.77-1.1) § 0.80 (0.55-1.2) 0.91 (0.68-1.2) 1.0 (0.74-1.3)
DM 2.0 (1.4-2.8) 1.5 (1.1-2.2) 1.7 (0.69-4.3) 2.1 (1.1-4.2) 1.2 (0.68-2.1)
20-year mortality
All patients 1.1 (1.0­1.2) 0.77 (0.66­0.90) 0.79 (0.67­0.93) 0.65 (0.50­0.84) 0.80 (0.67­1.0) ||
 *  Adjusted for age, previous MI, previous CABG, hypertension, diabetes, hyperlipidemia, family history, 
smoking status, renal dysfunction, anemia, discharge diagnosis and decade of hospital admission. 
†  interaction age and sex p = 0.41.
‡  interaction STEMI and sex p = 0.49.
§  interaction diabetes and sex p = 0.019.
||  10­year mortality hazard.
Chapter 9.    Sex­Related Trends in Outcome After MI     |     133
Secular trends in mortality 
Compared to 1985-‘87, 30-day mortality after MI in 2006-‘08 was significantly and 
substantially lower in both sexes (Figure 3). The Kaplan-Meier estimate of 30-day 
mortality decreased from 10% in 1985-’87 to 4% in 2006-’08. In women, adjusted 30-day 
mortality was 83% lower in 2006-‘08 compared to 1985-‘87. In men, adjusted 30-day 
mortality was 73% lower in 2006-‘08 compared to 1985-‘87 (p for interaction = 0.30). 
The Kaplan-Meier estimate of 5-year mortality decreased from 24% in 1985-’87 to 14% 
in 2006-’08. In both women and men, the adjusted 5-year mortality hazard was 52% 
lower in 2006-‘08 compared to 1985-‘87 (p for interaction = 0.16). Thus, improvement in 
short- and long-term mortality during the 24-year study period was similar in women 
and men. 
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Figure 3: Temporal trends according to gender and follow­up duration. Outcome of patients who 
were hospitalized for MI during three­year calendar periods is compared to outcome of patients 
who were hospitalized in 1985­87. P­values for interaction between gender and year of MI are 
shown. 
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Discussion
This study demonstrates that, during an observation period of 24 years, women 
hospitalized for an acute MI were more likely to present with a higher risk profile 
but were equally likely to receive pharmacological and invasive reperfusion therapy 
compared to men. The higher risk profile was mainly determined by an average 
age difference of 5 years between women and men. Women and men had the same 
adjusted mortality rates at 30 days, while during 20 years of follow-up the mortality 
hazard was lower in women. Importantly, temporal improvements in 30-day mortality 
and long-term mortality hazard from 1985 to 2008 were substantial and at least as 
high in women as in men. 
We showed that women were older and therefore presented with a higher risk profile 
compared to men, which is in line with previous studies. [11, 17-22] In our multivariable 
analysis, these differences fully account for the higher unadjusted mortality in 
women compared to men. Therefore, it is unlikely that other differences between 
women and men, including differences in biological factors and in treatment, caused 
the higher unadjusted mortality rate in women. 
Previous analyses have reported that in certain subgroups, such as younger 
patients, the mortality risk may be a higher in women compared with men. [23, 24] Data 
from the US National Registry of Myocardial Infarction collected in the 1990s indicated 
an increased in-hospital mortality risk for young women compared with young men, 
with no mortality difference in the older population. [24] In our analysis, mortality 
appeared higher in young women compared to young men in the same calendar 
period (i.e. the 1990s), however, this age dependent sex gap completely disappeared 
in the next decade. Furthermore, no significant interaction was detected between sex 
and age in case the patients of all three decades were pooled together. In this study 
there was also no significant interaction between sex and diagnosis. Most MI studies 
do not report significant interaction between sex and type of MI, [20, 25, 26] it therefore is 
likely that our conclusions are robust for STEMI and NSTEMI patients. 
We show borderline significant heterogeneity in the association between sex and 30-
day mortality in subgroups according to baseline diabetes, such that among patients 
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with diabetes female sex might be associated with increased 30-day mortality. This 
finding is in part consistent with prior studies that noted increased risk of adverse 
events following MI among women vs. men with diabetes. [27, 28] Clinical trials in the 
diabetic population might help to identify specific therapies to reduce their increased 
risk of death.
Our study is unique in that it shows long-term (20 year) mortality depending on sex. 
Once admitted to the hospital, the adjusted hazard for long-term mortality is more 
favorable in women compared to men, similar to findings of their survival advantage 
in the general population. Although several studies have also shown that women 
are at a lower risk up to 12 months after the onset of MI, [18, 25] our adjusted analysis 
demonstrates – for the first time – that this assertion can be extended for up to 20 years 
in a contemporary population. 
Contrary to previous studies that showed that mortality decreased less over time 
in women compared with men, [6-8] we now show that the improvement in outcome 
after MI over the last 24 years is at least as substantial in women as it is in men. In 
this respect, it should be noted that the calendar period that we studied differed from 
those in previous studies. Our study was initiated in 1985, at that time thrombolysis 
became standard therapy, and extents to the present era in which PCI became the 
standard therapy. [2] The conflicting observation between our study demonstrating 
that mortality improved over time at least as much in women as in men and 
previous studies that showed more improvement in men may be due to the relatively 
short time frame of these previous studies. [6-8] In addition, in the present study sex 
disparities in medical management were limited. This might have contributed to 
relatively favorable outcomes in women, compared to studies in countries were 
women less often receive evidence based management. [9] As such, the present study 
might demonstrate a best case scenario.
Strengths and limitations
To our knowledge, this is the first study investigating temporal trends in clinical 
characteristics, treatment and outcome of patients with an MI according to sex over a 
time period of 24 years and with follow-up data up to 20 years. Although the present 
study has unique strengths, some limitations should be mentioned. Firstly, given the 
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nature of sex this study reveals important associations but cannot prove causation. 
Secondly, this study is based on hospitalized patients only and did not account for 
possible sex differences in out-of-hospital deaths prior to admission. Finally, the 
present data are derived from a single center. 
Conclusion
We showed that, among patients hospitalized for acute MI, women are more likely 
to present with a higher risk profile and were almost as likely as men to receive 
contemporary medical therapy. After adjustment for baseline differences, 30-day 
mortality was equal among women and men, while the adjusted 20-year mortality 
hazard was lower in women. Importantly, temporal improvements in short- and long-
term mortality from 1985 to 2008 were substantial and similar for women and men. 
The temporal trends are encouraging and suggest that both men and women will 
benefit from further improvements in care for acute myocardial infarction.
Disclosures
None. 
Clinical perspective
During the past decades, medical management and outcomes of acute myocardial infarction have 
improved substantially. It has been suggested that women with a myocardial infarction have benefitted 
less from these improvements in treatment and outcome when compared to men, because they 
were underrepresented in clinical trials. With the present study, however, we are the first to test this 
suggestion over a 24 year study period. We demonstrate that  adjusted short­ and long­term mortality 
rates were similar and declined markedly and equally in women compared to men during the 24 years 
studied. Furthermore, we also present long­term mortality data, up to 20 years following the myocardial 
infarction, which is sparse. This study is important because it helps to direct both further research and 
further management, in which women deserve to be treated with the same evidence­based care. In 
addition, the observed temporal trends are encouraging and suggest that both men and women will 
benefit from further improvements in care for acute myocardial infarction.
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Abstract
Objectives
We compared survival in patients with prior MI with survival in the general population. 
Methods: We examined 14,434 consecutive patients admitted for MI to an intensive 
coronary care unit from 1985 to 2008 and compared survival in those patients with 
survival in the general population using (conditional) relative survival analyses. 
Relative survival, meaning survival in MI patients corrected for estimated mortality 
from all other causes, and conditional survival (that is ‘landmark’ survival) was 
computed. 
Results
Median survival from hospitalization for MI was >20, 17, 11, and 6 years in men, and 
>20, 19, 12, and 7 years in women, for ages <55, 55-65, 65-75 and ≥75 years, respectively. 
The 1-year relative survival (from hospitalization) was 98%, 97%, 95%, and 89% in 
men, and 97%, 95%, 94%, and 88% in women, for ages <55, 55-65, 65-75 and ≥75 years, 
respectively. In male patients aged 55-65 years, cumulative relative survival was 
73% at 20 years, while conditional 1-year relative survival was 97%, 99% and 98%, 
conditional on surviving 0, 5 and 20 years after index hospitalization. For all age and 
sex subgroups, conditional 1-year relative survival was lower during the first year and 
after 15 years.
Conclusions
Survival in patients with a prior MI is only a few percent lower per year compared to 
the general population for both sexes and all age groups. Although these results are 
encouraging, continuation of optimal treatment –in particular in the first year and 
after 15 years– might further improve survival in the future.
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Introduction
Patients who have experienced myocardial infarction (MI) often ask their physicians 
for an estimate of their prognosis. [1] Prognosis after MI is generally expressed as 
all-cause or cause-specific mortality rates. Neither approach assess the impact 
of the disease or health state of interest in comparison with expected survival in a 
similar population. Relative survival, which is the survival among patients divided 
by the expected survival of a the general population, is applied routinely in cancer 
studies and may improve on current methods for assessment of survival after MI. [2] 
In addition, estimates of cause-specific survival are limited by their dependence on 
reliable information on cause of death, whereas, relative survival is not. 
Patients who have survived for a certain amount of time after their hospitalization 
for MI are interested in their prognosis at that particular time point. Standard survival 
curves after hospitalization provide an overly pessimistic picture for these patients, 
because these are partly based on patients who are most seriously affected and 
consequently die within the first month. Conditional survival analysis (or ‘landmark’ 
analysis) is a method for estimating the survival rate, given the precondition of having 
already survived a certain period of time. Conditional survival rates can provide 
patients and treating physicians with more relevant information for personal health-
related future planning. Until now, relative survival analyses and conditional relative 
survival analyses have rarely been used in cardiovascular research. [2, 3]
With the current study, we aim to determine long-term relative survival rates in 
patients with a prior MI. In addition, we determine mortality for patients given they 
survived up to 20 years after MI by means of conditional survival estimates. For this 
purpose, we have analyzed data on 14,434 consecutive MI patients admitted to the 
Intensive Coronary Care Unit (ICCU) of the Erasmus Medical Center from 1985 to 2008. 
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Methods 
We included all 14,434 consecutive patients aged >18 years admitted for MI to the 
Intensive Coronary Care Unit (ICCU) of the Thoraxcenter, Erasmus Medical Center 
between June 1985 and December 2008, as previously described. [4]
The diagnosis of MI was made in the presence of the following characteristics: chest 
pain or equivalent symptoms in combination with dynamic ECG changes consistent 
with MI and a typical serial rise (to at least three times the upper normal value) and 
fall in serum biochemical markers of cardiac necrosis such as creatine kinase-MB or 
troponin-T. For patients admitted more than once, only the first hospitalization was 
taken into account. 
The study endpoint was all-cause mortality. Survival status and date were assessed 
through municipal Civil Registries in 2010 and were available for 98% of all patients. 
This project was carried out in accordance with current rules of ethics and legislature. 
The Ethical Committee of the Erasmus Medical Center waived the need for its approval 
because register-based studies do not require ethical approval according to Dutch law. 
 
Statistical analysis
Cumulative relative survival was calculated as the observed survival among the 
MI patients divided by the survival of persons from the general population (publicly 
available from Statistics Netherlands), matched for sex, age and calendar year. [2] 
Thus, relative survival provides a measure of the excess mortality experienced by 
MI patients compared to the general population, irrespective of whether mortality is 
directly or indirectly related to the index MI. As such, relative survival also captures 
excess mortality because of, for example, treatment-related acute kidney injury or in-
hospital infections, which is not possible when using cause-specific survival. 
Conditional 1-year relative survival depicts the 1-year relative survival given that a 
patient has survived for a certain period of time (for example, 0 year, 1 month, 1 year, 
5, 10, 15 or 20 years). We calculated conditional 1-year survival at year x by dividing 
cumulative survival rates of year x + 1 by the cumulative survival rate of year x. 
Subsequently, we combined relative and conditional survival estimates. A conditional 
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1-year relative survival of 100% indicates that, mortality in the patient group has 
become equivalent to that of the general population. 
We displayed survival rates according to both sexes and four age groups: <55, 55-65, 
65-75 and >75 years. Besides cumulative and conditional relative survival, we also 
estimated cumulative and conditional observed survival. Observed survival is the 
actual survival among the MI patients, considering all causes of death together. 
The period approach was used to provide predictions of (both cumulative and 
conditional) relative and observed survival. [5] The period approach combines survival 
rates in a recent period (in this study, 2000-2011) to obtain up-to-date survival 
estimates. This approach mirrors the standard predictions of life expectancy at birth 
from the most recently recorded death rates at each age. [6] 
Analyses were performed using SAS software version 9.2 (SAS Institute, Cary, NC, 
USA). Calculations were performed with a publicly available SAS macro that can be 
used for period analysis. [7] The macro calculated expected survival according to the 
Ederer II method from population life tables stratified by age, sex and calendar period. 
Standard errors of the survival estimates were calculated using Greenwood’s method, 
and 95% confidence intervals were reported for cumulative survival estimates. We 
presented only relative survival estimates with a standard error <=10% of the survival 
rate and conditional survival estimates with a standard error <=5% of the survival rate.
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Results
Study population and Median or Cumulative Observed Survival 
We included 14,434 patients who were hospitalized for MI between 1985 and 2008. 
Median observed survival after MI is shown in Table 1 (and Figure 1). Observed 
survival after MI was inversely related to age and better for women compared to men. 
Median observed survival in men was >20, 17, 11, and 6 years, and median observed 
survival in women was >20, 19, 12, and 7 years, for ages <55, 55-65, 65-75 and ≥75 years, 
respectively (Table 1). The 1-year observed survival (from hospital admission) was 
98%, 96%, 92%, and 82% in men, and 97%, 95%, 92%, and 83% in women, for ages <55, 
55-65, 65-75 and ≥75 years, respectively. The cumulative 20–year observed survival 
(from hospital admission) is 61%, 39%, 13%, and 0% in men, and 67%, 42%, 16%, and 3% 
in women, for ages <55, 55-65, 65-75 and ≥75 years, respectively (Figure 1). 
Figure 1: Observed survival after MI (follow­up period 2000­2011). Survival estimates (and 95%CIs) 
are shown at 5, 10 and 20 years follow­up.  
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table 1: Median observed survival after MI according to age and sex.
Gender age No. of MI patients Median survival after MI (years)
Men <55 3452 >20 a
55­65 3153 17
65­75 2684 11
≥75 1117 6
Women <55 867 >20 a
55­65 960 19
65­75 1278 12
≥75 923 7
a  Median survival is at least longer than 20 years (maximum follow­up duration).  
Conditional observed survival
Conditional 1-year observed survival in male patients aged 55 to 65 years was 96%, 
98%, 98%, 97%, 96%, and 88%, conditional on surviving 0 years, 1 month, 1 year, 5, 10 
and 20 years after hospital admission, respectively (Table 2). Conditional observed 
survival was lower with increasing age. 
table 2: Conditional one-year observed survival after MI.
Conditional one-year observed survival reliable 
estimates  
up to yearNo. of years already survived
Gender age 0 yrs 1/12 yr* 1 yr 5 yrs 10 yrs 15 yrs 20 yrs
Men <55 98% 98% 99% 98% 98% 97% 99% 20
55­65 96% 98% 98% 97% 96% 93% 88% 20
65­75 92% 95% 96% 95% 90% 82% a 17
≥75 82% 88% 91% 89% a a a 9
Women <55 97% 98% 99% 99% 100% 98% 97% 20
55­65 95% 96% 99% 99% 95% 94% 89% 20
65­75 92% 95% 96% 98% 93% 89% a 17
≥75 83% 91% 95% 88% a a a 9
* Conditional on 1 month survival.
a  Standard error of conditional survival proportion > 5%. 
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Relative survival
Relative survival rates were substantially higher than observed survival rates due 
to elimination of background mortality. The 1-year relative survival (from hospital 
admission) was 98%, 97%, 95%, and 89% in men, and 97%, 95%, 94%, and 88% in women, 
for ages <55, 55-65, 65-75 and ≥75 years, respectively. The cumulative 10-year relative 
survival (from hospital admission) was 89%, 90%, 87%, and 89% in men, and 92%, 
89%, 78%, and 90% in women, for ages <55, 55-65, 65-75 and ≥75 years, respectively 
(Figure 2). 
Figure 2: Relative survival after MI (follow­up period 2000­2011), as compared to survival in the 
general population with the same age and gender. Survival estimates (and 95%CIs) are shown at 5, 
10 and 20 years follow­up.   
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Conditional relative survival
Conditional relative survival rates combine the information from conditional survival 
and from relative survival. Conditional 1-year relative survival was lower directly 
after hospital admission and conditional on 15 or more years survival compared to the 
time-period between 1 and 15 years (Table 3). For example, one-year conditional relative 
survival in male patients aged 55 to 65 years was 97%, 99%, 99%, 99%, 99%, and 98%, 
conditional on surviving 0 years, 1 month, 1 year, 5, 10, and 20 years after hospital 
admission, respectively. This indicates that, for example, one-year survival of a patient 
aged between 65 and 75 years who suffered a MI 10 years ago (age at index MI was 55 
to 65 years) is 1% lower compared to 1-year survival in the general population. One-year 
conditional relative survival in other age groups (except ≥75 years) and in women was 
comparable. 
table 3: Conditional one-year relative survival after MI.
Conditional one-year relative survival reliable 
estimates  
up to yearNo. of years already survived
Gender age 0 yrs 1/12 yr* 1 yr 5 yrs 10 yrs 15 yrs 20 yrs
Men <55 98% 99% 99% 99% 99% 99% 100% 20
55­65 97% 99% 99% 99% 99% 98% 98% 20
65­75 95% 98% 99% 99% 97% 93% a 17
≥75 89% 95% 99% 100% a a a 9
Women <55 97% 98% 99% 99% 100% 99% 95% 20
55­65 95% 97% 99% 100% 97% 97% 93% 20
65­75 94% 96% 98% 101% 98% 96% a 17
≥75 88% 96% 101% 97% a a a 9
* Conditional on 1 month survival.
a  Standard error of conditional survival proportion > 5%.  
Relative survival, survival after MI compared to survival in the general population with the same age 
and gender.    
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Discussion
In this study of 14,434 MI patients we provide an overview of long-term prognoses 
according to age and sex, based on contemporary mortality rates. Our results 
demonstrate that the overall median life-expectancy after MI varies between 6 and 
more than 20 years, mainly depending on age at presentation. Our relative survival 
analyses show that survival in patients with a prior MI is only a few percent lower per 
year compared to the general population. Conditional survival analysis displays that 
survival after MI is especially decreased in the first year post MI and after 15 years 
follow-up. Information on long-term prognosis after MI is needed to guide medical 
decisions and might be of interest for patients because it affects their personal life 
choices.
Previous studies have determined temporal trends in mortality after MI by 
comparing groups of patients who were admitted during different calendar years. [8- 11] 
These studies have demonstrated that mortality has fallen substantially during the 
past decades, most likely due to the progress that has been made in improvement 
of emergency medical response, development of treatments and improvement of 
secondary prevention after MI. [8, 12] In the present study, we further investigate this 
improved prognosis by a comparison with the general population and performing 
conditional survival analyses. Such estimates of (conditional) relative survival in 
patients with prior MI are scarce. [2]
Relative survival provides a measure of the excess mortality experienced by MI 
patients compared to the general population. Relative survival after MI remains 
favorable during up to 20 years follow-up. At 10 years of follow-up, for example, 
cumulative relative survival is about 90% indicating that 10-year survival in 
MI patients is 10% lower compared to the general population. This prognosis is 
encouraging and highlights the effectiveness of current treatment following MI. 
However, according to the guidelines, even a 10% survival difference in ten years 
assures that intense surveillance and secondary prevention remains warranted in 
these patients. [13]
Chapter 10.    Relative survival estimates in MI     |     151
In view of the comparison with the general population, [1] it might be noteworthy 
that the excess mortality is not only due to the index MI and therefore cannot be 
interpreted as mortality due to cardiac death. Mortality after MI could also be higher 
compared to the general population as a result of risk factors that that are associated 
with both MI and mortality, such as smoking (associated with MI) and death from 
lung cancer (associated with smoking). 
Conditional one-year relative survival was relatively low directly following MI and 
decreased again slightly for patients who had already survived for some time (15 years). 
The relatively low survival directly following MI is due to a rather high in-hospital 
mortality. [14] The second decrease in survival in patients who had already survived for 
some time may partly be explained by the risk profile present in MI patients compared 
to the general population, or by late complications following MI such as death from 
heart failure. Still, since this risk profile, or such complications, did not cause such 
high mortality rates in the period from 1 to 15 years following MI, increased awareness 
with stringent secondary prevention for patients with a longstanding history of MI 
might be necessary.
Conditional one-year relative survival occasionally was 101% for older patients. 
Although absolute survival rates cannot be greater than 100%, relative survival rates 
can exceed 100%. This occurs if mortality in the general population is higher than 
mortality after MI. With conditional one-year relative survival we investigated relative 
survival in one-year intervals of follow-up. A survival exceeding 100% in such an 
interval could be explained by random variation or by selection of more healthy MI 
patients during follow-up. 
Strengths and limitations
To our knowledge, this is the first paper investigating (conditional) relative survival 
in MI patients with follow-up data up to 20 years. Although the present study has 
unique strengths, some potential limitations should be mentioned. First, the present 
data are derived from a single center, which could result in a lower external validity. 
However, we think that this is unlikely to be the case given the uniform definition 
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and therapeutic modalities of MI. Second, the current report is based on MI patients 
who survived until hospital admission for their index event, therefore the survival 
estimates apply to hospitalized patients or patients with a history of MI only. 
Conclusion
At present, MI patients have a substantial long-term survival. Compared to the general 
population survival after MI is only a few percent lower per year. Nevertheless, 
this survival difference remains an important target for treatment and secondary 
prevention. This applies even more to the first year after MI, and to those patients who 
survived more than 15 years after MI, because at these periods the relative survival 
difference is most pronounced. Insight into relative and conditional survival is useful 
for patients, who may use this information to plan their remaining life.
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Abstract
Objectives 
Several risk factors for coronary heart disease (CHD) have been associated with 
improved in-hospital survival after myocardial infarction (MI). We aimed to confirm 
this paradox and assess whether it extends to long-term outcome. In addition, we 
investigated temporal mortality trends. 
Methods 
We examined the relation between the presence of 4 modifiable risk factors for CHD 
(hypertension, dyslipidemia, diabetes mellitus and smoking) and mortality in 14,434 
consecutive patients admitted with MI to a coronary care unit from 1985 to 2008. 
Results 
Two-thirds of MI patients (n=10,003) had at least one risk factor for CHD on hospital 
admission. The presence of at least one compared to no CHD risk factors was 
associated with a favorable 30-day mortality rate (5% vs. 7%, adjusted odds ratio 0.72, 
95%CI: 0.62-0.83). There was significant interaction between the presence of CHD 
risk factors and decade of hospitalization (p = 0.001). The adjusted 10-year mortality 
hazard ratio (HR) of at least one CHD risk factor compared to none, was 1.2 (95% CI: 
1.0-1.4), 0.89 (0.65-1.2) and 0.89 (0.79-0.99) in 1985-1990, 1990-2000 and 2000-2008, 
respectively. Survival improved over time. Adjusted 10-year mortality fell (adjusted 
HR (2000-08 versus 1985-1990) 0.59 (95%CI 0.52-0.66) in patients with, and 0.76 (95% 
CI 0.65-0.89) in those without CHD risk factors).
Conclusions 
The presence of at least one modifiable CHD risk factor was associated with improved 
outcome after MI. Patients with CHD risk factors benefited from more substantial 
mortality reductions during the past decades. 
Keywords
Mortality, Coronary Heart Disease, STEMI, NSTEMI, Diabetes, Hyperlipidemia, 
Hypertension, Smoking, Long-term survival, Paradox.
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Introduction
Hypertension, dyslipidemia, smoking and diabetes mellitus are traditional risk factors 
for coronary heart disease (CHD) in patients without established cardio vascular 
disease. [1, 2] Contrary, two recent studies of patients with a myocardial infarction (MI) 
have shown the presence of these CHD risk factors to be associated with a significantly 
lower in-hospital mortality rate. [3, 4] However, further con fir mation of these findings is 
needed and the impact on long-term outcome has not been established yet. [5] 
Since 1985, considerable progress has been made in the management of MI; 
clinical evidence has guided the introduction of thrombolytic therapy, primary 
percutaneous coronary intervention (PCI), tailored treatment according to individual 
risk and improved secondary prevention. [6-8] As a result, outcome after MI has 
improved sub stantially. [6-8] Previous studies have shown that these treatments 
are used more frequently in patients with at least one modifiable CHD risk factor 
(hypertension, dyslipidemia, diabetes mellitus and smoking). [3, 4] As these treatments 
have increasingly been used in the past decades we also wondered whether the 
association between CHD risk factors and mortality changed between 1985 and 2008. 
Therefore, The main goal of this research was to establish the association between 
the presence of modifiable CHD risk factors and 30-day, as well as long-term (20-year) 
mortality after MI. In addition, we also compared the relation between the presence 
of CHD risk factors and outcome according to decades of hospital admission (i.e. 1985-
1990 vs. 1990-2000 vs. 2000-2008).
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Methods 
All consecutive patients aged >18 years with a first admission for ST-segment 
elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) to the Intensive 
Coronary Care Unit (ICCU) of the Thoraxcenter, Erasmus University Medical Center 
between June 1985 and December 2008 were included. [7] 
The primary discharge diagnosis of STEMI was made in the presence of the following 
characteristics: chest pain or equivalent symptoms in combination with dynamic ECG 
changes consistent with MI and a typical serial rise (to at least three times the upper 
normal value) and fall in serum biochemical markers of cardiac necrosis such as 
creatine kinase-MB or troponin-T. Patients were diagnosed as STEMI in the presence 
of ST-segment elevation >0.1 mV in at least two contiguous peripheral leads, or >0.2 
mV in at least two contiguous pre-cordial leads, and as NSTEMI otherwise. 
Four modifiable CHD risk factors were recorded at hospitalization and included 
hypertension, dyslipidemia, diabetes and current smoking. Hypertension, dysli pide-
mia and diabetes were defined as previously diagnosed by a physician or receiving 
medication to lower blood pressure, cholesterol levels or glucose levels, respectively. 
Smoking was defined as current smoking. Assessment of these risk factors was 
based on patient/family self-report or previous medical records. Demographic 
characteristics (age, gender), cardiac history (previous MI, PCI or coronary artery 
bypass surgery (CABG)), family history of coronary heart disease (defined as one or 
more relatives, parent or sibling, with an MI diagnosed before the age of 60 years), 
anemia (Hemo globin level <13.0 g/dl men, <12.0 g/dl women), renal dysfunction 
(creatinine >150 μmol/l), invasive treatment modalities (thrombolysis and PCI) and 
medication at ICCU discharge were collected. 
The study endpoint was all-cause mortality at 30 days and at 20 years. Survival date 
was assessed in 2010 through municipal Civil Registries which is updated regularly 
and therefore highly accurate in the Netherlands. Follow-up was available for 99% of 
all patients. 
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This project was carried out in accordance with current rules of ethics and 
legislature. The Ethical Committee of the Erasmus Medical Center waived the need 
for their approval because register-based studies do not require ethical approval 
according to Dutch law (entitled ‘WMO’). 
Statistical Analysis 
The patients were categorized depending on the presence or absence of CHD risk factors. 
Continuous variables were summarized as mean and standard deviation or median 
and interquartile range and Analysis of Variance (ANOVA) or Kruskal-Wallis test, 
respectively were used to calculate p-values. Categorical variables were summarized 
as percentages. Test for trend was performed using the number of CHD risk factors as 
a categorical measurement. Using Cox regression, age adjusted cumulative survival 
curves for the presence or absence of at least one CHD risk factor were constructed 
and examined using the log-rank test. The independent association between the 
presence of risk factors and mortality was examined using logistic regression for 30-
day outcome and the Cox proportional hazards model for long-term (20-year) outcome. 
Multivariate adjustment was performed for age, gender, previous MI, previous CABG, 
family history of CHD, renal dysfunction, anemia, decade of admission and discharge 
diagnosis. Sensitivity analysis were performed in patients who died the first day after 
admission and those without prior coronary heart disease. We tested for interaction 
between the presence of CHD risk factors and 1) decade of admission or 2) discharge 
diagnosis. Because there was significant interaction between the presence of CHD 
risk factors and decade of admission, results are also presented for each decade of 
admission separately. Temporal trends were assessed by comparing decades of 
hospital admission, i.e. 1985 to 1990 vs. 1990 to 2000 vs. 2000 to 2008. Complete long-
term (20-year) follow-up of patients admitted after 1990 is unavailable, therefore, we 
used 10-year outcomes when comparing decades of hospitalization. For these decades 
we also report the prevalence of modifiable risk factors. Results are reported as odds 
ratios (OR) –for 30-day mortality– and hazard ratios (HR) –for long-term mortality– 
and their respective 95% confidence intervals. All statistical tests were 2-tailed, and 
p-values were considered significant at <0.05. Analysis was performed using SPSS 
software version 17.0 (SPSS, Chicago, USA).
Ch
ap
te
r 
11
164     |     Myocardial infarction: temporal trends over the past three decades
table 1: Baseline characteristics and clinical presentation of patients hospitalized for MI according 
to absence, presence and number of coronary heart disease risk factors.
 No ChD risk factors
≥1 CHD risk 
factors
1 ChD risk 
factor
2 ChD risk 
factors
3 or 4 ChD 
risk factors
p 
for trend
No. of patients 4431 10 003 5652 3134 1217  
(31%) (69%) (39%) (22%) (8%)
Baseline
Age, mean (SD) 64 (12) 61 (12) 61 (12) 61 (12) 60 (12) <0.001
Gender (female), % 27% 28% 27% 29% 33% <0.001
Family history of CHD, % 15% 31% 28% 33% 41% <0.001
Cardiac history, %
Previous MI 35% 32% 31% 34% 33% 0.27
Previous PCI 15% 14% 13% 15% 17% 0.12
Previous CABG 11% 9% 9% 10% 9% 0.10
ChD risk factors, %
Hypertension 0% 51% 32% 69% 94% <0.001
Dyslipidemia 0% 40% 19% 57% 92% <0.001
Diabetes 0% 20% 9% 24% 62% <0.001
Current smoker 0% 47% 41% 50% 68% <0.001
Comorbidity
Renal dysfunction 9% 9% 8% 9% 12% <0.001
Anemia 45% 40% 39% 41% 41% <0.001
Discharge diagnosis, %
STEMI 51% 46% 50% 40% 41% <0.001
reperfusion therapy*, %
PCI 47% 56% 52% 59% 72% <0.001
Thrombolytic therapy 26% 23% 25% 21% 15% <0.001
Medication at ICCU, % discharge
Statin** 62% 76% 74% 77% 81% <0.001
Aspirin 62% 70% 66% 72% 79% <0.001
Beta­blocker 52% 61% 59% 63% 66% <0.001
ACE inhibitor or ARB 17% 21% 18% 22% 31% <0.001
Ca­antagonist 24% 23% 23% 24% 18% <0.01
Nitrates 13% 13% 13% 12% 11% 0.02
Diuretics 13% 13% 13% 12% 13% 0.19
Antiarrhythmics 5% 4% 4% 3% 4% <0.01
 CHD, coronary heart disease. CHD risk factors include: hypertension, diabetes mellitus, dyslipidemia, 
current smoking.
* STEMI patients only, n=6820.
** Only in patients admitted from 2000 to 2008, n= 7618.
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Results
Prevalence of CHD risk factors
A total of 10 003 (69.3%) out of the 14 434 MI patients had at least one modifiable CHD 
risk factor (hypertension, dyslipidemia, diabetes or smoking). A total of 5652 (39.2%) 
patients had one, 3134 (21.7%) had two, and 1217 (8.4%) had three or four of these 
CHD risk factors. In the overall study population, hypertension was present in 35%, 
dyslipidemia in 28%, diabetes mellitus in 14%, while 32% were current smokers. 
Patient characteristics and management
Patients with at least one CHD risk factor were younger, more often female, more 
often had a family history of CHD or renal dysfunction and less often had anemia or 
a discharge diagnosis of STEMI compared to patients with no CHD risk factors (p for 
trend < 0.001 for all). Patients with at least one CHD risk factor were significantly more 
likely to receive PCI for STEMI or medical therapy including statins, aspirin, β-blockers 
and ACE-inhibitors/angiotensin-receptor blockers compared to patients with no CHD 
risk factors (Table 1). 
Mortality
At 30 days, 892 patients had died. Age-adjusted cumulative 30-day mortality was 
lower in patients with at least one CHD risk factor as opposed to no such risk factors 
(5% vs. 7%; Figure 1A; Age-adjusted OR 0.63, 95%CI: 0.55-0.73). Multivariate adjusted 
30-day mortality was also lower (adjusted OR 0.72, 95%CI: 0.62-0.83) in patients with 
at least one CHD risk factor compared to patients with no CHD risk factor (Figure 
2). The association between one or more risk factors and 30-day survival remained 
significant after exclusion of patients who died on the first day after admission 
(adjusted OR 0.77, 95%CI: 0.65-0.91). Furthermore, the association did not change after 
excluding all patients with a previous MI, PCI or CABG (adjusted OR 0.66, 95%CI: 0.55-
0.81; Figure 2A).
With longer duration of follow-up, this paradox disappeared in the full cohort. At 20 
years, a total of 5269 patients had died. Age-adjusted cumulative 20-year mortality 
was about equal in patients with at least one CHD risk factor (71% vs. 68%; age-
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Figure 1: Age­adjusted short­ (up) and long­term (bottom) mortality according to the absence or 
presence and number of coronary heart disease risk factors. 
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 
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    
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Figure 2: Adjusted short­ (top) and long­term (bottom) mortality according to absence, presence 
and number of coronary heart disease risk factors in the total cohort and in a sub­cohort of 
patients without prior coronary heart disease.
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adjusted OR 1.0, 95%CI: 0.94-1.1; Figure 1B). Multivariate adjusted 20-year mortality 
was higher (adjusted HR 1.1, 95%CI: 1.0-1.1) in patients with at least one CHD risk factor 
with a gradual increase in mortality as the number of risk factors increased (Figure 2). 
There was no significant interaction between presentation without CHD risk factors 
and diagnosis (STEMI or NSTEMI) (p = 0.27 for 30-day mortality and p = 0.31 for 20-year 
mortality). 
Temporal trends
With time patients more often presented with dyslipidemia and diabetes and less 
often as a current smoker (Table 2). The inequality in prescription of medication and 
use of reperfusion therapy did not decrease over time. 
There was significant interaction between the presence of CHD risk factors and 
decade of hospitalization (p = 0.025 for 30-day mortality). The 30-day mortality 
odds ratio (CI) of at least one CHD risk factor compared to none, was 1.1 (0.79-1.5), 0.63 
(0.50-0.80) and 0.65 (0.51-0.82) in 1985-1990, 1990-2000 and 2000-2008, respectively. 
There was also significant interaction for long-term mortality (p = 0.001). The 10-year 
mortality hazard ratio (CI) of at least one CHD risk factor compared to none, was 1.2 
(1.0-1.4), 0.89 (0.65-1.2) and 0.89 (0.79-0.99) in 1985-1990, 1990-2000 and 2000-2008, 
respectively.
table 2: Changes in prevalence of modifiable risk factors over time. 
1985-1990 1990-2000 2000-2008 p for trend
No. of patients 2216 4600 7618  
(15%) (32%) (53%)
risk factor     
Hypertension 35% 21% 32% <0.001
Dyslipidemia 11% 22% 35% <0.001
Diabetes 7.9% 11% 17% <0.001
Current smoker 39% 31% 31% <0.001
1 or more risk factors 69% 64% 73% <0.001
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In temporal trend analyses, mortality after MI was lower in the 1990s and 2000s 
compared to the 1980s (Figure 3). This improvement over time differed significantly 
between patients with no and those with at least one CHD risk factor. In patients with 
no CHD risk factor, adjusted 30-day mortality was 62% lower in the 2000s compared to 
the 1980s. In patients with at least one CHD risk factor adjusted 30-day mortality was 
77% lower in the 2000s compared to the 1980s. 
Long-term mortality in patients with no CHD risk factor was 24% lower in the 2000s 
compared to the 1980s. Long-term mortality in patients with at least one CHD risk 
factor was 41% lower in the 2000s compared to the 1980s (Figure 3).
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   
   
 
  
  
   
  

  
  
Figure 3: Temporal trends: decrease in adjusted mortality from 1985 to 2008 depending on the 
absence or presence of at least one coronary heart disease risk factor. Mortality in 1990­2000 and 
2000­2008 is compared to 1985­1990. 
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Discussion 
In the present study of 14 434 MI patients, we confirm the presence of a CHD risk factor 
paradox for short-term (30-day) outcome. MI patients with at least one compared to 
none modifiable CHD risk factor had a favorable unadjusted and adjusted short-term 
survival. With longer duration of follow-up, this paradox sustained for patients admitted 
in the 1990s and 2000s, but completely disappeared for those admitted in the 1980s. 
Improvement in outcome after MI during the last two decades was more pronounced for 
patients with CHD risk factors as compared to those without any risk factor.
The absence of CHD risk factors should not necessarily be viewed as a guarantee of 
a favorable prognosis. It could be that the management associated with the presence 
of CHD risk factors is causally related to better outcome. Patients with CHD risk factors 
might receive MI targeted therapy at an earlier time after first symptoms because 
they appear to be at higher risk. In previous studies, rapid initiation of aspirin, heparin, 
clopidogrel, GP IIb/IIIa inhibitors, ß-blockers and ACE-inhibitors and investigation 
by coronary angiogram at hospitalization for MI was reported to be more frequent in 
patients with at least one CHD risk factor.(ref 3,4) Also, patients with CHD risk factors 
might receive more adequate treatment. In our analysis, as well as in previous studies, 
treatment with PCI and CABG surgery was more frequent in patients with compared 
to those without CHD risk factors. [3, 4] In addition, in our study patients with CHD risk 
factors more often received evidence based medical care at ICCU discharge. This 
treatment discrepancy could result in relatively poor outcome in patients without 
CHD risk factors. 
Some other potential explanations unlikely explain the relatively high mortality 
in patients without one compared to at least one CHD risk factor. Specifically, our 
findings were independent of mortality on the day of admission and prior coronary 
heart disease. In addition, according to our multivariate analysis confounding factors 
including older age and renal dysfunction did not cause the paradox. And previous 
studies show it is also not due to heart failure, presenting blood pressure, heart rate, 
body mass index, pre-hospital delay, infarct location and significance of coronary 
disease. [3, 4] Still, patients without CHD risk factors might have unmeasured risk factors 
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such as pre-diabetes, a high blood pressure or cholesterol level that did not reach the 
disease threshold, an unhealthy lifestyle and non-cardiovascular comorbidities. [9] 
Further studies should seek to gain more insight into the possible explanations of this 
CHD risk factor paradox.
Data from the CRUSADE Quality Improvements Initiative from 2001 to 2004, have 
shown that NSTEMI patients without documented CHD risk factors had a worse in-
hospital survival. [4] Also, an NRMI-registry study (from 1994 to 2006) demonstrated 
an inverse relation between the number of CHD risk factors and in-hospital mortality 
in MI patients without prior cardiovascular disease. [3] The authors of these studies 
mention confounding from unknown risk factors and inequalities in the use of short-
term treatment and use of cardiac procedures as most likely explanations, in line with 
our study results. [3, 4] Both these studies do not report outcome after 30-days. 
Our study is unique in that it relates data on long-term mortality conditional on 
the presence and absence of CHD risk factors. In the overall cohort, adjusted 20-
year mortality was 1.5-fold increased in patients with three or four CHD risk factors 
compared to none. Although this increase is statistically significant, it is rather small 
compared to the risk of MI associated with these CHD risk factors in the general 
population. [10, 11] However, in an ostensibly healthy population, persons with risk 
factors for CHD are compared to healthy individuals resulting in high relative risks. [2, 
10] In an MI population, patients with CHD risk factors are compared to other patients 
who have developed an MI. Therefore, relative risks might substantially decrease 
towards the null (so-called “index event bias”). [12] 
From our subgroup analyses it appears that patients without CHD risk factors 
admitted in the 1990s and 2000s also have impaired long-term mortality compared to 
those with CHD risk factors. Long-term mortality in patients with no CHD risk factors 
might be relatively high due to differences in prescription of or response to secondary 
prevention. Current treatment of CHD risk factors and secondary prevention is very 
effective and contributes to 50% of the observed cardiovascular mortality decline in the 
general population during the past 25 years. [13] Patients without CHD risk factors might 
less often receive secondary prevention or might benefit less in absolute terms.  [1] 
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By comparing the 2000s with the 1980s we provide evidence that MI patients 
with one or more compared to no CHD risk factors benefit significantly more from 
improved short- and long-term outcome over time. These improvements in outcome 
are attributable to improvements in medical care.6-11 Increased awareness of the 
relatively high risk of patients without –compared to those with– CHD risk factors, and 
subsequent equal treatment might improve outcomes in these patients. 
Limitations
Our study has several potential limitations. We combined patients with a STEMI and 
a NSTEMI in our analyses. However, we demonstrated that there is no significant 
interaction between discharge diagnosis and presence of risk factors and mortality. 
Thus, our results are applicable to both STEMI and NSTEMI patients. Our study is 
observational and its results may be limited by bias, unmeasured confounders, and 
residual confounding. Therefore, we cannot make causal inferences. In addition, data 
on comorbidity were quite limited. Last, ascertainment of risk factors was through 
medical record review at hospitalization and may have been incomplete. Still, we 
believe that our conclusion is robust. 
Conclusion
We showed that the presence of at least one CHD risk factor yielded a favorable 
short-term survival after MI. With longer duration of follow-up, this association was 
sustained for MI patients admitted in the 1990s and the 2000s. Future studies should 
aim to seek for mechanisms and subsequent solutions to improve short-term outcome 
in patients without CHD risk factors. 
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Abstract
Objectives
The aim was to investigate the 7-year clinical outcomes of patients treated with either 
drug-eluting stents (DES) or bare-metal stents (BMS) for saphenous vein graft disease 
(SVG). 
Background
Atherosclerotic disease in SVG has several peculiarities which make it not possible to 
extrapolate outcomes of the use of DES as compared to BMS, from outcomes observed 
in native coronary arteries. To date no long-term safety and efficacy results for DES in 
SVG have been published. 
Methods
Between January, 2000 and December, 2005 a total of 250 consecutive patients with 
saphenous vein graft disease were sequentially treated with DES (either sirolimus- or 
paclitaxel-eluting stents) or with BMS. Yearly follow-up was performed.
Results
At 7¼ years, a total of 101 patients died (58 (46%) in the BMS group and 43 (42%) in the 
DES group, p-value= 0.4). There was no significant difference in the combined endpoint 
mortality or myocardial infarction. Cumulative target vessel revascularisation (TVR) 
was higher in the BMS group compared to the DES group (41% vs. 29% respectively; 
adjusted hazard ratio (HR) 0.63, 95% confidence interval (CI): 0.39 to 1.0). The cumulative 
incidence of major adverse cardiac events was 73% versus 68% in the BMS and DES 
groups respectively (adjusted HR 0.93, 95% CI: 0.67 to 1.3).
Conclusions
In the present study, the unrestricted use of DES for SVG lesions appeared safe and 
effective up to 7¼ years- and the use of DES resulted in a clinically relevant lower rate 
of TVR. 
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Introduction
Coronary artery bypass graft surgery (CABG) often involves saphenous vein graft 
(SVG) conduits. [1] However, the lifespan of SVG has proven to be limited – at 10 years, 
50% of such grafts contain at least one significant stenosis. [2] Significant athero-
sclerotic disease of SVG, despite optimal medical therapy, may result in the recurrence 
of symptoms and a higher risk of major adverse cardiac events necessitating 
re-intervention. [1]
Given the high risk of redo-surgery, [3] and the availability of new technologies 
including embolic protection devices and dedicated catheters, PCI with bare-metal 
stents (BMS) has surpassed CABG as the treatment of first choice for treating saphenous 
vein graft disease. [4, 5] Still, the cumulative event rate after stent implantation remains 
high because of atherosclerotic disease progression and in-stent restenosis. [6, 7] Earlier 
the RRISC trial showed a catch-up in the repeat revascularization rates in patients 
treated with sirolimus-eluting stents (SES). Moreover, the authors reported significant 
increase in late mortality in patients treated with SES as compared to those treated 
with BMS. [8]
Atherosclerotic disease in SVG has several peculiarities – including the plaque 
composition and restenotic process [9-12] – that differ from native coronary arteries. 
Therefore, it is uncertain whether the beneficial effects of drug-eluting stents (DES) 
compared to BMS in native coronary arteries could be extrapolated to SVGs. The 
safety and efficacy for DES in SVG has been proven for clinical outcomes up to 3 years 
in multiple meta-analyses. [13-21] However, no study reports the long-term outcomes 
after DES in SVG.
We therefore set out to investigate the long-term safety and efficacy outcomes (up 
to 7 years) of a consecutive series of patients treated with BMS or DES for lesions in 
saphenous vein grafts. 
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Methods 
Patient selection
Between January 1, 2000 and December 31, 2005 a total of 250 percutaneous coronary 
interventions were performed in our institution using BMS (n=128), SES (n=21) or 
paclitaxel-eluting stent (PES; n=101) in saphenous vein graft lesions. Patients who 
received previous brachy therapy (n=27) and patients who received no stent (n= 35) or 
a SymbiotTM Covered Stent (n = 2) are not included in this number.
All patients remained in their first original enrolled cohort during the follow-up 
period. The BMS subgroup contained all consecutive patients before April 16, 2002. The 
16th of April our institution commenced the unrestricted use of drug-eluting stents as 
default strategy. Until January 2003 SES (CypherR, Cordis Corp., Johnson & Johnson, 
Warren, NJ, USA) were used exclusively, whereas from February 2003 PES (TAXUSTM, 
Express2TM or LibertéTM, Boston Scientific, Natick, MA, USA) replaced the SES as the 
device of choice for every percutaneous coronary intervention -including vein graft 
interventions. This study was approved by the local ethics committee and performed 
in accordance with the Declaration of Helsinki. 
All procedures were performed according to standard procedural guidelines and 
their details have been reported previously. [22] Every patient was pre-treated with 
aspirin and ≥300 mg clopidogrel. Angiographic success was defined as residual 
stenosis ≤30% by online quantitative coronary angiography in the presence of 
Thrombolysis In Myocardial Infarction flow grade 3. All patients were advised to 
maintain aspirin lifelong and clopidogrel for at least 1 month if BMS were used, for ≥3 
months for patients with SES, and ≥6 months for patients with PES. Distal embolisation 
protection devices and peri-procedural glycoprotein IIb/IIIa inhibitors were used 
according to the operator’s discretion. 
Definitions and clinical endpoints
Definitions of baseline characteristics are according to the RESEARCH and T-SEARCH 
registry definitions, and have previously been described. [22, 23] 
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Safety end-points included all-cause mortality, the composite of all cause mortality/ 
myocardial infarction (MI) and stent thrombosis, whereas the efficacy end point 
consisted of target vessel revascularization (TVR). The combined endpoint major 
adverse cardiac event (MACE) was defined as a composite of all-cause mortality, any 
MI related or unrelated to TVR stenting and TVR.
MI was diagnosed by recurrent symptoms and/or new electrocardiographic 
changes in association with a concomitant rise and fall in creatinin kinase-MB mass 
or troponin-T/ troponin-I to ≥3 times the upper limit of normal. A TVR was defined as 
a percutaneous or surgical re-intervention driven by any lesion (≥50% of the luminal 
diameter) located in the index graft, in the presence of ischemic symptoms, or a 
positive functional ischemia study. Stent thrombosis was defined as angiographically 
defined thrombosis with Thrombolysis In Myocardial Infarction flow grade 0 or 1 or 
the presence of a flow limiting thrombus, accompanied by acute onset of ischemic 
symptoms at rest, similar to the ARC definite criteria. [22, 24] 
Survival status was assessed through municipal civil registries. A prospectively 
developed questionnaire inquiring about patients’ current health status, clinical 
events and medication use was sent to all living patients on a yearly basis. In case of 
an event, medical records, discharge summaries and, when necessary, angiographic 
films, were systematically reviewed. Cause of death was acquired via the Central 
Bureau of Statistics, The Hague, The Netherlands or by directly contacting the 
patients’ General Physician. [22] 
Statistical analysis 
Continuous variables are presented as mean and standard deviation or as median 
and boundary of interquartile range, categorical variables as absolute numbers 
and percentage. Normality assumption was evaluated by the Kolmogorov-Smirnov 
test. Continuous variables were compared using Student’s unpaired t-test or Mann-
Whitney non-parametric test. Categorical variables were compared using chi-square 
statistics or Fischer’s exact test, as appropriate. 
Ch
ap
te
r 
12
184     |     Myocardial infarction: temporal trends over the past three decades
The cumulative incidence of adverse events was estimated according to the Kaplan-
Meier method, and curves were compared using log-rank test. Observed unadjusted 
and adjusted measures of association were obtained by Cox regression models and 
presented as hazard ratios. Due to the total number of events we had to restrict the 
number of possible confounders entered into the model. [25] Separate Cox regression 
analyses were performed to identify independent predictors of adverse events using 
all clinical and procedural variables listed in Tables I and II. These independent 
predictors are shown in the results section and were entered into the Cox regression 
model to obtain the adjusted hazard ratios (HR) and 95% confidence intervals (CI). 
All statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, 
Illinois).
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Results
Survival status was available for 98.4% of the BMS patients and 99.4% of the DES 
patients. Clinical follow-up consisted of 1 582 person-years. The baseline and 
procedural characteristics of patients in both groups are depicted in Table I. Overall 
both groups were very similar; however, patients in the DES group were less likely 
to have hyperlipidaemia or a family history of coronary artery disease. Further, 
procedural characteristics differed in terms of a higher frequency of three-vessel 
disease, a smaller average stent diameter and a longer total stented length in the 
DES group. The use of glycoprotein IIb /IIIa inhibitors decreased over time, from 41% 
in the BMS group to 21% in the DES group (p = 0.001). Whereas the duration of post-
discharge clopidogrel increased from a median of three (IQR 2-6) in the BMS group to 
six months (IQR 6-6; p < 0.001) in the DES group. In univariate analysis, the prescribed 
duration of clopidogrel was not significantly related to TVR (p-value=0.15) or any of the 
other clinical outcomes. No differences in self-reported long-term medications were 
observed (Table II).
Event rates are depicted in Table III.  At 7¼ years, a total of 101 patients died. Cause 
of death was cardiac in 66% in the BMS group and 70% in the DES group. Cumulative 
all-cause mortality was 46% versus 42% in the BMS and DES groups respectively 
(Figure 1). When adjusting for independent predictors there was no significant 
improvement in cumulative mortality. Independent predictors (p-value < 0.1) of both 
cardiac and all-cause mortality at 7¼ years were increasing age, diabetes mellitus, 
renal impairment, enrolment diagnosis, and the left anterior descending (LAD) as 
revascularization territory.
The cumulative incidence of the combined endpoint mortality or MI was 57% in the 
BMS group vs. 60% in the DES group (Figure 2). Independent predictors (p-value < 0.1) of 
mortality or MI at 7¼ years were diabetes mellitus, renal impairment, and enrolment 
diagnosis.
At 7¼ year, cumulative TVR was 41% in the BMS group as compared to 29% in the 
DES group (Figure 3). In the DES group TVR was reduced by 37% (adjusted HR 0.63, 95% 
CI: 0.39 to 1.0). Two separate TVRs in the BMS group and one TVR in the DES group that 
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were performed due to angiographic follow-up are not considered as an event. A total 
of six (5.0%) patients treated with BMS suffered from stent thrombosis occurring at a 
median of 220 days (IQR 163-1198) versus only one (0.8%) in the DES group occurring 
at 606 days. The only independent predictor (p-value < 0.1) of TVR at 7¼ years was 
previous MI.
Cumulative MACE in the BMS group was 73% versus 68% in the DES group (Figure 
4). Independent predictors (p-value < 0.1) of MACE at 7¼ years were increasing age, 
enrolment diagnosis and, average stent diameter.
table I: Baseline and procedural characteristics stratified according to stent type
BMS 
(n = 128)
DeS 
( n = 122) p-value
Male, n (%) 102 (80%) 103 (84%) 0.33
Age, mean±SD 69±9.6 68±8.7 0.31
Cardiac history
Previous MI 59 (46%) 61 (50%) 0.23
Previous PCI 34 (27%) 36 (30%) 0.77
risk factors
Diabetes mellitus 27 (21%) 38 (31%) 0.07
Hyperlipidaemia 57 (45%) 81 (66%) 0.001
Hypertension 55 (43%) 60 (49%) 0.33
Family history of CAD 22 (17%) 34 (28%) 0.043
Current smoker 21 (16%) 10 (8%) 0.049
Renal impairment 2 (2%) 6 (5%) 0.13
BMI 26 ±3.7 27 ±3.8 0.33
enrolment diagnosis 0.37
Stable angina 42 (33%) 50 (41%)
Unstable angina 68 (53%) 60 (50%)
Acute MI 18 (14%) 10 (8%)
Shock 0 (0%) 1 (1%)
(continues)
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table I: Baseline and procedural characteristics stratified according to stent type (continued)
BMS 
(n = 128)
DeS 
( n = 122) p-value
Procedural characteristics
revascularisation territory
LAD 39 (49%) 37 (33%) 0.40
LCX 67 (53%) 54 (49%) 0.53
RCA 39 (31%) 38 (34%) 0.56
Native vessels treated
LAD 14 (11%) 16 (13%) 0.70
LCX 13 (10%) 15 (12%) 0.43
RCA 16 (13%) 22 (18%) 0.38
LM 3 (2.3%) 2 (1.6%) 1.00
Disease complexity
3 vessel disease 24 (19%) 44 (36%) <0.01
Multiple grafts treated 4 (3.2%) 3 (2.6%) 1*
In stent restenosis 10 (8%) 10 (8%) 0.91
Number of stents per lesion 2 [1­2]† 2 [1­3]† 0.21
Total stent length, mm 26 [18­40]† 32 [18­57]† 0.02
Average stent diameter, mm 3.7±0.6 3.2±0.7 <0.001
Success rate
Angiographic success 124 (97%) 117 (98%) 0.46
Number of lesions successfully treated 1 [1­2]† 1 [1­2]† 0.97
Distal protection device used 6 (4.7%) 2 (1.6%) 0.28
Glycoprotein IIb/IIIa inhibitors 53 (41%) 26 (21%) <0.01
* P­value by Fisher’s exact test.
† Data presented as median [interquartile range].
 BMI, body mass index; BMS, bare­metal stent; CAD, coronary artery disease; DES, drug­eluting stent; 
IQR, interquartile range; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main; 
MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; SD, 
standard deviation.      
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table II: Self-reported medical treatment at 3 year follow according to stent type
BMS 
(n = 99)
DeS 
(n = 99) p-value
alive at 3 year
Aspirin 85 (86%) 81 (82%) 0.44
Anticoagulants 17 (17%) 22 (22%) 0.37
β­blockers 81 (82%) 83 (84%) 0.71
ACE inhibitors or AT1 antagonists 54 (55%) 56 (57%) 0.78
Diuretics 31 (31%) 30 (30%) 0.88
Statins 93 (94%) 93 (94%) 1.0
 ACE, angiotensin converting enzyme; AT1, angiotensine II type 1 receptor;  
BMS, bare­metal stent; DES, drug­eluting stent. 
table III: association between stent type used and event rates: at 30 days and at 7¼ years
Number of events 
(Kaplan Meier estimate)
Observed hr  
(95% CI)
adjusted hr  
(95% CI)
 BMS(n = 126)
DeS
 (n = 121)  DeS vs. BMS  DeS vs. BMS
events at 30 days after pCI
Total mortality 7 (5.6%) 4 (3.3%)
Cardiac mortality 6 (4.8%) 4 (3.3%)
Mortality or myocardial infarction 10 (7.9%) 7 (5.8%)
Target vessel revascularisation 4 (3.2%) 2 (1.7%)
Major adverse cardiac events 14 (11%) 8 (6.6%)
events at 7¼ years after pCI
Total mortality 58 (46%) 43 (42%) 0.84 (0.56­1.3) 0.90 (0.59­1.4)†
Cardiac mortality 38 (35%) 30 (33%) 0.90 (0.55­1.4) 0.93 (0.56­1.5)†
Mortality or myocardial infarction 72 (57%) 63 (60%) 1.0 (0.74­1.5) 0.97 (0.71­1.4)‡
Target vessel revascularisation 45 (41%) 28 (29%) 0.62 (0.38­0.99)* 0.63 (0.39­1.0)§
Major adverse cardiac events 92 (73%) 74 (68%) 0.81 (0.59­1.1) 0.93 (0.67­1.3)||
 The observed (unadjusted) and adjusted HR compares DES vs. BMS with BMS as the reference. 
* p­value < 0.05.
†, ‡, §, || adjusted for independent predictors of the outcome of interest as described in the results section.
 HR, Hazard ratio; CI, confidence interval; BMS, bare­metal stent; DES, drug­eluting stent; BMI, body 
mass index, PCI, percutaneous coronary intervention. 
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Figure 1: Kaplan Meier curve of cumulative 
mortality. BMS, bare­metal stent; DES, drug­
eluting stent.
Figure 3: Kaplan Meier curve of cumulative 
TVR. BMS, bare­metal stent; DES, drug­eluting 
stent; TVR, target vessel revascularization.
Figure 2: Kaplan Meier curve of cumulative 
mortality or MI. BMS, bare­metal stent; DES, 
drug­eluting stent; MI, myocardial infarction.
Figure 4: Kaplan Meier curve of cumulative 
MACE. BMS, bare­metal stent; DES, drug­
eluting stent; MACE, major adverse cardiac 
event (combined endpoint of all­cause 
mortality, myocardial infarction, and target 
vessel revascularization).
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Discussion
The present study shows that the unrestricted use of DES in SVG remains safe and 
effective as compared to BMS up to seven years of follow up, illustrated by similar 
mortality rates and clinically relevant lower rates of TVR in patients treated with DES. 
We have already reported the four-year follow up of DES vs. BMS in SVG. [23] At four 
years DES was considered safe and effective, illustrated by lower rates of TVR. These 
results have been validated by a meta-analysis of three randomized controlled trials 
–although the maximum follow-up duration in the three trials was 2.5 years. [17]
The treatment of SVG disease represents about 3-8% of the PCI cases in our centre. 
Atherosclerotic disease in SVG has several peculiarities which account for the 
poor outcome compared to native coronary arteries, including a different plaque 
composition, higher plaque burden, more friable material and frequent superimposed 
thrombus. [9, 10] Further, the restenotic process in SVGs is different with several distinct 
phenomena including intimal hyperplasia, progression of atherosclerosis, local 
inflammatory reaction and thrombosis [12] whilst the major process in the coronaries 
is intimal hyperplasia. [11] Therefore, regarding clinical outcomes it is unlikely that the 
results in native coronary arteries –improved outcomes with use of DES– also hold for 
SVG. 
The present study included a total of 250 ‘real world’ consecutive patients treated for 
SVG disease. In terms of absolute reduction, at 7¼ years we find a reduction in TVR of 
12%, which is identical to the absolute reduction in TVR at one year. The present study 
underscores the sustained clinical benefit with DES in SVG over BMS over 7¼ years. 
Further, the absolute risk reduction, representing the number needed to treat (NNT), is 
very comparable –if not equal- to studies in patients with single de novo lesions (12% 
absolute TVR reduction at 7¼ years in the present study, 16% at 5 year in the RAVEL 
study, [26] 11% at 5 year in the SIRIUS study, [27] and 10% at 5 year in the TAXUS study [28]). 
In the present study the overall event rates remain high as compared to event 
rates after native vessel stenting. [29] Overall morality at 7¼ years is 43%. The most 
likely explanation for the high event rates is the relatively high mean age, the high 
frequency of measured comorbidities and risk factors and the fact that all patients in 
the present study presented with an occlusion in a SVG.
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To date, other large-scale registries have not yet reported long-term outcome 
(>3 years) in this specific patient subset. [18, 30, 31] Therefore the duration of the follow-
up of the present study is probably the longer worldwide and the institution has 
unique reputation for long term follow-up. [32] Interestingly, the long term cumulative 
incidence of MACE of 73% in BMS patients at 7¼ years is identical to the cumulative 
incidence of MACE in Dutch patients at 5 years treated two decades ago with balloon 
angioplasty. [33] This suggests that the expected survival free of MACE increased with 
2¼ years between patients treated for SVG lesions in 1985 and in 2002. Today, with the 
use of DES the estimated cumulative incidence of MACE further improved to 68% at 
7¼ years. 
Of note, the study population stems from an era when embolic protection devices 
were not yet fully established. Embolic protection devices were used in less than 
5% of cases. Embolic protection devices have been shown to reduce MACE by up to 
40%. [34] As such the use of embolic protection devices in SVG PCI is a class I level 
of recommendation B recommendation in the recent ESC/EACTS guidelines on 
myocardial revascularisation. [35] The implementation of embolic protection devices 
could have had a positive impact on absolute numbers of short and longer-term 
outcome in our study cohort.
A limitation of the present study is that the results are based on a nonrandomized 
patient population without completely identical groups. In the DES group, more 
complex patients were being treated with PCI compared to the BMS group. Although 
we statistically adjusted for clinical and procedural differences between both groups, 
it could be debated whether this is sufficient. Further, the results are based on a 
relatively small patient cohort and therefore may have lack of power. Large-scale 
randomized controlled trials with long-term follow up are advocated to prove the long-
term benefit of DES over BMS in SVG.
Conclusions
In the present study, the use of DES for SVG lesions appeared safe and effective up to 
7¼ years, and DES resulted in a clinically relevantly lower rate of TVR. 
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Abstract 
Appropriate well-timed medical interventions can reduce mortality from ST-segment 
elevation myocardial infarction (STEMI) [1]. STEMIs occur every day. However staffing 
tend to be lower on weekends. This may lead to a lower use of invasive cardiac 
procedures for patients admitted during weekends. Higher mortality rates for patients 
admitted during the weekends may be the consequence [2, 3].
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Appropriate well-timed medical interventions can reduce mortality from ST-segment 
elevation myocardial infarction (STEMI) [1]. STEMIs occur every day. However staffing 
tend to be lower on weekends. This may lead to a lower use of invasive cardiac 
procedures for patients admitted during weekends. Higher mortality rates for patients 
admitted during the weekends may be the consequence [2, 3].
Recent reports that compared mortality rates among acute myocardial infarction 
patients who were admitted on weekends and those admitted on weekdays were 
inconsistent [3-7]. 
The aim of our study is to compare mortality rates among 6.820 STEMI patients 
admitted on weekends and on weekdays for three time intervals (1985-1990, 1990-
2000 and 2000-2008).
All consecutive patients aged >18 years with a first admission for ST-segment 
elevation myocardial infarction (STEMI) to the Intensive Coronary Care Unit (ICCU), 
between June 1985 and December 2008 were included [8]. 
Trained physicians and nurses accustomed to the use of standardized case 
report forms collected the data. The primary independent variable was admission 
on weekends (Saturday or Sunday) versus weekdays (Monday to Friday). The study 
endpoint was all-cause mortality at 30 days, 5 years and at 10 years. Survival data was 
assessed through municipal Civil Registries which is updated regularly and therefore 
highly accurate in the Netherlands. The author(s) of this manuscript have certified 
that they comply with the Principles of Ethical Publishing in the International Journal 
of Cardiology [9]. 
Data for the period 1985-2008 were grouped into 3 intervals according to decade 
of hospitalization (1985-1990, 1990-2000, and 2000-2008). Separate analyses were 
performed for each interval.
Cumulative survival curves according to admission were constructed using 
the Kaplan–Meier method, and compared by the log-rank test. We examined the 
independent association between admission on weekdays or weekends and mortality 
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using logistic regression for 30-day outcome and the Cox proportional hazards 
model for long-term outcome. Adjustment was performed for age, sex, previous MI, 
previous PCI, previous CABG, hypertension, diabetes, hyperlipidemia, family history 
of coronary artery disease and smoking status. Results are reported as odds ratios 
(OR) –for 30-day mortality– and hazard ratios (HR) –for long-term mortality– and their 
respective 95% confidence intervals. All statistical tests were 2-tailed, and p-values 
were considered significant at <0.05. Analysis was performed using SPSS software 
version 20.0 (SPSS, Chicago, Ill).
Between June 1985 and December 2008 a total of 6,820 consecutive patients were 
admitted to the ICCU with a STEMI, of whom 2,053 (30%) were admitted on weekends. 
table 1 Baseline characteristics  
1985-1990 1990-2000 2000-2008
                                   Weekday Weekend p Weekday Weekend p Weekday Weekend p
No. of patients 698 249 1413 515 2656 1289
Baseline
Age (years) 60±12 59±12 0.2 60±13 60±13 0.8 61±13 60±13 <0.001
Gender (male) 78 % 76 % 0.6 74 % 76 % 0.3 75 % 73 % 0.2
Cardiac history
Previous MI* 37 % 31 % 0.1 25 % 23 % 0.4 28 % 26 % 0.1
Previous PCI† 5 % 4 % 0.4 7 % 6 % 0.3 17 % 16 % 0.4
Previous CABG‡ 7 % 12 % 0.02 6 % 6 % 1.0 8 % 6 % 0.8
risk factors
Hypertension 33 % 37% 0.2 29% 27 % 0.4 34 % 31% 0.1
Diabetes 9 % 8 % 0.8 10 % 12 % 0.3 15 % 13 % 0.1
Hyperlipidemia 8 % 8 % 1.0 15 % 15 % 1.0 24 % 22 % 0.1
Family history 22 % 20 % 0.5 21 % 21 % 0.9 26 % 29 % 0.1
Current smoker 41 % 47 % 0.1 35 % 36 % 0.5 37 % 42 % 0.001
Renal dysfunction 12 % 10 % 0.6 12 % 11 % 0.5 6 % 5 % 0.2
Anemia 34 % 30 % 0.3 41 % 44 % 0.3 41 % 37 % 0.02
 *  Myocardial infarction
† Percutaneous coronary intervention
‡  Coronary artery bypass grafting  
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Baseline characteristics are presented in Table 1. With the exception of age between 
2000 and 2008 (61±13 vs 60±13 p=<0.001), previous CABG 1985-1990 (7% vs. 12% p=0.02), 
current smoking 2000-2008 (37% vs. 42% p=0.001) and anemia 2000-2008 (37% vs. 
41% p=0.02) no differences were found between the groups.
During the years studied there was an increase in the prevalence of baseline 
diabetes, hyperlipidemia, anemia and previous PCI. In contrast, there was a decrease 
in the prevalence of baseline smoking, previous CABG and renal dysfunction.
During the study period a total of 1,929 STEMI patients died of whom 543 patients 
were admitted during the weekends (28%). Compared to the period 1985-1990 both 
short and long term mortality of STEMI patients was substantially lower in the period 
2000-2008. 
Kaplan-Meier cumulate survival curves demonstrated no difference in 30-day en 
10 year mortality for weekend versus weekday admission in all 3 intervals (figure 1). 
After adjustment for age and baseline characteristics there was a difference between 
the weekends and weekdays in favor of STEMI patients who were admitted on 
weekends between 1990 and 2000 (OR=0.70 95% CI 0.51-0.97). The adjusted 5-year and 
10-year mortality showed no difference between the groups. 
Previous studies demonstrated the ‘Weekend effect”. Patients admitted on weekends 
to the acute care hospitals had higher mortality rates than those on weekdays [5]. 
Staffing levels are lower on weekends, consequently fewer urgent procedures are 
performed [5, 10]. 
Kostis et al found a higher mortality among patients with acute myocardial 
infarction admitted on weekends [3]. They concluded that the worse prognosis for 
patients admitted on the weekends is mediated in part by the lower rate of invasive 
procedures. A study in South Korea confirmed that the higher mortality rates in the 
weekends were due to differences in the rate of performance of medical or invasive 
procedures [7].
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Figure 1: Kaplan Meier curves for  30 day and 10 year cumulative mortality. Unadjusted and 
adjusted odds ratios (OR and adjOR) for 30­day mortality and the unadjusted and adjusted hazard 
ratios (HR and adjHR) for 5­year and 10­year mortality and their respective 95% confidence 
intervals. With weekday used as reference group.  
a) 1985­1990 
b) 1990­2000 
c) 2000­2008
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In contrast our results showed that admission either on weekends or on weekdays 
did not influence both the 30-day mortality and the long-term mortality. This indicates 
high quality of care. Probably these findings are due to the proper availability of staff 
and the possibility to perform invasive procedures during the weekends. 
Consistent with our results, three studies revealed no difference in mortality rates 
between weekend and weekday admissions for acute myocardial infarction patients. 
In a Japanese study Turin et al. found no difference in mortality (HR 1.07 95%CI 0.53–
2.16) [4]. In Canada Bell et al. reported no difference in mortality (OR 1.03 95%CI 1.00–
1.06) between 160,220 myocardial infarction patients admitted on weekends versus 
weekdays over a 10-year period. But they reported a lower rate of use of coronary 
angiography in the weekends [5, 11]. Another study from Japan Matsui et al. found no 
difference in mortality (6.6% vs 6.7%) even though they found a lower rate of stenting 
during the weekends [6]. These three studies compared respectively 28-day case 
mortality rates (Turin et al.), in hospital mortality (Bell et al.) and in-hospital, 30-day, 
and 1-year mortality rates (Matsui et al.). Our study not only compared short term 
mortality like these studies but also long term (5-year and 10-year) mortality.
Our study has important strengths. We analyzed all patients > 18 year admitted to 
our ICCU between 1985 and 2008 with STEMI, with no further in or exclusion criteria. 
We were not limited by a small study population, and our analyses cover an inclusion 
period of 24-years with follow-up data up to 10 years. A potential limitation is that the 
presented data are derived from a single center. 
In conclusion, STEMI patients admitted during the weekends have similar short 
and long-term survival rates as patients admitted during weekdays. 
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Abstract 
Aims
To evaluate the SYNTAX score (SXscore) calculated at two stages during a primary 
percutaneous intervention (PPCI), i.e., SXscore I (diagnostic), SXscore II (post wiring) 
and assesses its additional value to standard clinical risk scores in acute myocardial 
infarction.
Methods and Results
SXscores I and II were applied to 736 consecutive acute STEMI patients referred for 
PPCI between November 2006 and February 2008. SXscore changed significantly 
before - I = 16 (IQR: 9.5-23) and after wiring- II =11 (IQR: 6-19), p < 0.001. Kaplan Meier 
methods were used to compare the primary end point MACE (composite of repeat MI, 
TVR and mortality) and secondary endpoint mortality at 1.5 years in tertiles of SXscore 
I and SXscore II. MACE was highest in the higher SXscore I tertile (11% vs.15% vs 23%, 
log rank <0.01), driven primarily by increased rate of mortality (9% vs. 11% vs. 17%, log 
rank = 0.02). MACE was also highest in SXscore II tertile, by a combination of increased 
mortality but also TVR (TVR rate :
2% vs. 3% vs. 9%, log rank <0.01). Predictive cox regression models for mortality and 
for MACE were significantly and similarly improved by addition of either SXscore I or 
SXscore II (HR 1.63, 95%CI 1.18-2.26, p <0.01 for MACE) with respective c-indices of 0.61 
and 0.63 for MACE and 0.60 and 0.61 for mortality.
Conclusions
SXscore during PPCI is a useful tool that provides additional risk stratification to 
known risk factors of long term mortality and MACE in patients with STEMI.
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Introduction
The SYNTAX score (SXscore) [1] is a tool that can be used to cumulatively quantify 
the extent of angiographic coronary artery disease. It has been developed from the 
Leaman score [2] and therefore takes into account not only the number of lesions, 
their location and characteristics but also their functional impact. In fact scoring of 
lesions is weighed according to the size of the perfused territory of the left ventricle. 
The SXscore has been shown to be a good predictor of adverse cardiovascular events 
including cardiac death, myocardial infarction and target lesion revascularisation in 
patients treated with percutaneous coronary intervention for complex disease [3-4].
Coronary angiographic characteristics at primary percutaneous intervention 
(PPCI) that are known to affect prognosis include culprit artery (left versus right), 
TIMI flow at presentation and the presence of multivessel disease especially chronic 
total occlusions [5-7]. The SXscore derived from the diagnostic phase of the PPCI can 
quantify these features. By consideration of whether the culprit lesion is occluded 
on presentation and accordingly scoring it as a total occlusion or otherwise, it can 
incorporate a numerical value that takes into account both the volume and degree 
of ischaemic left sided myocardium. The SXscore derived after wiring of the culprit 
lesion defines better the underlying culprit vessel anatomy in cases where this is 
obscured by the occlusion in the diagnostic phase.
The detailed anatomical and functional consideration of the SXscore may make it an 
attractive quantification tool for use as a prognostic indicator in patients presenting 
with ST elevation myocardial infarction (STEMI). To this end we set out to investigate 
the predictive value of the SXscore on long term outcomes in patients undergoing 
PPCI. The aims of our study are two-fold. First to calculate the SXscore derived at the 
two stages during a PPCI procedure and assess their predictive value for long term 
clinical outcome. Second we studied whether the SXscore is able to offer additional 
predictive value of long term clinical outcome when compared to the classical risk 
factors for survival and major adverse coronary events (MACE) in STEMI.
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Methods
Between November 2006 and February 2008, 736 consecutive patients undergoing 
primary PCI for STEMI in our institution were screened for inclusion in the MI 
SYNTAXscore study. All patients in the referral area of the Thoraxcentre, Erasmus 
MC, Rotterdam that had symptoms of acute myocardial infarction (< 12 duration) were 
assessed clinically and by 12 lead ECG by paramedical personnel or peripheral hospital 
medical staff. Those who met criteria of acute myocardial infarction, were transported 
immediately to our centre for PPCI. Pre-treatment with aspirin, clopidogrel and heparin 
was administered pre-hospital. Urgent diagnostic angiography was followed by PPCI 
if appropriate. The procedure was performed using standard techniques. Drug eluting 
stents were implanted as first line choice of stents. Treatment of complications such as 
cardiogenic shock and cardiac arrest were performed according to guidelines.
Baseline clinical characteristics and procedural characteristics were prospectively 
recorded in a dedicated electronic database. For the purpose of this study, the only 
exclusion criteria were patients with previous coronary artery bypass grafting 
(CABG) in whom the SXscore could not be calculated. The SXscore for each patient 
was calculated by a team of two interventional cardiologists. All coronary lesions 
with a diameter stenosis ≥ 50%, in vessels ≥1.5 mm were scored using the SYNTAX 
score algorithm which is available on the website (www.syntaxscore.com). In case 
of disagreement with regards to the significance of a lesion quantitative coronary 
angiography was applied and the lesion included if it was ≥ 50 %. On agreement 
between the two cardiologists, the data was entered onto a dedicated software program. 
SYNTAX scoring was performed at 2 pre-defined stages of the index procedures:
SXscore I : Initial diagnostic angiogram. This takes into account the patency of the 
infarct related artery. Thus an infarct related artery (IRA) with a TIMI flow of 0 or 1 is 
scored as a total occlusion with thrombus.
SXscore II : After wiring/small balloon. If TIMI flow improves with these measures, 
this allows assessment of lesion severity as well as additional disease downstream. 
On the other hand, persistence of a TIMI 0/1 that does not allow adequate visualisation 
of the lesion is scored as in SXscore I. (total occlusion with thrombus) 
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The investigators calculating the SYNTAX score were blinded to the patients 
clinical characteristics. The scoring was done prospectively at each stage so that the 
investigators were blinded to the next stage film, to the procedural data and to the 
clinical outcomes. No change in scoring was allowed once a score was assigned. 
Intra- and inter-observer variability
The first 100 consecutive films from the cohort were analysed by a third independent 
observer to obtain inter-observer variability and by the same team 8 weeks after the 
first scoring phase to obtain intra-observer variability. The investigators remained 
blinded to the results of the first analysis. This number of patients was selected based 
on our previous experience with the variability of the SYNTAX score. [8]
Follow-up
Survival data for all patients was obtained from the municipal registry. A health 
questionnaire was subsequently sent to all living patients with specific questions on 
readmission and major adverse cardiac events. For patients with an adverse event 
at another centre, medical records, discharge summaries and, when necessary, 
angiographic films, were systematically reviewed. General practitioners, referring 
cardiologists and patients were contacted as necessary for additional information. 
Events were adjudicated by two experienced interventional cardiologists according to 
the definitions below. Written informed consent was obtained from all patients.
Definitions
ST elevation myocardial infarction was diagnosed when patients had symptoms of 
an acute myocardial infarction lasting at least 30 minutes and accompanied by >1mm 
(0.1mV) ST elevation in two or more contiguous leads and later confirmed by a CK and 
CK-MB rise and/or troponin rise.
Thrombolysis in myocardial infarction (TIMI) flow grade and corrected TIMI frame 
count as well as myocardial blush grade (MBG) at the start and end of the procedure 
were determined from the angiographic films as previously described. [9-10] TLR was 
defined as any PCI of the index lesion and including the 5mm adjacent segments 
in either main vessel or sidebranch. Stent thrombosis was defined according to the 
Academic Research Consortium (ARC). [11]
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Primary and secondary endpoints
The primary clinical end point was MACE at 1.5 years, defined as a composite of cardiac 
or non-cardiac death, repeat myocardial infarction (MI) and ischaemia driven target 
vessel revascularisation (TVR). Repeat MI in the acute post-PPCI phase was defined as 
clinical signs of re-infarction with recurrent or persistent symptoms and ST segment 
changes and requiring a repeat PPCI and/or a second peak in the CK-MB mass or 
troponin –T/troponin-I increase to ≥3 times the upper limit of normal not related to 
an interventional procedure and new pathological Q waves in 2 or more contiguous 
electrocardiograph leads. A repeat MI post discharge was defined as in the definitions 
section above. TVR was defined as revascularisation of any part of the index coronary 
artery. Secondary endpoints included separately, all cause mortality, repeat MI and 
TVR.
Statistical analysis
Normality assumption for continuous variables was evaluated by the Kolmogorov-
Smirnov test. These are presented as mean±1SD or as median and interquartile 
range accordingly. Student’s unpaired t test or Mann-Whitney non-parametric tests 
were used to evaluate differences in continuous variables. Categorical variables 
are presented as counts and percentages and differences in categorical variables 
between subgroups were evaluated with chi-square test or Fisher’s exact test. The 
cohort was divided into three groups determined by SXscore tertiles. Levene’s 
homogeneity-of-variance test was employed to test for equal variance. For those 
variables meeting the assumption of equal variance analysis of variance (ANOVA) 
was used to describe differences between the 3 groups. If the ANOVA assumptions 
were not met we used the Kruskal-Wallis One-Way Analysis of Variance.
Kaplan-Meier method was used to generate cumulative survival curves and curves 
of event free survival for the various predefined endpoints and the log rank test was 
used to assess the difference in survival between SXscore tertile groups. Independent 
variables from multivariable analysis were used to assess the significance of 
SXscore I and SXscore II and its contribution to improvement of the model with 
respect to the primary and secondary endpoints as measured by c-indices. To explore 
the applicability of the findings in our cohort to other STEMI populations, we also 
assessed the addition of the scores to the widely used TIMI risk score with variables 
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including age, diabetes, hypertension, systolic blood pressure, heart rate, Killip class, 
weight, anterior STEMI. On multivariate analysis we determined whether adding 
SXscore improved the model significantly. The omnibus test of model coefficients 
was used to assess the improvement of the model. Proportionality of hazards was 
tested graphically based on visual inspection of log–log survival curves, and by 
performing a formal test of proportionality based on Schoenfeld residuals for each 
variable in the model. [12] The performance of the multivariate model with the SXscore 
was studied with respect to calibration. Calibration refers to whether the model 
agrees with the observed probabilities; it was measured with the Hosmer-Lemeshow 
goodness-of-fit test.
The weighted Kappa value determined intra and interobserver variability. A Kappa 
value of > 0.0 to ≤ 0.2 was considered slight; > 0.2 to ≤ 0.4 fair; > 0.4 to ≤ 0.6 moderate; > 
0.6 to ≤ 0.8 substantial; and > 0.8 to ≤ 1.0 almost perfect [8].
All statistical tests were 2-tailed, and p values were significant at <0.05. Analysis 
was performed using SPSS software version 17.0 (SPSS, Chicago, USA).
No extramural funding was used to support this work.
The authors are solely responsible for the design and conduct of this study, all study 
analyses, the drafting and editing of the paper and its final contents.
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Results
From the intial 736 patients screened, 27 were excluded due to unavailability of a 
complete diagnostic coronary angiogram while 21 were excluded since they had prior 
CABG. Survival status and follow-up could not be obtained in 19 patients. Thus the 
final number of patients included in our analysis was 669 as shown in figure 1.
Among the 669 patients, 385 (58%) had significant disease in at least one vessel 
other than the IRA. The median SXscore I was 16 (IQR: 9.5-23). TIMI 0/1 flow in the 
IRA was present in 61% of patients. The median SXscore II was 11 (IQR: 6-19). Stent 
implantation was deemed appropriate and performed in 616 (92%) of patients.
Figure 1:  Flow chart of the MI SXscore study population.
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There were significant differences between SXscore I and II, p < 0.001 as determined 
by the Kruskal Wallis test. This is illustrated in figure 2. The difference between the 
stages were more apparent on analysis of TIMI 1/0 presenting subgroup (fig. 2b) I 19 
(IQR: 12-24.5) vs II 12 (IQR: 7-19), p <0.001.
The differences in basal clinical characteristics, angiographic characteristics, 
procedural characteristics and follow-up management according to three tertiles of 
SXscore I are shown in tables 1 and 2. Patients with higher SXscore I were older 
and more commonly had previous MI. These patients also presented with higher 
pulse rates, cardiogenic shock, anterior STEMI. The LAD was more commonly the 
culprit in the higher tertile while the RCA was more commonly the IRA in the lowest 
tertile. Stents implanted in the patients with higher scores were longer and more 
likely to involve bifurcations. Procedure failure with TIMI 0/1 flow, low MBG and high 
cTFC were more common in the highest tertile. Complete revascularisation within 3 
months was more commonly achieved in patients with lower scores.
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Figure 2:  Box plots showing the SXscore at the 2 stages during PPCI; SXscore I obtained from the 
diagnostic stage and SXscore II obtained after wiring or after use of a small balloon. A, The SXscore 
changed significantly from I to II when tested with Kruskal­Wallis and subsequently Mann­Whitney 
tests. B, When patients with TIMI 0/1 only are considered, higher change from I (median 19) to II 
(median 12) is observed.
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table 1: Clinical characteristics of patients presenting with myocardial infarction according to 
SXscore I tertiles.
SXscore I tertiles
Lower (<10)
n = 209
Intermediate 
(10-20) n = 241
higher (>20)
n = 219 p value*
Baseline Characteristics
Age, years 63±13 64±13 68±11 <0.01
Male 135(64%) 171 (71%) 163 (74%) 0.08
Diabetes 14 (8%) 21 (9%) 28 (13%) 0.09
Type I 9 (4%) 7 (3%) 12 (6%) 0.39
Type II 5 (2%) 15 (6% 17 (8%) 0.04
Hypertension 61 (29%) 87(36%) 76 (35%) 0.27
Hypercholesterolaemia 40 (19%) 51 (21%) 49 (22%) 0.71
Smokers
Current 100 (48%) 105 (44%) 75 (34%) 0.01
Ex­ 31 (15%) 29 (12%) 31 (14%) 0.66
Renal failure 3 (1%) 7 (3%) 8 (4%) 0.35
Family history of CAD 79 (38%) 73 (30%) 58 (27%) 0.04
Body Mass Index, Kg/m2 27±4 27±4 27±4 0.74
Previous Myocardial Infarction 12 (6%) 33 (14%) 40 (18%) < 0.01
Previous PCI 19 (9%) 23 (10%) 22 (10%) 0.95
Clinical presentation
Symptom onset to balloon time > 90 mins. 168 (87%) 179 (83%) 174 (87%) 0.38
Out of hospital cardiac arrest 8 (4%) 10 (4%) 13 (6%) 0.53
Pulse rate, bpm 78±17 77±17 81±18 0.04
Blood pressure, mmHg
Systolic 123±26 126±27 122±27 0.29
Diastolic 75±13 76±15 74±17 0.45
Cardiogenic Shock 11 (5%) 15 (6%) 29 (13%) < 0.01
Killip class 2­4 11 (5%) 19 (8%) 22 (10%) 0.18
 Data is expressed in numbers and (percentages), mean ± 1 standard deviation. Percentages are rounded. 
PCI = Percutaneous coronary intervention; * p value calculated using ANOVA for continuous variables or 
Kruskal Wallis test for non parametric variables and Chi­Square test for categorical variables.
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table 2: angiographic characteristics, procedural characteristics and management of patients with 
a cute myocardial infarction according to SXscore I tertiles.
SXscore I tertiles
Lower (<10)
n = 209
Intermediate 
(10-20) n = 241
higher (>20)
n = 219 p value*
angiographic Characteristics pre-procedural
Anterior STEMI 70 (34%) 128 (53%) 106 (48%) < 0.01
Infarct Related Artery
Left Main 0 (0%) 1 (0.4%) 4 (2%) 0.12
Left anterior descending 63 (30%) 115 (48%) 102 (47%) < 0.01
Left Circumflex 39 (19%) 42 (17%) 28 (13%) 0.21
Right Coronary 106 (51%) 83 (34%) 86 (39%) < 0.01
TIMI 0/1 in IRA 73 (35%) 169 (71%) 168 (77%) < 0.01
Stent thrombosis (cause) 4 (2%) 13 (5%) 8 (4%) 0.15
Diseased vessels incl. IRA
1­vessel disease 158 (76%) 95 (39%) 28 (13%) < 0.01
2­vessel disease 40 (19%) 103 (43%) 63 (29%) < 0.01
3­vessel disease ¶ 10 (5%) 43 (18%) 128 (58%) < 0.01
Left main disease 4 (2%) 3 (1%) 35 (16%) < 0.01
Chronic Total Occlusion 2 (1%) 3 (1%) 41 (19%) < 0.01
procedural characteristics
Stent Implantation 196 (94%) 225 (93%) 195 (89%) 0.10
Total Stent length, mm 26 (18­36) 28 (23­46) 32 (23­51) < 0.01
Stent diameter, mm 3.3 ± 0.5 3.1 ± 0.5 3.2 ± 0.5 0.02
Bifurcation treatment in IRA 20 (10%) 55 (23%) 48 (22%) < 0.01
Thrombectomy 37 (18%) 45 (19%) 42 (19%) 0.92
GP IIb/IIIa Inhibitors 46 (22%) 52 (22%) 49 (22%) 0.98
Inotropic agents 10 (5%) 9 (4%) 12 (6%) 0.67
Intra Aortic Balloon Pump 8 (4%) 13 (5%) 24 (11%) 0.01
Multivessel stenting 15 (7%) 26 (11%) 28 (13%) 0.16
angiographic characteristics post-procedural
TIMI 0/1 3 (1%) 7 (3%) 18 (8%) < 0.01
Corrected TIMI frame count  
at end procedure, fps 24 (16­36) 24 (18­35) 28 (20­44) 0.05 
§
Myocardial Blush Grade 0/1 1 (1%) 5 (2%) 16 (7%) < 0.01
Follow - up treatment
Complete revascularisation  
within 3 months (PCI n=331, CABG n= 4) 180 (86%) 119 (49%) 36 (16%) < 0.01
Medication at 1 year
Aspirin 182 (87%) 200 (83%) 191 (87%) 0.60
Clopidogrel 203 (97%) 231 (96%) 203 (93%) 0.13
B­Blocker 192 (92%) 209 (87%) 188 (86%) 0.41
ACE­inhibitors 117 (56%) 157 (65%) 166 (69%) 0.20
Statins 178 (86%) 219 (91%) 204 (93%) 0.45
 Data is expressed in numbers and (percentages), mean ± 1 standard deviation or median and (interquartile 
range); Percentages are rounded. STEMI = ST elevation myocardial infarction; TIMI = Thrombolysis in 
Myocardial Infarction; GP = Glycoprotein; PCI = Percutaneous coronary intervention; CABG = Coronary 
artery bypass graft; IRA = infarct related artery;
*  p value calculated using ANOVA for continuous variables and Chi­Square test for categorical variables. 
¶  includes cases with left main disease plus one vessel disease. 
§  p value by Kruskal Wallis test.
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Similarly, for Sxscore II (tables 3 and 4), significantly higher scores were observed in 
patients with a previous myocardial infarction and those presenting with cardiogenic 
shock. Patients with higher scores were more likely to have longer stents implanted, 
more bifurcation treatment and multivessel stenting during the index procedure. 
Procedure failure with final TIMI flow 0/1 and impaired myocardial perfusion as 
determined by myocardial blush grade was more common in the tertiles with the 
higher scores. Whereas complete revascularisation within 3 months was achieved in 
88% of patients in the lower tertiles, that in the highest tertile was low at 12.6%.
table 3: Clinical characteristics of patients presenting with myocardial infarction according to 
SXscore II tertiles.
Lower (<9)
n = 238
Intermediate (9-17)
n = 208
higher (>17)
n = 223 p value*
Baseline Characteristics
Age, years 62±12 66±13 68±11 0.10
Male 157 (66%) 145 (70%) 167 (75%) 0.10
Diabetes
Type I 9 (4%) 5 (2%) 14 (6%) 0.12
Type II 8 (3%) 10 (5%) 19 (9%) 0.46
Hypertension 74 (31%) 70 (34%) 80 (36%) 0.55
Hypercholesterolaemia 51 (21%) 36 (17%) 53 (24%) 0.25
Smoker
Current 117 (52%) 90 (44%) 73 (35%) < 0.01
Ex­ 31 (13%) 27 (13%) 33 (16%) 0.82
Renal failure 3 (1%) 5 (2%) 10 (5%) 0.10
Family history of CAD 93 (39%) 63 (30%) 54 (24%) < 0.01
Body Mass Index, Kg/m2 27±4 27±4 27±4 0.51
Previous Myocardial Infarction 14 (6%) 27 (13%) 44 (20%) < 0.01
Previous PCI 24 (10%) 19 (9%) 21 (9%) 0.94
Clinical presentation
Symptom onset to balloon time > 90 mins. 189 (86%) 161 (85%) 171 (86%) 0.98
Out of hospital cardiac arrest 8 (3%) 7 (3%) 16 (7%) 0.09
Pulse rate, bpm 77±17 78±17 81±19 0.09
Blood pressure, mmHg
Systolic 126±26 122±27 122±27 0.87
Diastolic 76±13 74±17 74±15 0.25
Cardiogenic Shock 13 (6%) 14 (7%) 28 (13%) 0.01
Killip class 2­4 11 (5%) 14 (7%) 27 (12%) 0.01
 Data is expressed in numbers and (percentages), mean ± 1 standard deviation. Percentages are rounded. 
PCI = Percutaneous coronary intervention; 
*  p value calculated using ANOVA for continuous variables or Kruskal Wallis test for non parametric 
variables and Chi­Square test for categorical variables.
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table 4: angiographic characteristics, procedural characteristics and management of patients with 
acute myocardial infarction according to SXscore II tertiles.
SXscore II tertiles
Lower (<9)
n = 238
Intermediate (9-17)
n = 208
higher (>17)
n = 223 p value *
angiographic Characteristics pre-procedural
Anterior STEMI 85 (36%) 119 (57%) 100 (45%) < 0.01
Infarct Related Artery
Left Main
Left anterior descending
Left Circumflex
Right Coronary
2 (1%)
75 (32%)
45 (19%)
116 (48%)
0 (0%)
111 (53%)
27 (13%)
70 (34%)
3 (1.3%)
94 (42%)
37 (17%)
89 (40%)
0.26
< 0.01
0.23
< 0.01
TIMI 0/1 in IRA 136 (57%) 130 (63%) 144 (65%) 0.26
Stent thrombosis (cause) 5 (2%) 13 (6%) 7 (3%) 0.06
Diseased vessels incl. IRA
1­vessel disease
2­vessel disease
3­vessel disease ¶
189 (79%)
42 (18%)
6 (3%)
76 (37%)
96 (46%)
36 (17%)
16 (4%)
68 (31%)
139 (62%)
< 0.01
< 0.01
< 0.01
Left main disease 5 (2%) 1 (1%) 36 (16%) < 0.01
Chronic Total Occlusion 3 (1%) 3 (1%) 40 (18%) < 0.01
procedural characteristics
Stent Implantation 218 (92%) 198 (95%) 200 (90%) 0.10
Total Stent length, mm 24 (18­32) 28 (23­51) 32 (23­51) < 0.01
Stent diameter, mm 3.3 ± 0.5 3.2 ± 0.5 3.3 ± 0.5 0.09
Bifurcation treatment in IRA 17 (7%) 47 (23%) 59 (27%) < 0.01
Thrombectomy 52 (22%) 37 (18%) 35 (16%) 0.22
GP IIb/IIIa Inhibitors 56 (24%) 46 (22%) 45 (20%) 0.69
Inotropic agents 8 (3%) 8 (4%) 15 (5%) 0.19
Intra Aortic Balloon Pump 9 (4%) 11 (5%) 25 (11%) < 0.01
Multivessel stenting 11 (5%) 25 (12%) 33 (15%) < 0.01
angiographic characteristics post-procedural
TIMI 0/1 3 (1%) 6 (3%) 19 (9%) < 0.01
Corrected TIMI frame count  
at end procedure, fps 26 (18­32) 32 (21­36) 28 (20­33) 0.02§
Myocardial Blush Grade 0/1 1 (1%) 5 (2%) 16 (7%) < 0.01
Follow - up treatment
Complete revascularisation  
within 3 months (PCI n=331, CABG n= 4) 210 (88%) 97 (47%) 28 (13%) < 0.01
Medication at 1 year
Aspirin 
Clopidogrel 
B­Blocker
ACE­inhibitors
Statins
200 (84%)
228 (96%)
212 (89%)
150 (63%)
207 (87%)
177 (85%)
202 (97%)
185 (89%)
123 (59%)
183 (88%)
198 (89%)
205 (92%)
194 (87%)
154 (69%)
210 (94%)
0.60
0.03
0.85
0.44
0.33
 Data is expressed in numbers and (percentages), mean ± 1 standard deviation or median and 
(interquartile range); Percentages are rounded. STEMI = ST elevation myocardial infarction;  
TIMI = Thrombolysis in Myocardial Infarction; GP = Glycoprotein; PCI = Percutaneous coronary 
intervention; CABG = Coronary artery bypass graft; IRA = infarct related artery;
*  p value calculated using ANOVA for continuous variables and Chi­Square test for categorical variables. 
¶  includes cases with left main disease plus one vessel disease. 
§  p value by Kruskal Wallis test.
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Long term clinical outcome
All patients had follow-up to 1.5 years. Mortality rate was 12.1%, TVR 4.6, MI 2.2% and 
cumulative MACE 16.4%. Angiographically defined stent thrombosis (ST) occurred in 
1.2%. Kaplan Meier curves for survival, repeat myocardial infarction, target vessel 
revascularisation, according to the tertiles of SXscore I are shown in figure 3. Log rank 
test shows that the differences in mortality was significant between the highest and 
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Figure 3: Kaplan­Meier event­free survival curves and their log­rank tests for patients presenting 
with STEMI and categorized in tertiles of the SXscore I. A, 1.5­year mortality. B, Repeat MI. C, TVR. 
D, MACE.
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lower 2 tertiles. There was no statistically significant differences between tertiles 
for repeat MI and TVR so that the difference in MACE between tertiles was primarily 
driven by difference in mortality. Stent thrombosis, although numerically higher in 
the highest tertile was not statistically different (1% vs. 0.4% vs. 2.3%; log rank 0.17) 
Figure 4 shows the Kaplan Meier curves for SXscore II. Log rank test shows difference 
in mortality (9% vs. 11% vs. 17%, log rank = 0.02) and TVR (2% vs. 3% vs. 9%, log rank 
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Figure 4: Kaplan­Meier event­free survival curves and their log­rank tests for patients presenting 
with STEMI and categorized in tertiles of the SXscore II. A, 1.5­year mortality. B, Repeat MI. C, TVR. 
D, MACE.
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<0.01) between the higher and lower tertiles but not between the intermediate and 
lower tertiles. There was no difference in repeat myocardial infarction. The difference 
in MACE between the highest and lower tertiles is determined mostly by differences 
in mortality, followed by TVR. Angiographic ST was higher in the highest tertile (0.8% 
vs. 1% vs. 1.8% vs. log rank 0.60). 
A cox regression model with independent variables from our data was significantly 
improved in discrimination for both mortality and MACE when SXscore I or Sxscore II 
were added to the model. The c-indices for SXscore I were 0.60 and 0.61 for mortality 
and MACE respectively while c-indices for SXscore II were 0.61 and 0.63 for mortality 
and MACE respectively. Similarly, when only TIMI risk score variables for STEMI were 
introduced in the model, SXscore showed a significant improvement. (table 5). In fact, 
adding either SXscore I or Sxscore II to the TIMI risk score model improved the 
prediction of MACE (p value = < 0.01), and mortality (p value = < 0.04). Hazards ratio 
for mortality with a 20 point increase in the SXscore in a combined model adjusted 
for TIMI risk variables was 1.52 (1.03 - 2.23), p = 0.04 and 1.51 (1.03 – 2.21), p = 0.03 for 
SXscore I and II respectively. For MACE, hazards were 1.63 (1.17 – 2.27), p < 0.01 for 
SXscore I and 1.63 (1.18 – 2.26), p <0.01 for SXscore II respectively.
table 5: hazard ratios from multivariate analysis of tIMI risk score and SXscore with value of 
model improvement for mortality and MaCe.
endpoint Mortality MaCe
risk Score hr (95%CI) p value hr (95%CI) p value
TIMI score 1.41 (1.29 ­ 1.55) < 0.01 1.32 (1.22 ­ 1.43) < 0.01
Model Improvement  
by adding SXscore I to TIMI 0.04* < 0.01*
SXscore I 1.52 (1.03 ­ 2.23) 0.04 1.63 (1.17 – 2.27) 0.04
TIMI score 1.42 (1.29 – 1.55) < 0.01 1.32 (1.22 – 1.43) < 0.01
Model Improvement  
by adding SXscore II to TIMI 0.04* < 0.01*
SXscore II 1.51 (1.03 – 2.21) 0.03 1.63 (1.18 – 2.26) < 0.01
 MACE= major adverse cardiac events; HR= hazard ratios; CI= confidence intervals;  
TIMI= thrombolysis in myocardial infarction risk score;
* by omnibus test of model coefficients
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Interobserver and intraobserver variability
Interobserver variability as measured by the weighted Kappa statistic was moderate 
(0.56 for both SXscores I and II). Intraobserver variability was substantial with values 
of 0.70 and 0.77 SX scores I and II respectively.
Discussion
The SYNTAX score (SXscore), originally designed for quantifying stable coronary 
artery disease, can be usefully employed in a STEMI population with disease in 
the native coronary arteries as demonstrated in our study. The extent of coronary 
artery disease and the successful intervention as determined by angiography at 
each stage during a PPCI and as graded by SXscores I and II is associated with the 
rate of mortality and major adverse cardiac events both at 1.5 years follow-up. Both 
SXscores are independent predictors of mortality and MACE adding incremental 
value to the TIMI risk score in STEMI patients treated with PPCI. This therefore adds 
to the well established risk factors of mortality as previously described in the major 
trials that studied the STEMI population. [13-15] Additionally, the score can be utilised 
by clinicians, interventional cardiologists and cardiac surgeons to better assess and 
quantify the risk of complications and tailor management strategies accordingly. 
This is the first study that reports the prognostic value of the SXscore, calculated 
purposely and exclusively for STEMI patients at two stages with the methodology 
described. Moreover since more than 99% of our cohort were treated with drug eluting 
stents in the setting of myocardial infarction, the study results are the first to show 
applicability of the SXscore in a ‘real world’ population with STEMI, treated almost 
exclusively with DES.
Risk scores in STEMI
The predictive power of clinical parameters derived from independent risk factors 
from the major reperfusion in acute coronary syndrome studies including the 
Thrombolysis In Myocardial Infarction (TIMI) trials, Global Registry of Acute 
Coronary Events (GRACE), Controlled Abciximab and Device Investigation to 
Lower Late Angioplasty Complications (CADILLAC) is considerable. [14-15] Angio graphic 
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characteristics that have additional independent prognostic significance include 
the infarct related artery (IRA), patency of the IRA, presence of 3 vessel disease 
and chronic total occlusions. This present study highlights the importance of more 
detailed characterisation of coronary artery disease in patients undergoing PPCI. 
In this present era of treatment of IRA lesions with stent implantation whenever 
possible, information about the lesion complexity is useful for prediction of future 
events which include revascularisation of the target vessel, stent thrombosis and 
repeat myocardial infarction in the territory of the index IRA. In fact 1.5 year TVR rates 
are considerably higher in patients in the higher SXscore II tertile. The higher disease 
complexity, the lower PCI success rate as well as the need for longer, more overlapping 
stents, bifurcation treatment are likely contributing factors for the increased need of 
revascularisation in this patient subgroup.
Functional consideration of the SXscore
By consideration of the flow to the left ventricle at the site of the lesion, a functional 
aspect has been added to the score. Thus for a right dominant coronary artery system, 
the right coronary artery (RCA) supplies approximately 16% of the flow to the left 
ventricle whereas the left coronary artery supplies 84%. In a left dominant system, the 
LAD supplies 66% and the left circumflex artery 33% of the flow to the left ventricle. 
Appropriately, the SXscore assigns 1 to the RCA lesions, 1.5 to the LCx and 3.5 to the LAD 
in consideration of function alone. In STEMI, a larger left ventricular infarct size can be 
anticipated when the culprit lesion is in the LAD. The level at which the occlusion occurs 
is also given weight in the score so that more proximal lesions which supply a larger 
myocardial territory, carry higher scores. Moreover SXscore I assigns a higher value 
to IRA’s which have TIMI 1/0 flow on diagnostic angiography during PPCI. Thus further 
points are added and may be appropriate as the extent of myocardial damage is known 
to be higher in patients presenting with closed versus patent IRAs. This functional 
combination is a plausible reason for the better early separation of the survival curves 
between all three tertiles of SXscore I when compared to SXscore II as illustrated in 
figure 3 and figure 4 respectively.
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Lesion complexity consideration
Angiographic characterisation of the culprit lesion is possible in the majority of 
patients presenting with acute STEMI. Patients with a patent IRA with TIMI 2 or 
higher flow can have characterisation outright from the diagnostic angiography 
unless the thrombus burden is high. In patients presenting with an occluded IRA 
with TIMI 1/0 flow, wiring or use of a small balloon can increase the flow to reveal 
the underlying lesion anatomy. SXscore II in these patients is lower than SXscore I 
since the increase in flow reduces the 5 points added in the latter for total occlusion. 
Patients in whom TIMI 0/1 flow persists after wiring may have higher intracoronary 
pressures from larger infarct sizes and possibly higher thrombus burden which is 
associated with a poorer prognosis. [16] In addition, higher SXscores are assigned to 
patients with complex lesions with points added for trifurcations, bifurcations, ostial 
stenosis, severe tortuosity, lesion length >20mm, heavy calcification, thrombus and 
diffuse disease or small vessels. [1] Although these features are historically and in 
our study more prevalent in patients who already have a poorer prognosis based on 
their high clinical risk factors alone (age, diabetes, smokers) SXscore can still give 
additional prognostic information. The better characterisation of the underlying 
disease anatomy in the SXscore II may be a major reason for the better prognostic 
impact on MACE in the long term.
Multivessel disease, STEMI and the SXscore
That patients with multivessel coronary artery disease have worse outcome when 
compared to single vessel disease in myocardial infarction has been reported since the 
pharmacological reperfusion era. [17] In the PPCI era, these patients have been shown to 
achieve less ST segment recovery, a sign of myocardial reperfusion in a substudy of 
the CADILLAC trial. [6] In this substudy, 1 year mortality and MACE rates also differed 
between patients with single-, double-, and triple-vessel disease and presence of 
the latter was the strongest amoung classical candidate predictors of outcome. The 
concomitant presence of a chronic total occlusion (CTO) in a vessel other than the 
IRA has been shown to be a considerably more important risk factor than presence 
of multivessel disease alone in a study by van der Schaaf et al. [7] In the present study, 
the mortality rate was highest in the highest tertile of SXscore which predominantly 
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included patients with 3 vessel disease and the largest number of CTOs. With the 
additional information about the nature of the lesions in multivessel disease subjects, 
the SXscore may be a better predictor than mere numeration of the vessels involved.
Implications for clinical practice
In patients undergoing PPCI for acute STEMI, quantification of the presence, 
severity and complexity of coronary vessel disease by the SXscore is a useful tool in 
determining short term and long term outcome independently of any other clinical 
and angiographic and procedural characteristics. Patients in the higher tertiles are at 
high risk and may need more intensive supportive and interventional management 
to improve their event free survival.
Implications for PCI trials
In ‘all comer’ revascularisation trials that include patients with a spectrum of 
coronary disease and patients treated for acute STEMI, the SXscore seems a useful 
tool in addition to the classical risk factors that ensures comparison of equal coronary 
disease anatomy between the cohorts being investigated.
Limitations
Although data was acquired prospectively the study has a retrospective design and is 
in fact a registry analysis and therefore suffers from limitations. Data on enzymatic 
or other imaging-derived infarct size quantification was not available in all patients. 
Also myocardial blush grade, ST segment resolution as markers of reperfusion 
could not be determined in all patients and we used cTFC instead. These could not 
be incorporated in the models and whether these would be better predictors than the 
SXscore remains unexplored.
Conclusion
The SXscore derived from angiography after during PPCI predicts long term 
mortality and MACE in patients with STEMI. The score is relatively easy to obtain and 
has a moderate reproducibility, making it a clinically useful tool.
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Abstract
The no-reflow phenomenon has been shown to have a significant effect on clinical 
outcome in patients with acute ST segment elevation myocardial infarction (STEMI). 
Angiographic features incorporated in the SYNTAXscore (SXscore) obtained on a 
diagnostic angiogram during primary percutaneous coronary intervention (PPCI) 
may be associated with the occurrence of myocardial no-reflow. The study aimed to 
assess the ability of the SXscore to predict no-reflow during PPCI. The SXscore was 
applied to 669 consecutive patients presenting with acute ST elevation myocardial 
infarction between November 2006 and February 2008. Angiographic analysis of the 
PPCI procedure was used to determine no-reflow. The median SXscore was 16 (9.5-23). 
No-reflow occurred in 77 (12%) patients. On univariate logistic regression analysis 
the SXscore showed strong association with odds ratio (OR) of 1.42, 95% CI (1.16-1.76), 
p < 0.001 for every 10 units increase in the score. On multivariate logistic regression 
in a model including clinical variables, SXscore was an independent predictor on no-
reflow: (OR); 1.29 95%CI 1.02-1.63), p <0.001. Classification and regression tree analysis 
identified SXscore of > 21 as best cut off with patients having a double risk of no-
reflow as compared to those with SXscore ≤ 21. (events 9% vs.18%, p value 0.006). In 
conclusion, the SXscore obtained in the diagnostic phase of PPCI for acute STEMI can 
identify patients at risk of developing no-reflow. Periprocedural pharmacological or 
mechanical preventive measures of no-reflow may in the future be directed at those 
at higher risk as identified by the SXscore. 
 
Keywords
ST segment elevation myocardial infarction, Primary percutaneous coronary 
intervention, SYNTAX score, myocardial no-reflow. 
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Introduction
Myocardial no reflow diagnosed angiographically during primary percutaneous 
coronary intervention (PPCI) is associated with a increased incidence of clinical events 
and a poor survival rate following an acute ST segment elevation myocardial infarction 
(STEMI). [1] The no-reflow phenomenon is in fact established as a good surrogate of 
adverse cardiovascular events in patients treated for STEMI. [2] Patients at a high risk of 
no-reflow include older subjects, those with previous coronary artery bypass surgery, 
those presenting with a higher Killip class and a longer ischaemic time. Angiographic 
characteristics of STEMI patients with a high risk of subsequent no-reflow include 
patency of the infarct related artery, saphenous graft as culprit vessel and multivessel 
disease. A high thrombus burden as assessed angiographically is also known to be 
associated with a higher risk of developing the no-reflow phenomenon. [3] 
Such angiographic characteristics can be quantified by the SYNTAX score (SXscore). [4] 
The latter, obtained on the diagnostic angiogram during PPCI incorporates information 
including the patency of the infarct related artery, the area of myocardium at risk, 
supplied by the culprit vessel at the level of occlusion, as well as information on the 
complexity of the lesion and extent and severity of coronary artery disease. [5] Patients 
with high SXscores are at increased risk of adverse events including mortality and the 
prognostic value has been shown to be independent and additive to other risk variables 
incorporated in risk scores such as the TIMI and PAMI scores. [4, 6-8] The mechanisms 
that relate a high SXscore to adverse cardiovascular events is unclear and may in part 
be mediated by a higher risk of failure to achieve an adequate myocardial reperfusion 
during PPCI.
We hypothesized that with its additional angiographic characterization of patients 
presenting for PPCI, the SXscore can stratify patients at risk of developing myocardial 
no-reflow. 
Ch
ap
te
r 
15
236     |     Myocardial infarction: temporal trends over the past three decades
Methods
Between November 2006 and February 2008, 736 consecutive patients undergoing 
primary PCI for STEMI in our institution were screened for inclusion in the MI 
SXscore study. [4] All patients in the referral area of the Thoraxcentre, Erasmus MC, 
Rotterdam that had symptoms of acute myocardial infarction (< 12 duration) were 
assessed clinically and by 12 lead ECG by paramedical personnel or peripheral 
hospital medical staff. Pre-treatment with aspirin, clopidogrel and heparin was 
administered pre-hospital. Urgent diagnostic angiography was followed by PPCI 
with standard techniques. Drug eluting stents were implanted as first line choice of 
stents. Treatment of complications such as cardiogenic shock and cardiac arrest were 
performed according to guidelines. 
The SXscore was calculated as previously described. [4] Patients with previous 
coronary artery bypass grafting (CABG) in whom the SXscore could not be calculated 
were excluded from the study. All coronary lesions with a diameter stenosis ≥ 50%, 
in vessels ≥1.5 mm were scored using the SXscore algorithm which is available on 
the website (www.syntaxscore.com). The SXscore for each patient was calculated by a 
team of two interventional cardiologists. In case of disagreement with regards to the 
significance of a lesion quantitative coronary angiography was applied and the lesion 
included if it was ≥ 50%. On agreement between the two cardiologists, the data was 
entered into a dedicated software program. 
The investigators calculating the SXscore were blinded to the patient’s clinical 
characteristics. The scoring was done prospectively at each stage so that the 
investigators were blinded to the next stage film, to the procedural data and to the 
clinical outcomes. No change in scoring was allowed once a score was assigned.
Thrombolysis In Myocardial Infarction (TIMI) flow and corrected TIMI frame count 
were assessed as previously reported [9]. Myocardial blush grade was assigned as 
described by van ‘t Hof et al. [10] Angiographic epicardial artery no-reflow was defined 
as an acute temporary or persistent reduction in coronary flow (TIMI 0/1) in the 
absence of dissection, thrombus, spasm or high grade residual stenosis at the target 
lesion. Slow flow was recorded if there was a temporary reduction from TIMI flow 
Chapter 15.    SYNTAX Score and No­Reflow in STEMI     |     237
grade 3 to 2. Distal embolisation was defined as visible downstream movement of a 
contrast filling-defect from the site of the culprit lesion. Distal occlusion was defined 
as a distal filling defect with an abrupt ‘cutoff’ in one of the peripheral coronary artery 
branches of the infarct-related vessel distal to the site of angioplasty.
Survival data for all patients was obtained from the municipal registry. A health 
questionnaire was subsequently sent to all living patients with specific questions on 
readmission and major adverse cardiac events. For patients with an adverse event 
at another centre, medical records, discharge summaries and, when necessary, 
angiographic films, were systematically reviewed. General practitioners, referring 
cardiologists and patients were contacted as necessary for additional information. 
Events were adjudicated by two experienced interventional cardiologists according 
to the definitions below. ST segment elevation myocardial infarction was diagnosed 
when patients had symptoms of an acute myocardial infarction lasting at least 30 
minutes and accompanied by >1mm (0.1mV) ST elevation in two or more contiguous 
leads and later confirmed by a creatinine kinase (CK) and CK-MB rise and /or troponin 
rise. Target vessel revascularisation was defined as any PCI of the index infarct-related 
artery. Major adverse cardiac events (MACE) was defined as a composite of death, repeat 
myocardial infarction and target vessel revascularisation. 
The no-reflow phenomenon was defined by at least one of the following: final 
TIMI flow grade <3; final myocardial blush grade <2; temporary epicardial coronary 
no-reflow; distal coronary occlusion; and a final corrected TIMI frame count of >100 
frames per second. [9]
Continuous variables are expressed as mean and standard deviation or as median 
and interquartile range while categorical variables are presented as absolute numbers 
and percentage. Normality assumption was evaluated by the Kolmogorov-Smirnov 
test. Continuous variables were compared using Student’s unpaired t-test or Mann-
Whitney non-parametric test. Categorical variables were compared using chi-square 
statistics or Fischer’s exact test, as appropriate. 
Observed unadjusted and adjusted measures of association were obtained by 
logistic regression models and presented as odds ratios (OR) and 95% confidence 
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intervals (CI). Separate logistic regression analyses were performed to identify 
independent predictors of no-reflow using all clinical variables. These univariate 
predictors were entered into a second logistic regression model to obtain the adjusted 
OR. The multivariate model consisted of SXscore and the clinical variables; age, sex, 
out of hospital arrest, Killip class, cardiogenic shock, pulse rate, and blood pressure. 
Classification and regression tree analysis was performed to determine the best 
SXscore value cut-off that stratifies patients at high versus low risk of developing no-
reflow.To assesswhich of the angiographic characteristics best impact the association 
of SXscore and no-reflow, a separate logistic regression analysis in a multivariate 
model with the angiographic variables infarct–related artery, TIMI flow pre-wiring, 
thrombus grade post-wire, number of vessels diseased, chronic total occlusion and 
bifurcation was performed. 
Also, the cumulative incidence of adverse events according to the presence of 
no-reflow was estimated according to the Kaplan-Meier method, and curves were 
compared using the log-rank test. A value of <0.05 was used to indicate statistical 
significance unless declared otherwise. All statistical analyses were performed using 
SPSS version 17.0 (SPSS Inc., Chicago, Illinois).
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Results
From the initial 736 patients screened, 27 were excluded due to unavailability of a 
complete diagnostic coronary angiogram while 21 were excluded since they had prior 
CABG. Survival status and follow-up could not be obtained in 19 patients. Thus the 
final number of patients included in our analysis was 669. The median SXscore was 
16 (9.5-23). Differences in the baseline clinical characteristics in patients with low and 
high SXscores are shown in table 1. Patients with a higher SXscore (≥16) were more 
commonly older, male, more often had type 2 diabetes and were more likely to be 
table 1: Baseline and presenting characteristics of patients with acute myocardial infarction 
according to low or high MI SYNtaX score.
Lower (<16)
n = 332
Higher (≥16)
n = 337 p value*
Age, years 63±13 67±12 <0.01
Male 221 (67%) 248 (74%) 0.047
Diabetes
Type I
Type II
22 (7%)
11 (3%)
12 (4%)
41 (12%)
17 (5%)
25 (7%)
0.014
0.26
0.03
Hypertension  101 (30%) 123 (37%) 0.096
Hypercholesterolaemia  64 (19%)  76 (23%) 0.30
Smoker
Current
Ex­
155 (47%)
46 (14%)
125 (37%)
45 (13%)
0.012
0.036
Renal failure 4 (1%) 14 (4%) 0.018
Family history of CAD 121 (36%) 89 (26%) <0.01
Body Mass Index, Kg/m2 27±4 27±4 0.74
Previous Myocardial Infarction 25 (8%)   60 (18%) < 0.01
Previous PCI  30 (9%) 34 (10%) 0.64
Symptom onset to balloon time > 90 mins.  257 (84%) 264 (87%) 0.27
Out of hospital cardiac arrest  13 (4%)  18 (5%) 0.38
Pulse rate, bpm 77±16 80±19 0.037
Blood pressure, mmHg 
Systolic
Diastolic
124±26
75±14
123±27
75±16
0.29
0.45
Cardiogenic Shock  19 (6%) 36 (11%) 0.02
Killip class 2­4  18 (5%) 34 (10%) 0.024
 Data is expressed in numbers and (percentages), mean ± 1 standard deviation. Percentages are rounded. 
 PCI = Percutaneous coronary intervention; 
*  p value calculated using ANOVA  for continuous variables or Kruskal Wallis test for non parametric 
variables and Chi­Square test for categorical variables.
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table 2: angiographic characteristics, procedural characteristics and management of patients with 
acute myocardial infarction with low and high MI SYNtaX score.
Lower (<16)
n = 332
Higher (≥16)
n = 337 p value*
Anterior STEMI 127 (38%) 177 (53%) <0.001
Infarct Related Artery 
Left Main 
Left anterior descending
Left Circumflex
Right Coronary
6 (2%)
111 (34%)
63 (19%)
156 (47%)
36 (11%)
169 (50%)
46 (14%)
119 (35%)
<0.01
<0.01
0.06
<0.01
TIMI 0/1 in IRA 157 (48%) 253 (75%) <0.01
Stent thrombosis (cause) 12 (4%) 13 (4%) 0.86
Diseased vessels incl. IRA
1­vessel disease
2­vessel disease
3­vessel disease¶
222 (67%)
91 (27%)
18 (5%)
59 (18%)
115 (34%)
163 (48%)
<0.01
0.06
<0.01
Left main disease 6 (2%) 36 (11%) <0.01
Chronic Total Occlusion 4 (1%) 42 (13%) <0.01
Stent Implantation 311 (94%) 305 (91%) 0.096
Total Stent length, mm 28 (18­40) 30 (23­51) <0.01
Stent diameter, mm 3.0±0.5 3.0±0.5 0.83
Bifurcation treatment in IRA 47 (14%) 76 (23%) <0.01
Thrombectomy 62 (19%) 62 (19%) 0.93
GP IIb/IIIa Inhibitors 73 (22%) 74 (22%) 0.99
Inotropic agents 14 (4%) 17 (5%) 0.61
Intra Aortic Balloon Pump 15 (5%) 30 (9%) 0.024
Multivessel stenting 26 (8%) 43 (13%) 0.036
TIMI 0/1 7 (2%) 21 (6%) <0.01
Corrected TIMI frame count at end, fps 24 (16­36) 26 (18­40) 0.052
Myocardial Blush Grade 0/1 3 (1%) 19 (6%) <0.01
 Data is expressed in numbers and (percentages), mean ± 1 standard deviation or median and 
(interquartile range); Percentages are rounded. STEMI = ST elevation myocardial infarction;  
TIMI = Thrombolysis in Myocardial  Infarction; GP = Glycoprotein;  
PCI = Percutaneous coronary intervention; IRA = infarct related artery;  
*  p value calculated using ANOVA for continuous variables and Chi­Square test for categorical variables. 
¶  includes cases with left main disease plus one vessel disease. 
§  p value by Kruskal Wallis test.
Chapter 15.    SYNTAX Score and No­Reflow in STEMI     |     241
current smokers. A history of previous myocardial infarction was also more common 
in the higher SXscore patients. Patients presenting in the acute phase with a higher 
pulse rate, cardiogenic shock and higher Killip class more often had a higher SXscore. 
Table 2 shows the differences in angiographic and procedural characteristics 
between patients with low and high SXscores. The left main stem and the left anterior 
descending coronary artery were more commonly the culprit vessels in patients with 
high SXscore whereas the left circumflex coronary artery and the right coronary 
artery were more commonly the IRA in low SXscore patients. Furthermore, the 
IRA more often had poor antegrade flow (TIMI 0/1) in patients with a high SXscore. 
Multivessel disease, chronic total occlusions and bifurcations were more often 
present in patients with higher scores. In fact multivessel stenting and bifurcation 
stenting were more often performed in these patients. These patients also had a 
higher total stent length implanted during the index PPCI. There was no difference in 
the procedural use of thrombectomy devices or GP IIb/IIIa inhibitors between the two 
groups. The use of an intra-aortic balloon pump was necessary in double the patients 
with SXscore of 16 or higher when compared to those with score below 16. 
 The no-reflow phenomenon occurred in 77 (12%) of patients included in the analysis. 
The components used to define the composite endpoint are shown in table 3. On 
univariate logistic regression analysis, the SXscore showed a strong association with 
no-reflow, unadjusted odds ratio (OR) of 1.42, 95% CI (1.16-1.76), p < 0.001 for every 10 unit 
increase in the score. The other univariate predictors of no-reflow were age, sex, out 
of hospital arrest, Killip class, shock, pulse rate and blood pressure. After adjusting for 
these predictors in multivariate logistic regression, the SXscore was an independent 
predictor of no-reflow: adjusted (OR); 1.29 95%CI 1.02-1.63), p <0.001 per 10 unit increase 
in the score. (table 4) 
Classification and regression tree analysis identified SXscore of > 21 as best cut off 
with patients having a double risk of no-reflow as compared to those with SXscore ≤ 21. 
(events 9% vs.18%, p value 0.006) 
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table 3:  Differences in angiographically detected complications between patients presenting with 
a low versus a high MI SYNtaX score. 
angiographic complication Lower (<16)n = 332
Higher (≥16)
n = 337 p value*
Dissection 17 (5%) 12 (4%) 0.322
Perforation 6 (2%) 4 (1%) 0.51
Distal Embolisation 16 (5%) 15 (5%) 0.82
Slow Flow 7 (2%) 14 (4%) 0.13
Angiographic no reflow 6 (2%)  11 (3%) 0.23
TIMI 0/1 final 7 (2%) 21 (6%) <0.001
Corrected TIMI frame count >100 fps 5 (2%) 24 (7%) <0.001
Myocardial Blush Grade 0/1 3 (1%) 19 (6%) <0.001
Composite No­reflow 29 (9%) 48 (14%) 0.026
 Data is expressed in numbers and (percentages).Percentages are rounded. 
table 4: predictors of myocardial no-reflow on multivariate analysis in model with clinical 
characteristics and MI SXscore.
predictors Odds ratio (95% CI) p value
MI SXscore 1.29 CI (1.02 – 1.63)  <0.001
Age 1.23 (0.99­1.54) 0.058
Pulse rate 1.02 (1.01­1.03)  0.012
table 5: angiographic predictors of no-reflow.
Univariate analysis Multivariate analysis
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Infarct related artery
Left Main Stem
Left anterior descending
3.46 (1.69­7.08)
1.50 (0.93­2.41)
0.001
0.098
2.42 (0.96­6.09)
1.37 (0.80­2.35)
0.060
0.25
Left circumflex 
Right coronary
0.41 (0.17­0.95)
0.96 (0.59­1.56)
0.037
0.86
0.56 (0.22­1.43) 0.22
Number of vessels with significant disease
2­vessel
3­vessel
0.71 (0.41­1.23)
1.54 (0.94­1.54)
0.218
0.094
­
1.18 (0.63­2.22)
­
0.60
Chronic Total Occlusion 1.99 (0.92­4.29) 0.081 1.03 (0.40­2.65) 0.95
Bifurcation at IRA 0.80 (0.42­1.53) 0.497 ­ ­
TIMI flow  pre­wiring 0.66 (0.53­0.82) <0.001 0.71 (0.56­090) 0.004
Thrombus grade post­wire 1.73 (1.43­2.10) <0.001 1.60 (1.32­1.95) <0.001
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Assessment of the relation of angiographic characteristics and no-reflow are 
summarized in table 5. Angiographic characteristics that were independent predictors 
of no-reflow on multivariate analysis included left main stem involvement, TIMI flow 
grade on presentation as well as thrombus grade after wiring. 
The Kaplan Meier curves in figure 1 and figure 2 show the increased mortality rate 
(31% vs. 10%, p <0.001) and MACE (35% vs. 14%, p <0.001) at 18 months in patients who 
developed no-reflow respectively.
Figure 1: Kaplan Meier curves with the survival in patients with and without no­reflow (control). At 
18 months follow­up, mortality rate was 31 % vs. 10%, Log rank p < 0.001.
Figure 2: Kaplan Meier curves with the MACE (major adverse cardiac events including death, 
repeat myocardial infarction and target vessel revascularisation) free survival in patients with and 
without no­reflow. At 18 months follow­up MACE rate was 35% vs. 14%, Log rank p <0.001. 
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Discussion
The SXscore is an independent predictor of myocardial no-reflow in patients with ST 
segment elevation myocardial infarction. A SXscore of > 21 carries a double risk of 
developing no-reflow. Myocardial no-reflow carries a poor prognosis with an increased 
mortality rate. Thus intra-procedural measures that can prevent this phenomenon 
would be especially beneficial in patients at high risk as can be identified by the SXscore. 
 In this study no-reflow was identified by changes in the TIMI flow in the epicardial 
artery which directly affect myocardial perfusion as well as more direct imaging of 
myocardial perfusion as measured by the myocardial blush grade. TIMI flow grade 
is a crude but accurate indicator for myocardial reperfusion if this is suboptimal i.e. 
<3. The corrected TIMI frame count adds more sensitivity for categorizing no-reflow 
for patients in whom TIMI flow is ≥2 is achieved. A cut-off of 100fps has been chosen 
based on data from previous studies. [9]
One of the major components of the SXscore that enhances its predictive value on 
the eventual achievement of microvascular perfusion is the patency or otherwise of 
the infarct related artery. An occluded infarct related artery (IRA) has been shown to 
be associated with a worse, postprocedural myocardial perfusion (TMPG 3: 54.9% vs. 
18.7%, p<0.0001). Patency of the IRA often signifies earlier spontaneous reperfusion 
which reduces the actual ischaemic time. As a result infarction size is limited and 
an improvement in left ventricular ejection fraction (LVEF) is higher in such patients, 
that is reflected in an improved 1-year outcome. [11] The SXscore adds 5 points if the 
IRA has TIMI 0/1 flow reflecting the importance of IRA patency on both no-reflow 
and short and long term mortality. A poor antegrade flow is also often associated 
with a higher thrombus load and this in turn has been associated with both slow 
flow and the no-reflow phenomenon. [12] Embolisation of atherothrombotic material 
has been implicated as an important pathophysiological mechanism leading to 
poor microvascular perfusion. Anti-thrombitc, thrombolytic or thrombus aspiration 
have all been shown to reduce the incidence of the no-reflow phenomenon. [13-15] Given 
the associated risks associated with these adjunctive therapeutic measures such 
as bleeding and cerebrovascular accidents, identification and limitation of use to 
patients who may benefit most from these treatments is desirable.
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The difference in the myocardial area at risk is also an important component of the 
SXscore and the different weighting given to the coronary arteries does influence the 
occurrence of no-reflow. While infarction in the left circumflex artery is less likely to 
result in detectable no-reflow, that in the proximal left coronary artery, especially the 
left main stem, carries a x 3.5 risk of no-reflow. 
In the present study, the presence of a chronic total occlusion (CTO) and three vessel 
disease have a non-significant trend of association with no-reflow. While the lack of 
statistical significance can be attributed to lack of power, the incorporation of these 
parameters in the SXscore ensure appropriate consideration of these parameters in 
the risk stratification of no-reflow. On the other hand CTO and multi-vessel disease are 
not as important as TIMI flow and location of occlusion. No reflow as an angiographic 
marker of myocardial perfusion focuses on the territory at risk which although as 
expected is affected mostly by the characteristics pertinent to the infarct related 
artery, can be affected by the presence and extent of disease elsewhere. Diffuse 
disease often signifies impaired microcirculatory resistance index. [16] Moreover, 
collateral circulation to the microvascular bed which is considered to be protective 
would be poorly developed or insufficient if the contributing artery is also diseased. 
Although observers scoring the SXscore were blinded to the next step angiographic 
film and changes to the score were not allowed after film review, bias of scoring 
no-reflow in patients with high SXscores may still have affected our observations. 
However the post hoc analytic nature of the study derived from the MI SXscore study 
database guarantees to a limited extent the validity of our findings. The relation of the 
SXscore and the outcome is unlikely to have been influenced by operator dependent 
choice of treatment. In fact in our study patients with higher scores were not treated 
differently especially with regards to stenting, thrombectomy devices or GP IIb/IIIa 
inhibitors. In determining no-reflow we chose to use only angiographic parameters. ST 
resolution as another measure of no-reflow was not available in all patients. Moreover 
we could not determine the effect of the SXscore and the occurrence of no-reflow on 
final infarct size since neither enzymatic infarct size nor infarct size by non-invasive 
imaging modalities were available in all patients. 
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Abstract
The latest Eropean Society of Cardiology (ESC) guidelines on myocardial revascula-
risation are reviewed. The nearly 300 recommendations make it almost impossible 
to apply them in their totality. We would propose 20 to 30 recommendations per 
guideline based on sound clinical evidence. Also, the scope of the current guideline 
is very wide, since it includes topics already incorporated in other guidelines, such 
as strategies for pre-intervention diagnosis and imaging as well as on secondary 
prevention. Some recommendations in the new guideline are sensible and will not be 
disputed. In particular, the encouragement of a balanced multidisciplinary decision 
process (the “Heart Team”) is welcome.
Although coronary revascularization in unstable high risk patients is well accepted, 
this is less the case for the low risk patient with chest pain. This issue is controversial 
and a balanced discussion of the pros and cons of percutaneous coronary intervention 
(PCI) is missing. Despite convincing evidence indicating lack of benefit of PCI for 
chronic total occlusion, this procedure is not discouraged.
Lastly, most committee members were interventional cardiologists or cardiac 
surgeons. Guideline committees should be representative of the whole group of 
professionals, since the interpretation of the evidence by specialists may be biased. 
There may be a role for procedure oriented guidelines but, in that case, the items at 
issue should remain confined to matters directly related to technical aspects of the 
procedure.
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Guidelines describe the current state of the art by formulating the current evidence 
base and recommendations for their application in clinical practice. On the 
basis of this premise, we reviewed the latest ESC guideline, those on myocardial 
revascularization.  [1] The new document is a follow-up on the percutaneous coronary 
intervention (PCI) guideline from 2005, which has previously been discussed in this 
Journal. [2, 3] The current document is a joint effort by interventional cardiologist as 
well as cardiovascular surgeons, and thus considers both percutaneous and surgical 
revascularization modalities. As a consequence, a “Heart Team,” a more formal 
multidisciplinary team approach to coronary revascularization, is advocated. As 
such, the new approach goes a long way into establishing a sound basis for clinical 
decision making for patients with coronary insufficiency, and we – and others before 
us – have no doubt that it will fulfil that purpose. [4] Nevertheless, some topics covered 
in the guideline require clarification. In this review, we comment on those topics with 
the aim of improving future versions of such documents.
Specific issues
Scope of the guideline
The new guideline, which comprises 13 sections, provides recommendations for 
percuta neous as well as surgical revascularizations. In reality however, it goes further. 
For instance, the various strategies for pre-intervention diagnosis and imaging are 
included as well (chapter 5). A useful chapter without doubt, but we question the 
appropriateness of including this issue in this procedure oriented document. This 
is relevant since the worth of diagnostic tests has previously been described in 
the ESC guideline on Stable Angina. [5] Similarly, chapter 13 of the current guideline 
provides recommendations for secondary prevention. That subject has been covered 
extensively in the guideline on CVD Prevention. [6] The reader is thus left with the 
question where these topics are covered in future versions of these guidelines; and 
if the recommendations are different, which ones are to be followed. The scope of the 
current new guideline is thus too wide.
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Number and levels of recommendations
The new guideline is quite lengthy but, with 52 pages, not extraordinarily so. However, 
its nearly 300 recommendations (table 1) make it almost impossible to apply them in 
their totality. [7]
We are of the opinion that I A (“strongly recommended“) and III A (“strongly 
discouraged”) recommendations should be issued only in the context of relevant 
changes in clinical outcomes resulting from performing (or withholding) specific 
interventions that were rigorously scrutinized and tested, preferably in randomized 
clinical trials. Unfortunately, this view was not taken by the current committee, with a 
very large number of recommendations based on “expert opinion” as a result. Leaving 
out such assessments would not only go a long a way in strengthening the value of 
the recommendations based on sound clinical evidence but, in addition, would make 
it much easier to apply the guideline in clinical practice. We also believe that some 
of the current recommendations are not appropriate or incorrect. For instance, the 
stratification scores used to estimate peri-procedural intervention risks (chapter 4, 
table 3) have been given specific recommendations. However, we are unaware of any 
studies that have shown that actual patient outcome will improve as a result of the 
table 1: Summary of recommendations in the new eSC guideline on coronary revascularization
Class * Level † No of recommendationsper level
No of recommendations
per class
 I A 53
 I B 48 144
 I C 43
 Ila A 8
 Ila B 38 59
 Ila C 13
 Ilb A 3
 Ilb B 18 39
 Ilb C 18
 Ill A 12
 Ill B 23 45
 Ill C 10
 * Class of recommendation
† Level of evidence
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use of such scores and levels of recommendations are thus not applicable. The same is 
true for many other recommendations. For instance, the recommendations depicted 
in table 7 (chapter 5), which compares the value of different imaging techniques in 
(sub) groups of patients, are not based on studies in which these techniques were 
directly compared with each other. 
Still, most recommendations in the new guideline are quite sound and will 
not lead to much controversy. For instance, mechanical, percutaneous coronary 
intervention of the infarct related vessel as early as possible in ST segment elevation 
MI, the preference for surgical revascularization intervention in case of multi-vessel 
disease, poor left ventricular function or diabetes, appropriate risk stratification and 
revascularization in patients in unstable clinical conditions, as well as physiologic 
assessment of the importance of intermediate coronary lesions prior to intervention, 
all seem very appropriate and sound. In particular, the encouragement of a balanced 
multidisciplinary decision process (“Heart Team”) is a very welcome addition, which 
was given appropriate credit in a recent editorial by Taggart et al in this Journal. [4]
PCI in stable angina and chronic total occlusion
Although in suitable high risk patients coronary revascularization in unstable clinical 
conditions is generally well accepted, this is not true for low risk patients with stable 
chest pain. This is a controversial issue and, given the large number of procedures 
performed for this indication, not without reason. This topic is covered in chapter 6, 
and the reader would expect a concise but objective textual review of this subject. This 
section is, however, quite short and does not provide such an evaluation. However, 
from review of tables 8 and 9 in that chapter, it becomes clear that the authors do 
recommend PCI for this indication, with a (noteworthy) class IC (expert opinion) 
indication for 1 or 2 vessel disease not involving the proximal left anterior descending 
(LAD). Although the lack of references given for this recommendation is in line with 
the given C, the results of the randomized trials performed in these patients do not 
support this recommendation (see below). The table gives a IIa B recommendation 
for PCI when the proximal LAD is involved. This recommendation is based on two 
meta-analyses and two other studies comparing coronary artery bypass grafting 
(CABG) with PCI and are therefore not applicable. In fact, all but two references in this 
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table compare the results of PCI with surgical revascularization, and therefore do not 
address the issue of medical therapy versus PCI.
We realize that an objective assessment of the appropriateness of PCI in stable 
angina is not easy and confounded by specific issues. Observational data showing 
superiority of revascularization over medical treatment are not helpful because of 
significant treatment bias [8] and –unfortunately – the actual evidence base is quite 
small. 
A summary of all randomized controlled clinical trials studies comparing PCI with 
medical therapy for stable angina is given in table 2 and figure 1. This analysis differs 
from previous analyses because we have excluded trials performed in the early 
nineties. [9-13] In that era, medical treatment was more or less placebo: for instance, 
statins and ACE inhibitors - currently considered standard medical treatment - were 
not available or not used. In addition, we excluded trials that investigated early post 
MI patients. [14-18] Overall, the combined results of these trials provide limited evidence 
for the superiority of PCI over medical therapy in stable chest pain syndromes. Of 
course, we acknowledge that some of these trials have come under criticism, and that 
patients switched from medical treatment to PCI (or CABG) (typically in about 25%). 
On the other hand, all subjects considered in these trials qualified for intervention 
on the basis of their specific coronary anatomy and were therefore quite selected. 
table 2: Characteristics of randomized clinical trials comparing pCI with medical treatment
trial
Year of 
Most recent 
publication
enrolment 
period
total No. 
of patients
Nonprotocol 
revascularizations 
in Medical Group (%)
Follow-up 
Length 
(Months)
Statin  
use at 
baseline (%) 
AVERT  [20] 1999 1995–1996 341 12 20 22
Bech et al. [21] 2001 NR 181 7 24 37
RITA 2 [22] 2003 1992–1996 1,018 35 84 13
TIME [23] 2004 1996–2000 301 42 48 23
Hambrecht et al. [24] 2004 1997–2001 101 6 12 75
MASS II [25] 2006 1995–2000 408 24 60 NR
COURAGE [26] 2007 1991–2004 2,287 31 54 88
Nishigaki et al. [27] 2008 2002­2004 384 37 26 47
NR: not reported
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This is different from the practical situation in which the patient with chest pain 
but with unknown coronary anatomy is contemplated. In the latter situation, 
eligibility for revascularization (and PCI) is uncertain, and a considerable number of 
Figure 1. PCI versus medical treatment in stable angina.  
For each trial we calculated the summary odds ratios and 95% confidence intervals for the clinical 
outcomes. We pooled studies using random effects models . [28]
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such patients will not be eligible for such a procedure because of anatomic or other 
circumstances. For instance, in the ICTUS trial, which investigated the possible 
benefit of revascularization in subjects with unstable angina, less than 60% of 
the patients scheduled to undergo intervention actually qualified for subsequent 
revascularization. [8] Thus, in the depicted trials, the true effectiveness of PCI in 
clinical practice may well have been exaggerated, and one could argue that, given 
their specific eligibility criteria, the randomized trials overestimated the true worth 
of PCI. Against this background, a balanced discussion of the pro and cons of PCI 
in this setting would have been helpful in the guideline. It is unreasonable to base 
a positive recommendation for PCI on the basis of results obtained in a subgroup 
of a subgroup of the (overall negative) COURAGE trial: an “evidence base” of 100 
patients does not meet the criteria to justify millions of costly invasive procedures of 
uncertain clinical benefit. [8, 19] A strategy of initial medical treatment is certainly the 
preferable option for the low risk patient with stable angina or in someone in whom 
the presence of obstructive coronary artery disease has just been established during 
diagnostic coronary angiography.
It is also noteworthy that, despite two negative randomized trials that specifically 
addressed this topic, the performance of percutaneous intervention for chronic 
total occlusion is not discouraged. Instead, an “experienced” intervention team is 
called to order, perhaps suggesting that the care was sub-standard in the trials that 
investigated this very issue.
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General issues
Format of the guideline and composition of the writing committee
The current format of the guideline differs significantly from the previous version, 
and this makes it difficult to assess why, and on the basis of which information, the 
current recommendations have changed from those issued in the earlier document. 
We recommend that future versions of the guideline should be based upon and, where 
necessary, expand on previous versions. 
Specific to this guideline, we have noted that the majority of the current committee 
members (and reviewers) were interventional cardiologists or cardiac surgeons. 
By contrast, other guideline development groups (such as NICE) also include other 
stakeholders such as primary care physicians, nurses, health economists, epidemio-
logists, cardiac radiologists, patient members and pharmacists (Timmis A. et al. 
Stable Angina: full guideline. 2011. www.nice.org.uk (accessed Aug 2011)). Guideline 
committees should be representative of the whole group of professionals and 
stakeholders, since it is likely that the interpretation of the evidence by specialists 
will be biased. There may be some role or place for procedure oriented guidelines but, 
in that case, the items at issue should remain confined to matters directly related to 
technical aspects of the actual procedure.
Regarding the number of recommendations, we think that 20 to 30 sound recom-
men dations would be a reasonable number per guideline and, in view of our earlier 
comments and given the low number of recommendations based upon high quality 
clinical data; this should not be too difficult. A summary of our recommendations is 
given in box 1, and we hope that these will be helpful in developing future versions of 
the current as well as upcoming guidelines. 
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Box 1: Summary of our comments and suggestions
• Medical treatment should be the initial management of the patient with stable 
chest pain. Strong recommendation, high quality data (Class IA)
• Percutaneous opening of a chronic total coronary occlusion is not 
recommended. High quality data (Class IIIA)
• The composition of the guideline committee must be representative of the 
profession at large
• The number of recommendations per guideline should be limited (e.g. between 
20 and 30), and be based on sound (high quality) clinical evidence 
• As a rule, recommendations based on opinion are not very useful and should be 
avoided. This pertains to most class II recommendations
• The scope of the guideline must not be too wide
• New versions of guidelines must build on and expand on previous versions, and 
relevant changes in recommendations must be addressed specifically.
Disclosure
JWD was member of the ESC Committee on Practice Guidelines from 2002 to 2006, 
and was the review coordinator of the (previous) PCI guideline.
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Abstract
Current recommendations on myocardial revascularisation advocate coronary artery 
bypass grafting (CABG) in case of early cardiogenic shock and primary percutaneous 
coronary intervention (PCI) in all other ST-segment elevation myocardial infarction 
(STEMI) cases. In non-STEMI (NSTEMI), risk stratification is essential because benefit 
of revascularisation is strongest in high risk patients. In NSTEMI, unstable and 
stable angina, coronary artery disease distribution and severity dictate the mode of 
intervention, PCI or CABG. Observational and trial data support CABG in multi-vessel 
or left main disease.
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Box 1: Multidisciplinary decision-making (heart team)
The creation of a so-called ‘Heart Team’ serves the purpose of a balanced multi-
disciplinary decisionmaking process. Complex cases should be reviewed by the 
Heart Team to determine which type of intervention (PCI or CABG) is best, and to 
document the consensus reached. If there is no urgency, patients should also be 
allotted sufficient time to arrive at an informed decision. For the very same reasons, 
a so-called ad hoc PCI, a percutaneous intervention that immediately follows the 
diagnostic coronary angiogram, is not encouraged.
Myocardial revascularisation by either percutaneous coronary intervention (PCI) 
(a percutaneous procedure first clinically applied in 1977) and coronary artery bypass 
grafting (CABG) (a surgical procedure originally developed in the 1960s) both fulfill an 
important role in  the treatment of the more severe forms of coronary artery disease 
and its acute manifestations. Still, differences between the two revascularisation 
strategies are important and should be acknowledged. 
With CABG, venous and/or arterial bypass grafts are placed on the epicardial mid-
coronary vessel beyond the obstructive culprit lesion and, as such, provide extra 
sources of blood and nutrients to the distal myocardium. The nature of the surgical 
procedure implies that the additional distal flow through the graft (and distal 
coronary artery) can impede the regular, normal flow through the coronary vessel 
from its native origin. The consequence of this ‘steal’ phenomenon is that, with time, 
the original native vessel proximal to the bypass may become completely occluded. 
A second surgical procedure (redo) can be technically challenging for this reason. In 
addition, venous bypass grafts may become stenotic and obstructed when the ongoing 
systemic atherosclerotic process has not been brought under control. Fortunately, 
arterial bypass grafts, such as the internal mammary arteries, remain patent for 
much longer periods of time and these are therefore preferentially employed in the 
past two decades. 
Ch
ap
te
r 
17
268     |     Myocardial infarction: temporal trends over the past three decades
PCI aims to restore the normal conductance capacity of the native vasculature by 
mechanical removal of a localised obstruction lesion. The coronary stent that almost 
always is left behind maintains patency and tries to limit the occurrence of restenosis. 
This process, caused by local inflammatory response, is nowadays counteracted by 
stent or balloon covered drugs (drug-eluting stents) that prevent the proliferation 
of cells involved in this reaction. Compared with surgical revascularisation, PCI 
can be repeated quite often, at least in theory. Given the specific characteristics of 
both revascularization techniques, PCI would seem the method of choice for single 
vessel disease, whereas CABG should be more suited for complex, multiple vessel or 
left main stem disease. Although both techniques thus seem to be complimentary, 
a considerable group of patients will qualify for either one of these therapeutic 
modalities and many clinical conditions, stable or unstable, can be treated with a 
choice of available but quite different therapeutic options, including PCI, surgical 
revascularisation or even medical treatment. In theory, most coronary lesions are 
amenable to PCI, but technological feasibility is only one component of the decision-
making process. Other elements include clinical presentation, severity of angina, 
response to medical therapy, and extent of coronary artery disease, usually assessed 
with coronary angiography and/or computer tomography. Both revascularisation 
methods carry their specific procedure-related risks. Therefore, the balance between 
the short-term convenience of the less invasive PCI procedure against the durability of 
the more invasive surgical approach must be weighted carefully, both by physicians 
but also by the (well-informed) patients. 
Against this background, it is fortunate that, at the European Society for Cardiology 
meetings in Stockholm in 2010, the new joint European Society of Cardiology 
and European Association for Cardiothoracic Surgery guidelines on myocardial 
revascularisation have been issued. [1] This completely new set of guidelines followed 
the 2006 PCI guidelines, and formalised the multidisciplinary approach to coronary 
intervention. The make-up of the writing committee, which mainly consisted of 
interventional cardiologists and cardiac surgeons, reflected this new collaborative 
effort, and the resulting document has rightfully received acclaim. [2, 3] 
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By its nature, myocardial revascularisation provides best results in the presence 
of ischaemia. Cardiac conditions that qualify for myocardial revascularization are, 
in order of procedure effectiveness: ST-segment elevation myocardial infarction 
(STEMI); non-ST-segment elevation myocardial infarction (NSTEMI); unstable angina, 
and (chronic) stable angina. The most pertinent recommendations from the new 
revascularisation guidelines will be presented in the following sections.
Figure 1:  Organisation of ST­segment elevation myocardial infarction (STEMI) patient pathway 
describing pre and in­hospital management and reperfusion strategies within the 12 hours of first 
medical contact (see Ref 1).
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Revascularisation in STEMI
Without doubt, acute coronary revascularisation with primary PCI is an extremely 
effective intervention in the setting of STEMI, the result of a sudden thrombotic 
coronary occlusion. The PCI reperfusion modality carries not only less risk of bleeding 
than thrombolytic treatment, but will also lead to more effective restoration of vessel 
patency, less re-occlusion, improved residual function, and better clinical outcome 
including better survival. However, in order to achieve its full potential, time delays 
must be avoided, and a system of care network should be established around each 
cardiac intervention centre to make sure that this is indeed the case. The currently 
recommended treatment and decision algorithm is presented in Figure 1. Of course, 
pre-hospital triage that includes a 12-lead ECG should be an integral element of such 
a scheme. The delay between first medical contact and injection of contrast material 
into the coronary artery must be less than 90 minutes. It goes without saying that this 
requirement calls for considerable  organisational efforts, not only during the normal 
working hours, but also during the off hours and on weekends. Because a primary 
PCI is technically more demanding than an elective procedure, and given the strong 
inverse volume–outcome relationship in high-risk and emergency PCI procedures, 
primary PCI operators should perform at least two PCI procedures per week in an 
institution with an annual volume over 400 elective and 40 primary PCI procedures. 
Given the nature of the pathophysiology of STEMI, the culprit lesion will be 
proximally located in one of the three large epicardial coronary arteries, and should 
almost always be amenable to PCI. Emergency CABG will be necessary in case a 
very large myocardial area is at risk, for instance in patients who present early in 
cardiogenic shock and/or are found to have complete obstruction (of dissection) of 
the left main stem. Emergency coronary bypass surgery will also be necessary then 
it proves to be impossible to reach the culprit vessel by percutaneous technique. In 
practice, this will rarely be the case. When severe three-vessel or left main stem 
disease is found to be present following primary PCI and CABG is deemed necessary, 
the operation can often be delayed until the patient has reached a more stable clinical 
condition, for example, between three and seven days following hospitalisation. 
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According to the current recommendations, administration of fibrinolytic therapy 
must be restricted to those instances in which PCI cannot be performed within two 
hours of the first contact between patient and the medical system (in the first 12 hours 
following symptom onset). This can still be the case in some mountainous or rural 
areas. 
Box 2: risk scores
Risk assessment is an important aspect of contemporary clinical practice and, in the 
framework of challenging invasive procedures with (small but not negligible) risk of 
complications, of considerable importance. Different models are available to assess 
the risk associated with PCI or CABG, although it has not yet been established whether 
the actual use of such models in clinical practice will improve outcome in an individual 
patient. Still, it is generally agreed that such prediction models provide useful guidance 
in the often difficult decision-making process of myocardial revascularisation. 
EuroSCORE: Independent predictor of major adverse events in PCI and CABG: the score 
can be used to determine the risk of revascularisation associated with both procedures. 
SYNTAX score: Independent predictor of adverse events in PCI. Has a role in 
identifying those patients at highest risk of adverse events with PCI. 
GRACE score: Developed in patients with NSTEMI and the preferred risk classification 
scheme in these patients. 
National Cardiovascular Database Registry risk score (NCDR): This score has been 
validated in patients undergoing PCI only. 
Society of Thoracic Surgeons (STS) score: Relatively simple score that considers age, 
left ventricular ejection fraction and renal function. Applicable only in CABG.
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The recommended medical treatment in STEMI is straightforward: dual antiplatelet 
therapy must be initiated as early as possible and preferably prior to hospitalisation, 
unless there is serious risk of bleeding. Pain relief (with 4–8mg morphine) is usually 
necessary. Anticoagulation must be given immediately following hospitalisation. 
Aditional platelet inhibition with (intravenous) IIa/IIIb inhibitors is needed when 
restoration of coronary flow after PCI remains incomplete. Oral administration of 
beta-blockers is next, and ACE inhibitors and statins will be given subsequently. In the 
early phase of the hospitalisation, elevated blood pressure can be treated with high 
doses of (intravenous) nitrates.
Key points
•  Percutaneous coronary intervention (PCI) would seem the method of choice for 
single vessel disease, whereas CABG should be more suited for complex, multiple 
vessel or left main stem disease.
•  The creation of a so-called ‘Heart Team’ serves the purpose of a balanced 
multidisciplinary decision-making process for the patient who qualifies for either 
one of these treatment options.
•  In order of procedure effectiveness, myocardial revascularisation is most effective 
in ST-elevation myocardial infarction (STEMI), non-STEMI, unstable angina, and 
(chronic) stable angina pectoris.
•  In patients with mild-to-moderate angina, an initially cautious approach to 
coronary revascularisation is reasonable: watchful waiting seems appropriate.
•  In case PCI of coronary lesions of moderate severity is considered, a functional 
assessment of the stenosis, the determination of coronary flow reserve, is 
recommended.
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Revascularisation in NSTEMI and unstable angina 
NSTEMI is the most frequent manifestation of acute coronary syndromes and represents 
the largest group of patients undergoing myocardial revascularisation. In contrast 
to STEMI, NSTEMI usually occurs in elderly subjects, often in  those with previously 
diagnosed athero sclerotic heart disease. By definition, the diagnosis of NSTEMI is made 
in the presence of myocardial necrosis. Unstable angina, the third member of the acute 
coronary syndrome family, is diagnosed in the presence of myocardial ischaemia at 
rest without evidence of myocardial damage. However, the extremely high sensitivity 
of the current generation of myocardial biomarkers, specifically the high sensitive 
troponin, makes it increasingly difficult to establish the diagnosis of unstable angina 
since elevated levels of these markers will be present in almost all instances of true 
‘angina at rest’. In clinical practice therefore, the difference between unstable angina 
and NSTEMI has become somewhat blurred and, for all practical purposes, the approach 
to both syndromes has been combined under this heading. 
Patients with NSTEMI or unstable angina constitute a heterogeneous group 
with a variable prognosis. Most, but not all, randomised clinical trials performed in 
the setting of NSTEMI have shown beneficial effects of an early invasive strategy. 
However, the interpretation of their findings is hampered by the relatively frequent 
switches (cross-over) from one treatment allocation to the alternative and/ or the 
inability to perform  revascularization for technical reasons (complex anatomy or 
normal findings) in the intervention arm. In other words, the contrast between the 
two treatment arms in many studies has usually been modest. In most trials, the rate 
of intervention was approxi mately 60–70%, with PCI by far being the most frequently 
performed revascularisation technique. 
A substantial benefit with an early invasive strategy has only been proven in 
patients at high risk, and early risk stratification is therefore essential. To this end, 
the guidelines recommend the GRACE score (www.outcomes-umassmed.org/grace) 
as the preferred risk classification scheme. Not surprisingly, factors associated with 
increased risk in NSTEMI and unstable angina include haemodynamic instability, 
advanced age, ST segment depression, renal  dysfunction, diabetes and previous 
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revascularisation. Patients at low risk can be managed medically, unless severe 
ischaemia is found to be present with subsequent non-invasive testing. 
The issue of timing and type (PCI or CABG) of revascularisation also remains a 
matter of debate. The guidelines advocate coronary angiography to be performed 
within 24 hours in patients with elevated (>140 units) GRACE score. Otherwise, a time 
window of 72 hours is considered appropriate. No prospective trial has addressed the 
selection of mode of intervention: as in stable angina (see below), this should be based 
on the severity and distribution of the coronary abnormalities. The SYNTAX risk score 
has been advocated for this purpose, and CABG is then the preferred revascularization 
option when the score has a value that exceeds a value of about 30 units. 
The medical regimen in NSTEMI is not unlike that of STEMI and includes platelet 
inhibition, intensive use of anticoagulant drugs and medication to lower myocardial 
oxygen need (heart rate and blood pressure reducing agents). 
Stable angina pectoris
Depending on its symptomatic, functional, and anatomical complexity, stable angina 
pectoris can be treated by medical treatment or with myocardial revascularisation 
using PCI or CABG. The main indications for intervention are persistence of angina 
symptoms, despite extensive medical therapy and/or severe ischaemia during low 
levels of exercise. In all fairness, the evidence base for performing PCI or CABG in stable 
angina is quite limited. Randomised clinical trials that compared PCI with medical 
treatment have shown ambiguous results. Mortality seems unaffected although, 
at least in the short-term, PCI may be associated with better symptomatic relief. 
Observational data support the use of CABG in symptomatic subjects with multivessel 
and/ or left main disease. In clinical practice, an initially cautious approach to 
percutaneous or surgical coronary intervention seems reasonable in patients with 
mild-tomoderate angina and, certainly in the early phases of the disease, an approach 
of watchful waiting might be most appropriate. In case PCI of coronary lesions of 
moderate severity is considered, a functional assessment of the impact of the stenosis 
on coronary flow, the assessment of coronary flow reserve, is recommended. 
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Abstract
No abstract is available for this article.
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To the Editor
Recently Haukka et al [1] investigated the association of statin use with all-cause and 
disease specific mortality utilizing nationwide databases in Finland. We feel that the 
interpretation of these results is difficult, and that a more appropriate study design 
might have improved the study. 
In their large study, all persons in Finland who had purchased at least one statin 
prescription between 1997 and 2005 were compared to a control group matched for age, 
sex and place of residence from the general population. We think that the authors have 
chosen the wrong control group. Statins are predominantly prescribed in patients with 
coronary heart disease. [2] Thus, as secondary prevention. However, the control group of 
the present study includes predominantly patients without coronary heart disease. In 
our opinion, these two groups are by definition incomparable. 
The study by Haukka et al concludes that due to the pronounced baseline 
differences a bias is likely, and it was therefore not possible to draw conclusions from 
this comparison. [1] Given their access to rich data, it seems that the authors could 
have chosen a more dedicated comparison group. Previously, observational studies 
that compared statin users with otherwise similar non-users demonstrated that it is 
possible to obtain reliable results. [3-4] 
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Background
Clustered data are common in the field of interventional cardiology. Often multiple 
lesions are examined within the same patient and intravascular imaging modalities, 
such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT), result 
in multiple measurements from the same vessel segment. Multiple observations 
from one patient are likely to be correlated, which has implications for the statistical 
approach used to analyze the data. 
The approach in the statistical analysis should be based on the study objective. If we 
study the effect of medication versus no medication, the level of analysis should be the 
patient. If we study the effect of stent implantation, the level of analysis could be the 
stented segment. One patient can have multiple stented segments and these are likely 
to be correlated. Ignoring this correlation in the analysis leads to too strong statistical 
inference. Specifically, misleadingly small standard errors (and thus p-values and 
confidence intervals) will be found because all observations are considered as 
independent observations. This wrongly inflates statistical power. Thus, analyses of 
data that include multiple observations per patient require some form of adjustment 
to account for the correlation between observations. This is common knowledge in 
the statistical literature (see for example Molenberghs [1]), however, clustered data 
are often analyzed without taking the within-cluster correlation into account in the 
medical literature [2]. 
The aim of this paper is to review the current analytical approach to clustered 
data in the field of interventional cardiology, and to present and illustrate statistical 
methods that take into account possible correlation within clusters. We provide 
syntax for different statistical packages to allow researchers to apply these methods. 
Chapter 19 .    Analysis of clustered data     |     287
Current practice
We conducted a systematic review to gain insight in the current statistical approaches 
to clustered data in the field of interventional cardiology. We focused on studies on 
optical coherence tomography (OCT), since this technique results in large numbers 
of observations per patient. We conducted a PubMed literature search, for original 
studies published between January 1, 2012 and December 31, 2012, in six important 
(interventional) cardiology journals: Circulation, Circulation cardiovascular inter-
ventions, EuroIntervention, European Heart Journal, Journal of the American College 
of Cardiology (JACC) and JACC cardiovascular interventions. A search with “optical 
coherence tomo graphy” yielded 25 potentially eligible studies which were reviewed by 
two independent reviewers. In case of disagreement a third reviewer was consulted. 
Case-reports, reviews and editorials were excluded, leaving 17 studies (Appendix 1), 
all reporting data derived from multiple observations per patient. In 15 (88%) of the 17 
studies inferences made from these multiple observations per patients were reported. 
Of those 15 studies, only 5 (33%) took the clustered nature of the data clearly into account 
in the statistical analysis. In 3 (20%) studies it was not clear whether the clustering was 
taken into account. In 7 (46%) studies it was clear that the clustering within patients 
was not taken into account. In these studies t-tests were mostly conducted, which 
assume that all observations are independent. 
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Methods to analyze clustered data
We illustrate the use of different statistical methods with data from a study that 
evaluated late recoil of a novel bioabsorbable everolimus-eluting coronary scaffold 
(BVS) [3]. The study consisted of 16 patients, who were treated with elective BVS 
implantation. All patients underwent an IVUS examination post-procedure and at 6 
months of follow-up. A total of 484 paired cross-sectional areas (CSAs) were acquired, 
on average over 30 per patient. Late absolute stent recoil was defined as stent area at 
post-procedure minus stent area at follow-up. In each CSA, plaque morphology was 
assessed qualitatively and classified as calcific, fibronecrotic, or fibrocellular plaque. 
In these data we address two research questions with different methods in line with 
the reviewed literature. 
Research question 1: What is the stent recoil in this population? We can hereto 
provide a mean with a 95% confidence interval (CI). 
Research question 2: What is the difference in stent recoil between the three different 
plaque types? We can hereto provide differences between plaque types with 95% CI.
Method 1: Independent observations 
The simplest method is to analyze the data at CSA level, without taking into account 
the clustering within patients. Formally this approach assumes that each observation 
is statistically independent, i.e. that there is no correlation between different CSAs from 
the same patient. We calculate mean absolute recoil and 95% confidence interval (95% 
CI) based on all 484 CSAs. Alternatively the mean and 95% CI can be obtained from 
a linear regression model without any covariates. In this model only the intercept is 
estimated which equals the mean recoil. To estimate the differences between plaque 
types, a linear regression model with plaque type as a categorical covariate can be 
fitted. The linear models estimate unconditional effects, i.e. the average difference 
between plaque types in the population.
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Method 2: Clustered observations 
In contrast to the first approach, we can take the correlations between recoil values 
within patients into account. We can thereto use a linear multilevel model, also called 
random effect, mixed, or hierarchical model. The multilevel model contains two levels: 
patient and CSA. Patient is included in the model as a random effect, which allows 
estimation of patient specific recoil values. The estimated intercept equals the mean 
recoil, with clustering taken into account. 
To estimate the differences between plaque types we used a linear multilevel model 
with a random intercept for patient and plaque type as a categorical covariate.
The interpretation of the differences between plaque types is somewhat different 
than in method 1. In method 1, we estimate differences within and across patients, 
while in method 2, we strictly estimate differences within patients.
Method 3: Patient level 
Another approach simply averages the recoil values per patient. These means are 
saved. In a second step, the means are averaged to obtain an overall mean over all 
observations.
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Results 
All three methods estimated a similar mean absolute recoil of about 0.65 to 0.66 mm2 
(Table 1). As expected, the 95% confidence interval of the absolute recoil was smallest 
(-0.80; -0.49) when all CSAs were analyzed as independent observations and largest 
(-1.32; -0.01) when the CSAs were first summarized per patient. When the CSAs were 
analyzed as clustered observations with a multilevel model, the 95% CI was -1.27 mm2 
to -0.05 mm2, which is clearly larger than the 95%CI obtained with method 1, and close 
that the width obtained with method 3.
table 1: Methods for estimating mean recoil in total population (n CSa=484, n patients=16) 
Method Clustering  
taken into 
account? 
Statistical method Level Mean recoil (95% CI)
Use all CSAs as 
independent observations
No Calculate mean+se/95% CI; 
Linear regression with one 
common intercept
CSA ­0.65 (­0.80 ; ­0.49)
Use all CSAs as clustered 
observations
Yes Multilevel linear regression CSA ­0.66 (­1.27 ; ­0.05)
Summarize CSAs per 
patients
Yes Calculate mean+se/95% CI;
Linear regression with one 
common intercept
Patient ­0.66 (­1.32;­0.01)
See appendix 2 for syntax for presented methods
 When estimated with a naïve linear model, ignoring clustering, the mean recoil 
per plaque type was -0.75 mm2 in fibro-cellular, -0.20 mm2 in calcific, and -1.03 in 
fibro-necrotic plaques. The corresponding betas (95% confidence interval) were 0.54 
mm2 (0.19; 0.89) for fibro-cellular vs. calcific plaques and -0.29 mm2 (-0.66; 0.09) for 
fibro-cellular vs. fibro-necrotic plaques (Table 2). When clustering was taken into 
account in the multilevel model, the differences were 0.60 mm2 (0.21; 1.00) and -0.06 
mm2 (-0.38; 0.26), respectively. This difference could be explained by the fact that the 
multilevel model estimates conditional, or within patient differences. When all CSAs 
are considered independent, fibro-necrotic plaques have 0.29 mm2 less recoil than 
fibro-cellular plaques. However, when we acknowledge that CSAs are clustered within 
patients, this difference almost disappeared (0.06 mm2 less recoil). In this example the 
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29 mm2 absolute recoil difference is contributed to a high or low recoil level in some 
patients, instead of to the plaque type itself. Within a patient, fibro-cellular plaques 
appear to give no more recoil than calcific plaques. 
In this particular example the estimated mean recoil in the overall population was 
not largely affected by using a multilevel model, only the confidence interval increased. 
The estimated difference between plaque types was however affected. The difference 
between fibro-cellular and calcific plaques was only borderline significant in the 
multilevel model. 
In general, the change in point estimates between naïve models and multilevel model 
will be influenced by the correlation within patients, and the difference in number 
of observations between patient. When both are small, point estimates are likely to 
be very similar between the methods. However, the standard error and confidence 
intervals will generally increase, and corresponding p values decrease when using a 
multilevel model. Ignoring clustering using naïve models will exaggerate statistical 
significance. 
table 2: Methods for difference in recoil between plaque types (n CSa=484, n patients=16) 
Method Clustering  
taken into 
account? 
Statistical method Level Difference between 
plaque types (95% CI) 
Use all CSAs as 
independent observations
No Calculate mean+se/95% CI; 
Linear regression with one 
common intercept
CSA ­0.65 (­0.80 ; ­0.49)
Use all CSAs as independent 
observations
No Linear regression CSA   0.54 (0.19 ; 0.89)*
­0.29 (­0.66 ; 0.09)**
Use all CSAs as clustered 
observations
Yes Multilevel linear regression CSA   0.60 (0.21; 1.00)*
­0.06 (­0.38; 0.26)**
*  Difference between fibro­cellular (reference) and calcific plaques, 
** Difference between fibro­cellular (reference) and fibro­necrotic plaques. 
 See appendix 2 for syntax for presented methods
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Conclusion and recommendations
According to literature review, the current analytical approach to clustered data in the 
field of interventional cardiology, specifically OCT, is suboptimal. A large number of 
studies ignored the clustered nature of their data, or it was unclear which statistical 
methods were used. If we assume that observations within one patient are correlated, 
ignoring clustering may lead to wrong conclusions. 
Our data example shows that indeed misleadingly small confidence intervals can 
be estimated with standard linear regression. The third method -summarizing CSAs 
per patient- is statistically correct when analyses on patient level are performed, but 
inefficient. 
When observations within patients are not correlated, the clustering can 
theoretically be ignored. However, this is clinically unlikely. And, in the absence of 
correlation the results from standard and multilevel analysis will be the same. We 
therefore recommend to always use multilevel models when analyzing multiple 
observations per patient, to make correct statistical inferences and not inflate 
statistical power. These models are now widely available in statistical software, and 
syntax is provided in appendix 2. 
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Appendix 1
15 studies with inference based on clustered data; 5 clearly analyzed with taking 
structure into account
author Journal Inferences made on 
clustered data? 
Clustered data structure taken 
into account in analyses?
Fukunaga et al. EI Yes Not clear
Wykrzkowska et al. EI No n.a. 
Alegría­Barrero et al. EI Yes Not clear
Okamura et al. EI Yes No 
Sheehy et al. EI Yes No 
Brugaletta et al. EI Yes No 
Gomez­Lara et al. EI Yes No 
Belkacemi et al. JACC Yes No 
Van Geuns et al. JACC CI Yes Yes
Kato et al. JACC CI No n.a. 
Räber et al. JACC CI Yes Yes
Gutiérrez­Chico et al. JACC CI Yes Yes
Guagliumi et al. JACC CI Yes No
Ormiston et al. Circulation CI Yes Not clear
Gutiérrez­Chico et al. Circulation CI Yes Yes
Guagliumi et al. Circulation CI Yes Yes
Tada et al. Circulation CI Yes No
EI = EuroIntervention,
JACC = Journal of the American College of Cardiology
JACC CI = JACC cardiovascular interventions
Circulation CI = Circulation cardiovascular interventions
n.a.= not applicable
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Appendix 2
Syntax code for the performed analyses in SPSS, SAS and R
SPSS
* Import data 
GET DATA
  /TYPE=XLS
  /FILE=’V:\UserData\MyPaper\data.xls’
  /SHEET=name ‘recoil and plaque characteristi’
  /CELLRANGE=full
  /READNAMES=on
  /ASSUMEDSTRWIDTH=32767.
EXECUTE.
DATASET NAME DataSet1 WINDOW=FRONT.
* RQ 1, method 1 
EXAMINE VARIABLES=Recoil
  /PLOT NONE
  /STATISTICS DESCRIPTIVES
  /CINTERVAL 95
  /MISSING LISTWISE
  /NOTOTAL.
COMPUTE constant = 1.
EXECUTE.
REGRESSION
  /MISSING LISTWISE
  /STATISTICS COEFF OUTS CI(95) R ANOVA
  /CRITERIA=PIN(.05) POUT(.10)
  /ORIGIN 
  /DEPENDENT Recoil
  /METHOD=ENTER constant.
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* RQ 1, method 2
MIXED Recoil WITH constant
  /CRITERIA=CIN(95) MXITER(100) MXSTEP(10) SCORING(1) SINGULAR(0.000000000001) 
HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE)
  /FIXED=  constant | SSTYPE(3)
  /METHOD=ML
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(Patient) COVTYPE(VC).
* RQ 1, method 3
AGGREGATE
  /OUTFILE=’V:\UserData\521825\Paper Eurointervention\aggr.sav’
  /BREAK=Patient
  /Recoil_mean=MEAN(Recoil).
GET
  FILE=’V:\UserData\521825\Paper Eurointervention\aggr.sav’.
DATASET NAME DataSet2 WINDOW=FRONT.
EXAMINE VARIABLES=Recoil_mean
  /PLOT NONE
  /STATISTICS DESCRIPTIVES
  /CINTERVAL 95
  /MISSING LISTWISE
  /NOTOTAL.
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*RQ 2, method 1 
xGET DATA
  /TYPE=XLS
  /FILE=’V:\UserData\521825\Paper Eurointervention\recoil and plaque characteristics data for Ron 
and Nico 08.04.22.xls’
  /SHEET=name ‘recoil and plaque characteristi’
  /CELLRANGE=full
  /READNAMES=on
  /ASSUMEDSTRWIDTH=32767.
EXECUTE.
DATASET NAME DataSet1 WINDOW=FRONT.
COMPUTE x1=0 .
IF Plaque = 1 x1 = 1.
EXECUTE.
COMPUTE x2=0 .
IF Plaque = 2 x2 = 1.
EXECUTE.
REGRESSION
  /MISSING LISTWISE
  /STATISTICS COEFF OUTS CI(95) R ANOVA
  /CRITERIA=PIN(.05) POUT(.10)
  /NOORIGIN 
  /DEPENDENT Recoil
  /METHOD=ENTER x1 x2.
* RQ 2, method 2
MIXED Recoil WITH x1 x2
  /CRITERIA=CIN(95) MXITER(100) MXSTEP(10) SCORING(1) SINGULAR(0.000000000001) 
HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE)
  /FIXED=  x1 x2 | SSTYPE(3)
  /METHOD=ML
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(Patient) COVTYPE(VC).
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SAS
proc import 
   out=a 
   datafile=”V:\UserData\MyPaper\data.csv” 
   dbms=csv
   replace;
   getnames=yes;
   datarow=2; 
run;
title1 ‘Research Question 1’;
title2 ‘Method 1’;
title3 ‘First simply calculate overall mean and s.e.’;
proc univariate data=a;
   var Recoil;
run;
title3 ‘Then calculate overall mean and s.e. using linear regression’;
proc reg data=a;
   model Recoil = ;
run;
title2 ‘Method 2’;
title3 ‘Calculate overall mean and s.e. using multilevel model’;
proc mixed data=a;
   class Patient;
   model Recoil = / solution cl;
   random int / subject=Patient solution;
run;
title2 ‘Method 3’;
title3 ‘First calculate means per patient’;
proc means data=a;
   var Recoil;
   output out=b mean=PatAvg;
   by Patient;
run;
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title3 ‘Then average the calculated means’;
proc univariate data=b;
   var PatAvg;
run;
title1 ‘Research Question 2’;
title2 ‘First a general linear model with Plaque as discrete predictor’;
proc glm data=a;
   class Plaque Patient;
   model Recoil = Plaque / solution;
run;
title2 ‘Then a mixed model with Plaque as discrete predictor’;
proc mixed data=a;
   class Plaque Patient;
   model Recoil = Plaque / solution cl;
   random int / subject=Patient solution;
run;
R 
#load libraries
library(Hmisc)
library(rms)
library(foreign)
library(lme4)
#import data
data <­ as.data.frame(read.table(file= ‘V:\\UserData\\MyPaper\\data. csv’,header=T,sep= “,”))
names(data)
nrow(data)
attach(data)
#rQ 1, method 1a
mean1b <­ mean(Recoil)
sd1b <­ sd(Recoil)
n1b <­ nrow(data)
se1b <­ sd1b / sqrt(n1b)
cil1b <­ mean1b ­ 1.96*se1b
ciu1b <­ mean1b + 1.96*se1b
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#rQ 1, method 1b
rq1mod1 <­ lm(Recoil~1) 
mean1a <­  coef(summary(rq1mod1))[1,1]
se1a <­  coef(summary(rq1mod1))[1,2]
cil1a <­ mean1a ­ 1.96*se1a
ciu1a <­ mean1a + 1.96*se1a
rq1method1a <­ cbind(‘1a’, round(mean1a,2), round(cil1a,2), round(ciu1a,2))
rq1method1b <­ cbind(‘1b’, round(mean1b,2), round(cil1b,2), round(ciu1b,2))
#rQ 1, method 2
rq1mod2 <­ lmer (Recoil~1 + 1|Patient)
mean2 <­ coef(summary(rq1mod2))[1,1]
se2 <­coef(summary(rq1mod2))[1,2]
cil2 <­ mean2 ­ 1.96*se2
ciu2 <­ mean2 + 1.96*se2
rq1method2 <­ cbind(‘2’, round(mean2,2), round(cil2,2), round(ciu2,2))
#rQ 1, method 3
meanRecoil <­ tapply(Recoil, Patient, mean)
mean3 <­ mean(meanRecoil)
sd3 <­ sd(meanRecoil)
n3 <­ length(meanRecoil)
se3 <­ sd3 / sqrt(n3)
cil3 <­ mean3 ­ 1.96*se3
ciu3 <­ mean3 + 1.96*se3
rq1method3 <­ cbind(‘3’, round(mean3,2), round(cil3,2), round(ciu3,2))
summaryRQ1 <­rbind(rq1method1a, rq1method1b, rq1method2, rq1method3)
colnames(summaryRQ1) <­ c(‘method’,’mean’, ‘lower 95% CI’, ‘upper 95% CI’)
summaryRQ1
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# rQ 2, method 1
rq2mod1 <­ lm(Recoil~as.factor(Plaque))
beta1cat1 <­ coef(summary(rq2mod1))[2,1]
beta1cat2 <­ coef(summary(rq2mod1))[3,1]
se1cat1 <­ coef(summary(rq2mod1))[2,2]
se1cat2 <­ coef(summary(rq2mod1))[3,2]
cil1cat1 <­ beta1cat1 ­ (1.96*se1cat1)  
ciu1cat1 <­ beta1cat1 + (1.96*se1cat1)
cil1cat2 <­ beta1cat2 ­ (1.96*se1cat2)  
ciu1cat2 <­ beta1cat2 + (1.96*se1cat2)
rq2method1 <­ cbind(‘1’, round(beta1cat1,2), round(cil1cat1,2), round(ciu1cat1,2),round(beta1cat2,2), 
round(cil1cat2,2), round(ciu1cat2,2))
#rQ 2, method 2
rq2mod2 <­ lmer (Recoil~ as.factor(Plaque) + (1|Patient))
beta2cat1 <­ coef(summary(rq2mod2))[2,1]
beta2cat2 <­ coef(summary(rq2mod2))[3,1]
se2cat1 <­ coef(summary(rq2mod2))[2,2]
se2cat2 <­ coef(summary(rq2mod2))[3,2]
cil2cat1 <­ beta2cat1 ­ (1.96*se2cat1)  
ciu2cat1 <­ beta2cat1 + (1.96*se2cat1)
cil2cat2 <­ beta2cat2 ­ (1.96*se2cat2)  
ciu2cat2 <­ beta2cat2 + (1.96*se2cat2)
rq2method2 <­ cbind(‘2’, round(beta2cat1,2), round(cil2cat1,2), round(ciu2cat1,2),round(beta2cat2,2), 
round(cil2cat2,2), round(ciu2cat2,2))
summaryRQ2 <­rbind(rq2method1, rq2method2)
colnames(summaryRQ2) <­ c(‘method’,’beta1’, ‘lower 95% CI’, ‘upper 95% CI’,’beta2’,’lower 95% CI’, 
‘upper 95% CI’)
summaryRQ2
#save data 
save.image(“V:\\UserData\\MyPaper\\Ranalysis.RData”)
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In each year between 1900 and 2006 except for 1918, cardiovascular disease accounted 
for more deaths in the United States than any other major cause of death. [1] In the 
Netherlands, cardiovascular disease was the main cause of death until 2007: in 2007 
mortality due to cardiovascular disease, and coronary artery disease in particular, 
had decreased considerably such that the total number of deaths due to cancer was 
higher (Statistics Netherlands, www.cbs.nl). This is the result of the combined effects 
of improvements in primary prevention, initial recognition of acute events, well 
organized care and effective treatment. 
In the present thesis, we investigate relevant treatment evolutions in patients with 
heart disease, clinical outcomes of these patients, changes in outcome over time, and 
specific high risk groups that could benefit from tailored clinical care. 
Changes in clinical profile, treatment, and mortality
The Thoraxcenter is one of the few centers worldwide that is able to compare clinical 
profile, treatment, and outcome of patients hospitalized for myocardial infarction 
over a calendar period of three decades. During this period, substantial improvements 
in acute and long term survival in these patients could be documented, most likely 
related to improved treatment (Chapter 3). 
Cardiovascular disease is the single largest cause of death in patients with renal 
impairment, and these cardiovascular deaths often occur before end-stage renal 
failure has been reached. [2]  We show that, during the past 25 years, there was a similar 
decline in mortality after myocardial infarction for all stages of kidney function, 
including stage 4–5 chronic kidney disease (CKD). Still, the prognosis remains poor 
for patients with stage 4–5 CKD: adjusted mortality was 8.6-fold higher at 30 days, 
compared with patients with normal renal function (Chapter 4).
Anemia usually develops during the course of chronic kidney disease and may be 
associated with adverse outcomes. [3] In acute coronary syndrome patients, little was 
known about the effect of anemia on outcome and about the interaction between 
anemia and renal impairment. We show that that the extent of anemia at hospital 
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admission for acute coronary syndrome is associated with increased both in-hospital 
and long-term mortality, and we discuss anemia as a potential treatment target in 
these patients (Chapter 5).
Ageing and glucose metabolisms: emerging risk factors
Approximately 80% of people who die of coronary artery disease are 65 years of age 
or older. [1] In chapter 6 we showed that, in absolute terms, older patients benefited most 
from the improved medical care for myocardial infarction during the past decades. 
Favorable changes with more frequent use of evidence-based medical care, also in the 
elderly, are documented in this chapter. 
The western world has experienced substantial increases in the prevalence of 
diabetes mellitus over the past 20 years. In 2011 approximately 60 million adult 
Europeans were thought to have diabetes mellitus, half of them with a clinical 
diagnosis, the other half undetected. More than 50% of the mortality in people with 
diabetes mellitus is related to cardiovascular disease. Cardiovascular risk probably 
develops early, before onset of diabetes mellitus. [4]
Against this background we show that there is also an increasing prevalence of 
diabetes in patients with a myocardial infarction. In the most recent decade, diabetes 
was not associated with underuse of evidence-based therapies. The absolute long-
term mortality rate remained about 1.5-fold higher in patients with diabetes compared 
with those without diabetes. Additionally, we show that admission glucose levels are 
strongly related with increased mortality (up to 20 years). Compared with diabetes, 
hyperglycemia is a better discriminator for short-term mortality. This is important 
because the prevalence of elevated admission glucose levels has also increased 
substantially over the last years. The association between hyperglycemia and short-
term mortality was significantly stronger in the present decade when than in previous 
decades. Therefore, although we showed that mortality after acute myocardial 
infarction decreased from 1985 to 2008, the observed decrease was less pronounced 
in patients with hyperglycemia. Finally, we demonstrate that the association between 
admission glucose levels and short-term mortality was not dependent on diabetic 
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status; a high admission glucose level was a predictor of mortality in patients with 
diabetes and in those without previously diagnosed diabetes (Chapters 7, 8). 
Gender differences 
The total number of women who die of cardiovascular disease is higher than the 
number of men. [1] In Chapter 9 we demonstrate that women hospitalized for an acute 
myocardial infarction were more likely to present with a higher risk profile but were 
equally likely to receive pharmacological and invasive reperfusion therapy compared 
with men. The higher risk profile of women was mainly determined by an average age 
difference of 5 years between women and men. Women and men had the same adjusted 
mortality rates at 30 days, whereas during 20 years of follow-up, the mortality hazard 
was lower in women. Importantly, temporal improvements in 30-day mortality and 
long-term mortality hazard from 1985 to 2008 were substantial and at least as high in 
women as in men.  
In Chapter 10 we provide an overview of long-term prognosis according to age and 
sex, based on contemporary mortality rates. Our results demonstrate that the overall 
median life-expectancy after myocardial infarction varies between 6 and more than 
20 years, mainly depending on age at presentation. In this chapter, we compare 
survival in the general population with survival after myocardial infarction.  
Traditional risk factors
Hypertension, dyslipidaemia, smoking and diabetes mellitus are traditional risk 
factors for the development of coronary heart disease in patients without established 
cardiovascular disease. [5, 6] Contrary to this, two recent studies of large populations of 
myocardial infarction patients admitted in the United States have shown the presence 
of these coronary heart disease risk factors to be associated with a significantly lower 
in-hospital mortality rate. [7, 8] We confirm this paradox: myocardial infarction patients 
with at least one compared with no modifiable coronary heart disease risk factor 
have a favorable unadjusted and adjusted short-term survival (Chapter 11). We are the 
first to show that with longer duration of follow-up this association was sustained 
for myocardial infarction patients admitted between 1990 and 2008 (Chapter 11). The 
interpretation of these findings is that the absence of coronary heart disease risk 
factors should not necessarily be viewed as a guarantee of favorable prognosis. It could 
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be that the management associated with the presence of coronary heart disease risk 
factors is causally related to better outcome.
Percutaneous coronary interventions
It has been estimated that percutaneous coronary interventions reduce mortality 
by more than 30% in patients who present with an acute myocardial infarction. [9, 10] 
In addition revascularization for acute coronary syndrome relieves symptoms and 
shortens hospital stay. [11] We assessed 7 year outcome after percutaneous coronary 
intervention in saphenous vein graft lesions, and compared the safety and efficacy 
of drug-eluting stents versus bare-metal stents. We show that the unrestricted use of 
drug-eluting stents in saphenous vein graphs remains safe and effective as compared 
to bare metal, as illustrated by similar mortality rates and clinically relevant lower 
rates of target vessel revascularization in patients treated with drug eluting stents 
(Chapter 12). There is no previous study with a comparable duration of follow-up. At 
last follow-up, nearly 50% of patients were dead, and almost 70% of deaths were due 
to cardiac causes. 
We show that there was no difference in both short term (30-day) mortality and long 
term mortality up to 10 years among ST-segment elevation myocardial infarction 
(STEMI) patients who present during the weekend compared to weekdays in the 
three decades between 1985 and 2008 (Chapter 13). This suggests that a system with 
immediate primary percutaneous coronary intervention for STEMI patients is as 
effective in weekend- compared to weekdays. 
In two related studies we demonstrate that the syntax score, originally designed 
for quantifying stable coronary artery disease, can be usefully utilized in a STEMI 
population with disease in the native coronary arteries. We are the first to report the 
prognostic value of the syntax score in STEMI patients (Chapter 14). The syntax score, 
derived from angiography during primary percutaneous coronary intervention, 
predicts long-term mortality and major adverse cardiac event in patients with STEMI 
independently of the TIMI risk score (Chapter 14). In addition, the syntax score is an 
independent predictor of myocardial no-reflow in these patients. An syntax score of 
over 21 doubles the risk for developing no-reflow. Myocardial no-reflow carries a poor 
prognosis and an increased mortality rate (Chapter 15). 
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In a literature review on the benefits of PCI in patients with stable angina, we 
concluded that medical treatment should be the initial management of the patient 
with stable chest pain (Chapter 16). In addition, based on our literature search, 
percutaneous opening of a chronic total coronary occlusion is not recommended. We 
reviewed the most recent guidelines on myocardial revascularization. [12] Specifically, 
we recommend that the composition of such a guideline committee must be more 
representative of the medical profession at large (Chapter 16).
In another review article we argue that percutaneous coronary intervention seems 
the method of choice for single vessel disease, whereas bypass surgery (CABG) 
should be more suited for complex, multiple vessel or left main stem disease (Chapter 
17). Also, we advocate the creation of a so-called ‘Heart Team’. A Heart Team allows 
for a multidisciplinary decision-making process for a patient who qualifies for either 
one of these treatment options. In order of procedure effectiveness, myocardial 
revascularization is most effective in STEMI, non-STEMI, unstable angina, and 
(chronic) stable angina pectoris. In patients with mild-to-moderate angina, an initially 
cautious approach to coronary revascularization is reasonable: watchful waiting 
seems appropriate. In case percutaneous coronary intervention of coronary lesions 
of moderate severity is considered, a functional assessment of the stenosis, the 
determination of coronary flow reserve, is recommended (Chapter 17). 
Methodology
The present thesis includes two methodological chapters. In chapter 18 we explain the 
need for an appropriate control group for an observational study design. In chapter 
19 we reviewed the current analytical approach to clustered data in the field of OCT-
imaging during percutaneous coronary intervention We conclude that these analyses 
are frequently performed suboptimal and this may lead to wrong inferences We 
recommend to always use multilevel models when analyzing multiple observations 
per patient. 
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In this thesis we aimed to expand the knowledge on treatment, risk factors and 
outcome in patients with coronary artery disease. Specifically, we documented 
changes over the past decades: the temporal trends shown in this thesis, covering 24 
years of observation, are unique. 
The main conclusions of this thesis are as follows: 
In patients hospitalized for myocardial infarction acute (30 day) mortality has 
decreased over the past decades, and the decrease in short-term mortality is sustained 
during long-term follow-up. These improvements in outcome relate to improved acute- 
as well as long-term treatment.
Renal impairment, anemia and older age are important predictors of mortality after 
myocardial infarction. We demonstrate a substantial mortality decrease over the past 
decades in older patients and those with renal impairment; this mortality decrease 
is comparable with the decrease in younger patients and those with normal renal 
function, respectively. 
Diabetes and hyperglycemia are emerging risk factors. Optimal medical care for 
these patients and awareness of their high-risk profile remains warranted.
Women were equally likely to receive pharmacological and invasive reperfusion 
therapy compared with men. Women and men had the same adjusted mortality rates 
at 30 days, whereas during 20 years of follow-up, the mortality hazard was lower in 
women.
Relative survival, which is the survival among patients divided by the expected 
survival of a the general population, may well be an appropriate and useful measure 
for assessment of survival after myocardial infarction. 
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